The O
present O
study O
was O
undertaken O
to O
explore O
the O
protective O
effects O
of O
tuberous O
root O
extract O
of O
Pueraria B-Medicinal food
tuberosa I-Medicinal food
on O
chronic O
foot O
shock O
stress B-Symptom_TestedFor
( O
CS O
) O
induced O
physiological O
, O
neurobehavioral O
and O
neuropathological O
alterations O
. O

Male O
Wistar O
rats O
( O
120 O
- O
150 O
g O
) O
were O
divided O
into O
seven O
groups O
, O
consisting O
of O
ten O
animals O
in O
each O
. O

Group O
I O
served O
as O
normal O
, O
group O
II O
as O
positive O
control O
, O
while O
group O
III-VII O
as O
test O
drug O
treated O
. O

P B-Medicinal food
tuberosa I-Medicinal food
tuber I-Medicinal food
extract I-Medicinal food
( O
PTE O
) O
was O
given O
to O
rats O
of O
groups O
III-VI O
at O
the O
doses O
of O
50 O
, O
100 O
, O
200 O
and O
400 O
mg O
/ O
kg O
respectively O
, O
while O
group O
VII O
treated O
with O
Withania B-Other_ingredients
somnifera I-Other_ingredients
rhizome I-Other_ingredients
extract I-Other_ingredients
( O
WSE O
) O
( O
100 O
mg O
/ O
kg O
) O
as O
reference O
drug O
. O

Group O
II O
( O
stress O
control O
) O
received O
only O
equivalent O
volume O
of O
distilled O
water O
( O
0.5 O
ml O
/ O
100 O
g O
) O
orally O
. O

All O
the O
drugs O
were O
given O
orally O
once O
/ O
day O
for O
14 O
consecutive O
days O
. O

The O
last O
dose O
was O
given O
1 O
h O
before O
study O
. O

Simultaneously O
, O
all O
the O
animals O
( O
except O
group O
I O
) O
were O
subjected O
to O
1 O
h O
of O
foot-shock O
( O
2 O
mA O
) O
through O
a O
grid O
floor O
for O
those O
14 O
days O
in O
a O
standard O
conditioning O
chamber O
with O
the O
escape O
route O
closed O
[ O
Chronic O
stress O
( O
CS O
) O
] O
. O

Thereafter O
, O
the O
rats O
were O
placed O
on O
open-field O
and O
plus O
maze O
apparatus O
for O
studying O
the O
behavioral O
patterns O
of O
them O
, O
and O
the O
anxiolytic O
effects O
of O
the O
putative O
drug O
. O

Sexual O
activities O
of O
the O
animals O
were O
also O
studied O
. O

Finally O
, O
the O
animals O
were O
sacrificed O
and O
their O
ulcer O
formation O
in O
gastric O
mucosa O
was O
noted O
. O

Weights O
of O
adrenals O
and O
spleen O
were O
also O
taken O
. O

Further O
, O
plasma O
corticosterone O
levels O
were O
estimated O
spectroflurometrically O
. O

Results O
indicated O
that O
, O
CS O
significantly O
altered O
the O
behavioral O
patterns O
, O
decreased O
the O
sexual O
urge O
and O
activities O
, O
damaged O
the O
gastric O
mucosal O
layers O
, O
enhanced O
plasma O
corticosterone O
levels O
and O
increased O
adrenal O
glands O
and O
spleen O
weights O
. O

PTE O
and O
WSE O
showed O
significant O
anxiolytic O
activity O
, O
protected O
the O
gastric O
mucosa O
, O
lowered O
plasma O
corticosterone O
level O
( O
indicating O
HPA O
axis O
inhibition O
) O
and O
negated O
the O
hypertrophy O
of O
adrenals O
and O
spleen O
. O

PTE O
also O
enhanced O
the O
sexual O
urge O
and O
activities O
in O
animals O
exposed O
to O
chronic O
stress O
. O

The O
findings O
suggest O
significant O
anxiolytic O
and O
anti-stress O
properties O
of O
PTE O
, O
confirming O
the O
clinical O
efficacy O
of O
the O
plant O
mentioned O
in O
Ayurveda O
( O
Indian O
system O
of O
traditional O
medicine O
) O
. O

Objective O
: O
To O
assess O
existing O
reported O
human O
trials O
of O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
WS O
; O
common O
name O
, O
ashwagandha B-Medicinal food
) O
for O
the O
treatment O
of O
anxiety B-Symptom_WorkedFor
. O

Design O
: O
Systematic O
review O
of O
the O
literature O
, O
with O
searches O
conducted O
in O
PubMed O
, O
SCOPUS O
, O
CINAHL O
, O
and O
Google O
Scholar O
by O
a O
medical O
librarian O
. O

Additionally O
, O
the O
reference O
lists O
of O
studies O
identified O
in O
these O
databases O
were O
searched O
by O
a O
research O
assistant O
, O
and O
queries O
were O
conducted O
in O
the O
AYUSH O
Research O
Portal O
. O

Search O
terms O
included O
" O
ashwagandha B-Medicinal food
, O
" O
" O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
, O
" O
and O
terms O
related O
to O
anxiety B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
. O

Inclusion O
criteria O
were O
human O
randomized O
controlled O
trials O
with O
a O
treatment O
arm O
that O
included O
WS O
as O
a O
remedy O
for O
anxiety B-Symptom_WorkedFor
or O
stress B-Symptom_WorkedFor
. O

The O
study O
team O
members O
applied O
inclusion O
criteria O
while O
screening O
the O
records O
by O
abstract O
review O
. O

Intervention O
: O
Treatment O
with O
any O
regimen O
of O
WS O
. O

Outcome O
measures O
: O
Number O
and O
results O
of O
studies O
identified O
in O
the O
review O
. O

Results O
: O
Sixty-two O
abstracts O
were O
screened O
; O
five O
human O
trials O
met O
inclusion O
criteria O
. O

Three O
studies O
compared O
several O
dosage O
levels O
of O
WS O
extract O
with O
placebos O
using O
versions O
of O
the O
Hamilton B-Metric
Anxiety I-Metric
Scale I-Metric
, O
with O
two O
demonstrating O
significant O
benefit O
of O
WS O
versus O
placebo O
, O
and O
the O
third O
demonstrating O
beneficial O
effects O
that O
approached O
but O
did O
not O
achieve O
significance O
( O
p O
= O
0.05 O
) O
. O

A O
fourth O
study O
compared O
naturopathic O
care O
with O
WS O
versus O
psychotherapy O
by O
using O
Beck B-Metric
Anxiety I-Metric
Inventory I-Metric
( O
BAI O
) O
scores O
as O
an O
outcome O
; O
BAI O
scores O
decreased O
by O
56.5% O
in O
the O
WS O
group O
and O
decreased O
30.5% O
for O
psychotherapy O
( O
p O
< O
0.0001 O
) O
. O

A O
fifth O
study O
measured O
changes O
in O
Perceived B-Metric
Stress I-Metric
Scale I-Metric
( O
PSS O
) O
scores O
in O
WS O
group O
versus O
placebo O
; O
there O
was O
a O
44.0% O
reduction O
in O
PSS O
scores O
in O
the O
WS O
group O
and O
a O
5.5% O
reduction O
in O
the O
placebo O
group O
( O
p O
< O
0.0001 O
) O
. O

All O
studies O
exhibited O
unclear O
or O
high O
risk O
of O
bias O
, O
and O
heterogenous O
design O
and O
reporting O
prevented O
the O
possibility O
of O
meta-analysis O
. O

Conclusions O
: O
All O
five O
studies O
concluded O
that O
WS O
intervention O
resulted O
in O
greater O
score O
improvements O
( O
significantly O
in O
most O
cases O
) O
than O
placebo O
in O
outcomes O
on O
anxiety B-Symptom_WorkedFor
or O
stress B-Symptom_WorkedFor
scales O
. O

Current O
evidence O
should O
be O
received O
with O
caution O
because O
of O
an O
assortment O
of O
study O
methods O
and O
cases O
of O
potential O
bias O
. O

Ethnopharmacological O
relevance O
: O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( O
L O
. O
) O

Dunal O
, O
commonly O
known O
as O
Ashwagandha B-Medicinal food
, O
is O
an O
important O
medicinal O
plant O
that O
has O
been O
used O
in O
Ayurvedic O
and O
indigenous O
medicine O
for O
more O
than O
3000 O
years O
. O

According O
to O
Charaka O
Samhita O
, O
Susruta O
Samhita O
and O
other O
ancient O
texts O
, O
Ashwagandha B-Medicinal food
is O
known O
as O
Balya O
( O
increases O
strength O
) O
, O
Brusya O
( O
sexual O
performance O
enhancer O
) O
, O
vajikari O
( O
spermatogenic O
) O
, O
Kamarupini O
( O
libido-enhancing O
) O
, O
Pustida O
( O
nourishing O
) O
. O

Aim O
of O
the O
review O
: O
This O
review O
article O
documented O
and O
critically O
assessed O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
regarding O
its O
ethnopharmacology O
, O
traditional O
use O
, O
botanical O
description O
, O
phytochemicals O
present O
, O
pharmacological O
activities O
, O
clinical O
trials O
, O
and O
marketed O
formulations O
. O

Materials O
and O
methods O
: O
The O
sources O
of O
information O
used O
in O
the O
study O
are O
traditional O
Ayurvedic O
books O
like O
Charaka O
Samhita O
, O
Susruta O
Samhita O
, O
Astanga O
Hridaya O
etc O
, O
government O
reports O
, O
dissertations O
, O
books O
, O
research O
articles O
and O
databases O
like O
Science-Direct O
, O
SciFinder O
, O
Web O
of O
Science O
, O
PubMed O
, O
Wiley O
Online O
Library O
, O
and O
ACS O
Publications O
on O
Ashwagandha B-Medicinal food
and O
Withania B-Drug/Scientific name
somnifera I-Drug/Scientific name
( I-Drug/Scientific name
L I-Drug/Scientific name
. O
) O

Dunal O
. O

Results O
: O
Traditional O
uses O
of O
Ashwagandha B-Medicinal food
in O
Ayurveda O
are O
very O
prominent O
in O
several O
texts O
where O
formulations O
with O
various O
dosage O
forms O
have O
been O
mentioned O
in O
Charaka O
Samhita O
, O
Susruta O
Samhita O
, O
Astanga O
Hridaya O
, O
different O
nighantus O
etc O
. O

The O
drugs O
were O
identified O
based O
on O
their O
composition O
containing O
Ashwagandha B-Medicinal food
as O
one O
of O
the O
major O
ingredients O
and O
their O
medicinal O
uses O
. O

Phytochemical O
studies O
on O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
revealed O
the O
presence O
of O
important O
chemical O
constituents O
such O
as O
flavonoids O
, O
phenolic O
acids O
, O
alkaloids O
, O
saponins O
, O
tannins O
, O
and O
withanolides O
. O

The O
phytochemicals O
showed O
various O
pharmacological O
activities O
like O
anti-cancer O
, O
immunomodulatory O
, O
cardioprotective O
, O
neuroprotective O
, O
anti-aging O
, O
anti-stress O
/ O
adaptogenic O
and O
anti-diabetic O
. O

Various O
clinical O
trials O
show O
that O
the O
plant O
extract O
and O
its O
bioactive O
compounds O
are O
used O
in O
the O
prevention O
and O
treatment O
of O
many O
diseases O
, O
such O
as O
arthritis B-Symptom_WorkedFor
, O
impotence B-Symptom_WorkedFor
, O
amnesia B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
cancer B-Symptom_WorkedFor
, O
neurodegenerative B-Symptom_WorkedFor
and I-Symptom_WorkedFor
cardiovascular I-Symptom_WorkedFor
diseases I-Symptom_WorkedFor
, O
and O
others O
. O

Conclusions O
: O
Pharmacological O
data O
reviewed O
here O
revealed O
that O
W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
is O
a O
potential O
source O
for O
the O
treatment O
of O
a O
wide O
range O
of O
diseases O
especially O
anxiety B-Symptom_WorkedFor
and O
other O
CNS O
disorders O
. O

From O
its O
ancient O
use O
to O
its O
modern O
application O
it O
has O
been O
proven O
to O
be O
non-toxic O
and O
effective O
clinically O
for O
human O
health O
and O
wellness O
. O

W B-Drug/Scientific name
. I-Drug/Scientific name
somnifera I-Drug/Scientific name
based O
herbal O
formulation O
has O
been O
marketed O
in O
the O
form O
of O
supplement O
, O
extract O
, O
capsule O
, O
powder O
etc O
. O

This O
review O
will O
be O
helpful O
to O
correlate O
the O
mechanism O
of O
action O
with O
the O
phytochemical O
profile O
of O
this O
well-known O
plant O
from O
Ayurveda O
. O

Perment B-Medicinal food
, O
a O
polyherbal O
Ayurvedic O
formulation O
that O
contains O
equal O
parts O
of O
Clitoria B-Medicinal food
ternatea I-Medicinal food
Linn I-Medicinal food
. O
, O
Withania B-Medicinal food
somnifera I-Medicinal food
Dun I-Medicinal food
. O
, O
Asparagus B-Medicinal food
racemosus I-Medicinal food
Linn I-Medicinal food
. I-Medicinal food
, O
Bacopa B-Medicinal food
monniera I-Medicinal food
Linn I-Medicinal food
. I-Medicinal food
, O
is O
used O
clinically O
as O
mood O
elevators O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
explore O
the O
behavioural O
effects O
and O
to O
understand O
possible O
mode O
of O
action O
of O
Perment B-Medicinal food
in O
stress O
induced O
depressive B-Symptom_WorkedFor
model O
. O

Chronic O
unpredictable O
mild O
stress O
( O
CUMS O
) O
was O
used O
to O
induce O
depression O
in O
rats O
. O

Open O
field O
exploratory O
behaviour O
, O
elevated O
plus O
maze O
, O
social O
interaction O
and O
behavioural O
despair O
tests O
were O
used O
to O
assess O
behaviour O
. O

Using O
standard O
protocols O
plasma O
noradrenaline O
, O
serotonin O
, O
corticosterone O
and O
brain O
/ O
adrenal O
corticosterone O
levels O
were O
measured O
to O
support O
the O
behavioural O
effects O
of O
Perment B-Medicinal food
. O

Exposure O
to O
CUMS O
for O
21 O
days O
caused O
anxiety O
and O
depression O
in O
rats O
, O
as O
indicated O
by O
significant O
decrease O
in O
locomotor O
activity O
in O
the O
open O
field O
exploratory O
behaviour O
test O
and O
increased O
immobility O
period O
in O
the O
behavioural O
despair O
test O
. O

Perment B-Medicinal food
predominantly O
exhibited O
antidepressant B-Symptom_WorkedFor
action O
than O
anxiolytic B-Symptom_TestedFor
activity O
. O

Further O
Perment B-Medicinal food
increased O
the O
plasma O
noradrenaline O
and O
serotonin O
levels O
in O
stressed O
rats O
. O

No O
significant O
alteration O
in O
the O
brain O
corticosterone O
level O
in O
stressed O
rats O
was O
observed O
with O
Perment B-Medicinal food
treatment O
. O

However O
the O
adrenal O
corticosterone O
level O
is O
decreased O
with O
Perment B-Medicinal food
. O

It O
can O
be O
concluded O
that O
the O
Perment O
formulation O
exhibited O
synergistic O
activity O
, O
has O
a O
significant O
antidepressant B-Symptom_WorkedFor
and O
anxiolytic B-Symptom_TestedFor
activity O
, O
which O
may O
be O
mediated O
through O
adrenergic O
and O
serotonergic O
system O
activation O
. O

Currently O
the O
formulation O
is O
clinically O
used O
as O
anxiolytic B-Symptom_TestedFor
but O
the O
present O
results O
suggest O
that O
the O
formulation O
can O
also O
be O
indicated O
in O
patients O
affected O
with O
depression B-Symptom_WorkedFor
. O

Sleep B-Symptom_WorkedFor
is O
a O
profound O
regulator O
of O
cellular O
immunity O
, O
and O
the O
curtailment O
of O
sleep B-Symptom_WorkedFor
in O
present O
day O
lifestyle O
leads O
to O
disruption O
of O
neuro-immune-endocrine O
interactions O
. O

No O
therapeutic O
remedy O
is O
yet O
known O
for O
the O
amelioration O
of O
detrimental O
effects O
caused O
by O
sleep B-Symptom_WorkedFor
deprivation I-Symptom_WorkedFor
( O
SD O
) O
. O

The O
current O
study O
was O
aimed O
to O
elucidate O
the O
effects O
of O
acute O
SD O
on O
immune O
function O
and O
its O
modulation O
by O
water O
extract O
from O
leaves O
of O
Withania B-Medicinal food
somnifera I-Medicinal food
( O
ASH-WEX O
) O
. O

Three O
groups O
of O
animals O
, O
i.e O
. O

Vehicle-Undisturbed O
sleep O
( O
VUD O
) O
, O
Vehicle-Sleep O
deprived O
( O
VSD O
) O
and O
ASH-WEX O
fed O
sleep O
deprived O
( O
WSD O
) O
rats O
were O
tested O
for O
their O
anxiety-like B-Symptom_WorkedFor
behaviour O
and O
further O
used O
for O
the O
study O
of O
inflammatory O
and O
apoptotic O
markers O
expression O
in O
piriform O
cortex O
and O
hippocampus O
regions O
of O
the O
brain O
. O

VSD O
animals O
showed O
high O
level O
of O
anxiety B-Symptom_WorkedFor
in O
elevated O
plus O
maze O
test O
, O
which O
was O
ameliorated O
in O
WSD O
group O
. O

The O
stress O
induced O
expression O
of O
inflammatory O
and O
immune O
response O
markers O
GFAP O
, O
TNFα O
, O
IL O
- O
6 O
, O
OX O
- O
18 O
and O
OX O
- O
42 O
in O
VSD O
animals O
was O
found O
to O
be O
modulated O
by O
ASH-WEX O
. O

Further O
, O
the O
stress O
induced O
apoptosis O
was O
suppressed O
in O
WSD O
group O
as O
indicated O
by O
expression O
of O
NF-κB O
, O
AP O
- O
1 O
, O
Bcl-xL O
and O
Cytochrome O
c O
. O

This O
study O
provides O
scientific O
validation O
to O
the O
anxiolytic O
, O
anti-inflammatory O
and O
anti-apoptotic O
properties O
of O
ASH-WEX O
, O
which O
may O
serve O
as O
an O
effective O
dietary O
supplement O
for O
management O
of O
SD O
induced O
stress B-Symptom_WorkedFor
and O
associated O
functional O
impairments O
. O

Bacopa B-Medicinal food
monnieri I-Medicinal food
, O
commonly O
known O
as O
Brahmi B-Medicinal food
, O
has O
been O
extensively O
used O
as O
a O
neuromedicine O
for O
various O
disorders O
such O
as O
anxiety B-Symptom_WorkedFor
, O
depression B-Symptom_WorkedFor
and O
memory B-Symptom_WorkedFor
loss I-Symptom_WorkedFor
. O

Chemical O
characterization O
studies O
revealed O
the O
major O
active O
constituents O
of O
the O
herb O
as O
the O
triterpenoid O
saponins O
, O
bacosides O
. O

Bacoside O
A O
, O
the O
vital O
neuroprotective B-Symptom_WorkedFor
constituent O
, O
is O
composed O
of O
four O
constituents O
viz O
. O
, O
bacoside O
A3 O
, O
bacopaside O
II O
, O
jujubogenin O
isomer O
of O
bacopasaponin O
C O
( O
bacopaside O
X O
) O
and O
bacopasaponin O
C O
. O

B B-Medicinal food
. I-Medicinal food
monnieri I-Medicinal food
extracts O
as O
well O
as O
bacosides O
successfully O
establish O
a O
healthy O
antioxidant O
environment O
in O
various O
tissues O
especially O
in O
the O
liver O
and O
brain O
. O

Free O
radical O
scavenging O
, O
suppression O
of O
lipid O
peroxidation O
and O
activation O
of O
antioxidant O
enzymes O
by O
bacosides O
help O
to O
attain O
a O
physiological O
state O
of O
minimized O
oxidative O
stress O
. O

The O
molecular O
basis O
of O
neuroprotective O
activity O
of O
bacosides O
is O
attributed O
to O
the O
regulation O
of O
mRNA O
translation O
and O
surface O
expression O
of O
neuroreceptors O
such O
as O
AMPAR O
, O
NMDAR O
and O
GABAR O
in O
the O
various O
parts O
of O
the O
brain O
. O

Bioavailability O
as O
well O
as O
binding O
of O
neuroprotective O
agents O
( O
such O
as O
bacosides O
) O
to O
these O
receptors O
is O
controlled O
by O
the O
Blood O
Brain O
Barrier O
( O
BBB O
) O
. O

However O
, O
nano O
conversion O
of O
these O
drug O
candidates O
easily O
resolves O
the O
BBB O
restriction O
and O
carries O
a O
promising O
role O
in O
future O
therapies O
. O

This O
review O
summarizes O
the O
neuroprotective B-Symptom_WorkedFor
functions O
of O
B B-Medicinal food
. I-Medicinal food
monnieri I-Medicinal food
extracts O
as O
well O
as O
its O
active O
compounds O
( O
bacoside O
A O
, O
bacopaside O
I O
) O
and O
the O
molecular O
mechanisms O
responsible O
for O
these O
pharmacological O
activities O
. O

Anxiety O
disorders O
are O
one O
of O
the O
most O
common O
mental O
disorders O
, O
and O
benzodiazepines B-Other_ingredients
( O
BDZs O
) O
, O
acting O
on O
gamma-aminobutyric O
acid O
type O
A O
( O
GABA-A O
) O
receptor O
complex O
, O
represent O
the O
most O
common O
antianxiety O
medications O
in O
the O
world O
. O

However O
, O
chronic O
BDZ O
use O
elicits O
several O
adverse O
reactions O
. O

Reportedly O
, O
aromatherapy O
is O
safer O
for O
the O
management O
of O
anxiety B-Symptom_WorkedFor
. O

Bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
extracted O
from O
Citrus B-Drug/Scientific name
bergamia I-Drug/Scientific name
Risso I-Drug/Scientific name
et I-Drug/Scientific name
Poiteau I-Drug/Scientific name
fruit O
, O
like O
other O
essential O
oils O
, O
is O
widely O
used O
in O
aromatherapy O
to O
relieve O
symptoms O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

Interestingly O
, O
preclinical O
data O
indicate O
that O
BEO O
induces O
anxiolytic-like O
/ O
relaxant O
effects O
in O
animal O
behavioural O
tasks O
not O
superimposable O
to O
those O
of O
benzodiazepine B-Other_ingredients
diazepam I-Other_ingredients
. O

To O
better O
elucidate O
the O
involvement O
of O
GABAergic O
transmission O
, O
the O
present O
study O
examines O
the O
effects O
of O
pretreatment O
with O
flumazenil O
( O
FLZ O
) O
, O
a O
benzodiazepine O
site O
antagonist O
, O
on O
BEO O
effects O
using O
open-field O
task O
( O
OFT O
) O
in O
rats O
. O

The O
data O
yielded O
show O
that O
FLZ O
does O
not O
significantly O
affect O
behavioural O
effects O
of O
the O
phytocomplex O
. O

These O
results O
demonstrate O
the O
lack O
of O
overlapping O
between O
BEO O
and O
BDZ O
behavioural O
effects O
, O
contributing O
to O
the O
characterization O
of O
the O
neurobiological O
profile O
of O
the O
essential O
oil O
for O
its O
rational O
use O
in O
aromatherapy O
. O

The O
essential O
oil O
obtained O
by O
the O
fresh O
fruit O
of O
Citrus B-Drug/Scientific name
bergamia I-Drug/Scientific name
Risso I-Drug/Scientific name
et I-Drug/Scientific name
Poiteau I-Drug/Scientific name
is O
used O
worldwide O
in O
aromatherapy O
to O
reduce O
pain B-Symptom_WorkedFor
, O
facilitate O
sleep O
induction O
, O
and O
/ O
or O
minimize O
the O
effects O
of O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

Preclinical O
pharmacological O
data O
demonstrate O
that O
bergamot B-Medicinal food
essential O
oil O
( O
BEO O
) O
modulates O
specific O
neurotransmissions O
and O
shows O
an O
anxiolytic-relaxant O
effect O
not O
superimposable O
to O
that O
of O
the O
benzodiazepine B-Other_ingredients
diazepam I-Other_ingredients
, O
suggesting O
that O
neurotransmissions O
, O
other O
than O
GABAergic O
, O
could O
be O
involved O
. O

Several O
studies O
on O
essential O
oils O
indicate O
a O
role O
for O
serotonergic O
( O
5 O
- O
HT O
) O
neurotransmission O
in O
anxiety B-Symptom_WorkedFor
. O

Interestingly O
, O
among O
serotonergic O
receptors O
, O
the O
5 O
- O
HT1A O
subtype O
seems O
to O
play O
a O
key O
role O
in O
the O
control O
of O
anxiety B-Symptom_WorkedFor
. O

Here O
, O
we O
report O
that O
modulation O
of O
the O
5 O
- O
HT1A O
receptor O
by O
selective O
agonist O
( O
( O
± O
) O
8 O
- O
OH-DPAT O
) O
or O
antagonist O
( O
WAY O
- O
100635 O
) O
may O
influence O
some O
of O
the O
anxiolytic-relaxant O
effects O
of O
BEO O
in O
Open O
Field O
and O
Elevated O
Plus O
Maze O
tests O
. O

Objectives O
: O
Dysfunctions O
in O
stress O
biology O
are O
hypothesized O
to O
contribute O
to O
anxiety B-Symptom_WorkedFor
disorders O
, O
and O
to O
be O
ameliorated O
during O
successful O
treatment O
, O
but O
limited O
clinical O
data O
exist O
to O
support O
this O
hypothesis O
. O

We O
evaluated O
whether O
increases O
in O
morning O
cortisol O
and O
the O
diurnal O
cortisol O
slope O
, O
markers O
of O
stress O
biology O
, O
are O
associated O
with O
clinical O
response O
to O
chamomile O
therapy O
among O
subjects O
with O
generalized B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
( O
GAD B-Symptom_WorkedFor
) O
. O

Methods O
: O
Among O
45 B-#Participants
subjects O
with O
DSM-IV O
diagnosed O
GAD B-Symptom_WorkedFor
in O
an O
open-label O
clinical O
trial O
of O
chamomile B-Medicinal food
, O
salivary O
cortisol O
was O
assessed O
for O
three O
days O
each O
pre O
- O
and O
post-treatment O
, O
at O
8am O
, O
12pm O
, O
4pm O
, O
and O
8pm O
. O

Mixed O
model O
analyses O
assessed O
whether O
GAD B-Symptom_WorkedFor
symptom O
change O
predicted O
the O
degree O
to O
which O
cortisol O
levels O
changed O
during O
treatment O
. O

Results O
: O
Symptom O
improvement O
during O
treatment O
was O
significantly O
associated O
with O
pre-to-post O
treatment O
changes O
in O
cortisol O
. O

Subjects O
who O
experienced O
more O
symptomatic O
improvement O
experienced O
significant O
increases O
in O
their O
morning O
salivary O
cortisol O
( O
β O
= O
0.48 O
, O
p O
< O
0.001 O
) O
, O
and O
a O
greater O
decrease O
in O
cortisol O
from O
morning O
to O
the O
rest O
of O
the O
day O
( O
β O
= O
0.55 O
, O
p O
< O
0.001 O
) O
. O

In O
addition O
, O
at O
baseline O
a O
lower O
cortisol O
level O
( O
β O
= O
- O
0.24 O
, O
p O
= O
0.023 O
) O
and O
a O
lesser O
decrease O
in O
cortisol O
after O
morning O
( O
β O
= O
0.30 O
, O
p O
= O
0.003 O
) O
were O
associated O
with O
greater O
symptomatic O
improvement O
. O

Conclusion O
: O
Increases O
in O
morning O
salivary O
cortisol O
and O
the O
diurnal O
cortisol O
slope O
are O
associated O
with O
symptom O
improvement O
in O
chamomile B-Medicinal food
treatment O
of O
GAD B-Symptom_WorkedFor
. O

Response O
to O
treatment O
for O
GAD B-Symptom_WorkedFor
could O
partially O
stem O
from O
normalization O
of O
stress O
biology O
dysfunction O
, O
but O
further O
work O
involving O
establishing O
abnormalities O
within-sample O
, O
ruling O
out O
of O
confounds O
( O
e.g O
. O
, O
sleep O
) O
, O
and O
a O
placebo O
control O
is O
necessary O
to O
conclude O
an O
amelioration O
effect O
. O

Registration O
code O
: O
NCT01072344 O
. O

URL O
: O
https O
: O
/ O
/ O
clinicaltrials.gov O
/ O
ct2 O
/ O
show O
/ O
NCT01072344 O
. O

Background O
and O
objectives O
: O
Although O
perfectionism O
has O
been O
proposed O
to O
be O
a O
risk O
factor O
for O
the O
development O
of O
anxiety O
, O
research O
on O
perfectionism O
and O
anxiety B-Symptom_WorkedFor
symptoms O
in O
adolescents O
is O
scarce O
and O
inconclusive O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
two O
higher-order O
dimensions O
of O
perfectionism O
- O
perfectionistic O
strivings O
and O
perfectionistic O
concerns O
- O
predict O
the O
development O
and O
maintenance O
of O
anxiety B-Symptom_WorkedFor
symptoms O
. O

An O
additional O
aim O
of O
the O
present O
study O
was O
to O
examine O
potential O
reciprocal O
effects O
of O
anxiety B-Symptom_WorkedFor
symptoms O
predicting O
increases O
in O
perfectionism O
. O

Design O
: O
The O
study O
used O
a O
longitudinal O
design O
with O
three B-Duration
waves I-Duration
spaced I-Duration
4 I-Duration
- I-Duration
5 I-Duration
months I-Duration
apart I-Duration
. O

Methods O
: O
A O
non-clinical O
sample O
of O
489 B-#Participants
adolescents O
aged O
12 O
- O
19 O
years O
completed O
a O
paper-and-pencil O
questionnaire O
. O

Results O
: O
As O
expected O
, O
results O
showed O
a O
positive O
effect O
from O
perfectionistic O
concerns O
to O
anxiety O
symptoms O
, O
but O
the O
effect O
was O
restricted O
to O
middle-to-late O
adolescents O
( O
16 O
- O
19 O
years O
old O
) O
: O
Perfectionistic O
concerns O
predicted O
longitudinal O
increases O
in O
adolescents O
' O
anxiety O
symptoms O
, O
whereas O
perfectionistic O
strivings O
did O
not O
. O

Furthermore O
, O
anxiety O
symptoms O
did O
not O
predict O
increases O
in O
perfectionism O
. O

Conclusions O
: O
Implications O
for O
the O
understanding O
of O
the O
relationship O
between O
perfectionism O
and O
anxiety O
symptoms O
are O
discussed O
. O

Mothers O
with O
an O
infant O
in O
the O
neonatal O
intensive O
care O
unit O
( O
NICU O
) O
are O
at O
risk O
for O
depression B-Symptom_WorkedFor
, O
anxiety B-Symptom_WorkedFor
, O
and O
trauma B-Symptom_WorkedFor
symptoms O
, O
with O
negative O
implications O
for O
maternal-infant O
bonding O
, O
maternal O
well-being O
, O
and O
infant O
development O
. O

Few O
interventions O
to O
promote O
NICU O
mothers O
' O
mental O
health O
, O
however O
, O
have O
been O
developed O
or O
tested O
. O

This O
pre-post O
pilot O
study O
assessed O
feasibility O
, O
acceptability O
, O
and O
preliminary O
outcomes O
of O
a O
mindfulness O
intervention O
for O
NICU O
mothers O
. O

Twenty-seven B-#Participants
mothers O
were O
recruited O
from O
a O
university O
NICU O
and O
offered O
a O
mindfulness O
intervention O
via O
introductory O
video O
and O
audio-recorded O
practices O
. O

Participants O
completed O
a O
baseline O
self-report O
survey O
. O

After O
2 O
weeks O
of O
engaging O
with O
intervention O
materials O
, O
participants O
completed O
a O
second O
survey O
and O
in-depth O
interview O
. O

Quantitative O
data O
were O
analyzed O
using O
paired O
t O
tests O
; O
qualitative O
data O
were O
analyzed O
using O
thematic O
coding O
. O

Twenty-four O
women O
( O
89% O
) O
completed O
the O
study O
. O

Quantitative O
data O
indicated O
significant O
improvements O
in O
depressive O
, O
anxiety O
, O
and O
trauma O
symptoms O
, O
negative O
coping O
, O
NICU-related O
stress O
, O
and O
sleep O
( O
p O
< O
0.05 O
) O
. O

Qualitative O
data O
identified O
themes O
of O
perceived O
improvements O
in O
psychological O
distress B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
symptoms O
, O
self-care O
, O
and O
relationships O
. O

Findings O
support O
the O
mindfulness O
intervention's O
feasibility O
, O
acceptability O
, O
and O
potential O
promise O
for O
reducing O
maternal O
distress O
and O
promoting O
well-being O
. O

Use O
of O
video O
and O
audio O
modalities O
may O
facilitate O
program O
sustainability O
and O
scale O
up O
. O

Further O
research O
on O
the O
program O
is O
merited O
. O

Euthanasia O
of O
unwanted O
or O
sick O
animals O
should O
always O
be O
done O
in O
a O
humane O
manner O
. O

This O
study O
involving O
two O
groups O
of O
12 O
dogs O
evaluated O
a O
two O
step O
method O
of O
euthanasia O
using O
first O
acepromazine O
or O
pentazocine O
then O
inhalation O
of O
carbon B-Medicinal food
monoxide I-Medicinal food
. O

During O
the O
experiment O
, O
behavioral O
reactions O
( O
anxiety B-Symptom_WorkedFor
, O
agitation B-Symptom_WorkedFor
, O
vocalization B-Symptom_WorkedFor
and O
sphincter B-Symptom_WorkedFor
relaxation I-Symptom_WorkedFor
) O
and O
physiological B-Metric
parameters I-Metric
( O
electro-encephalogram O
, O
electrocardiogram O
, O
arterial O
blood O
pressure O
, O
respiratory O
and O
heart O
rates O
and O
serum O
cortisol O
) O
were O
monitored O
. O

The O
results O
showed O
that O
both O
drugs O
modified O
many O
behavioral O
reactions O
and O
physiological O
changes O
associated O
with O
administration O
of O
carbon B-Medicinal food
monoxide I-Medicinal food
. O

Acepromazine B-Other_ingredients
and O
pentazocine B-Other_ingredients
reduced O
by O
25% O
and O
20% O
respectively O
the O
number O
of O
dogs O
that O
showed O
vocalization O
and O
agitation O
. O

In O
acepromazine B-Other_ingredients
premedicated O
dogs O
, O
the O
duration O
of O
these O
signs O
was O
significantly O
diminished O
and O
sphincter O
relaxation O
did O
not O
occur O
in O
more O
than O
50% O
of O
cases O
. O

Furthermore O
, O
with O
the O
use O
of O
acepromazine B-Other_ingredients
, O
no O
significant O
peaks O
or O
drastic O
drops O
were O
noticed O
in O
the O
heart O
and O
respiratory O
rates O
and O
in O
the O
arterial O
blood O
pressure O
. O

These O
manifestations O
are O
usually O
related O
to O
stress B-Symptom_WorkedFor
. O

In O
light O
of O
these O
results O
, O
it O
is O
recommended O
to O
premedicate O
dogs O
with O
acepromazine B-Other_ingredients
before O
submitting O
them O
to O
euthanasia O
by O
carbon B-Medicinal food
monoxide I-Medicinal food
inhalation O
. O

Folate B-Medicinal food
deficiency O
has O
been O
linked O
to O
neurodegenerative O
and O
stress-related B-Symptom_TestedFor
diseases O
such O
as O
stroke B-Symptom_TestedFor
, O
dementia B-Symptom_TestedFor
and O
depression B-Symptom_TestedFor
. O

The O
role O
of O
the O
neurotrophins O
nerve O
growth O
factor O
( O
NGF O
) O
and O
neurotrophin O
- O
3 O
( O
NT O
- O
3 O
) O
in O
stress-related O
disorders O
and O
neurodegeneration O
has O
garnered O
increasing O
attention O
in O
recent O
years O
. O

Uracil O
misincorporation O
is O
involved O
in O
the O
neuropsychiatric O
dysfunction O
induced O
by O
experimental O
folate B-Medicinal food
deprivation O
. O

However O
, O
the O
effects O
of O
folate O
deficiency O
on O
the O
expression O
of O
NGF O
and O
NT O
- O
3 O
in O
brain O
tissue O
have O
not O
yet O
been O
investigated O
. O

In O
a O
2 O
× O
2 O
design O
, O
aged O
mice O
lacking O
uracil-DNA O
N-glycosylase O
( O
Ung O
( O
- O
/ O
- O
) O
) O
versus O
wild-type O
( O
Ung O
( O
+ O
/ O
+ O
) O
) O
controls O
were O
subjected O
to O
a O
folate-deficient O
diet O
versus O
a O
regular O
diet O
for O
three B-Duration
months I-Duration
. O

Independent O
of O
genotype O
, O
folate O
deficiency O
led O
to O
decreased O
NGF O
protein O
levels O
in O
the O
frontal O
cortex O
and O
amygdala O
. O

In O
the O
hippocampus O
, O
NGF O
levels O
were O
increased O
in O
UNG O
( O
- O
/ O
- O
) O
mice O
on O
the O
normal O
diet O
, O
but O
not O
under O
folate B-Medicinal food
deficiency O
, O
while O
in O
UNG O
( O
+ O
/ O
+ O
) O
mice B-Medicinal food
, O
folate O
deprivation O
did O
not O
affect O
hippocampal O
NGF O
content O
. O

NT O
- O
3 O
protein O
concentrations O
were O
neither O
affected O
by O
genotype O
nor O
by O
folate B-Medicinal food
deficiency O
. O

Altogether O
, O
the O
results O
of O
our O
study O
show O
that O
folate O
deficiency O
affects O
NGF O
levels O
in O
the O
frontal O
cortex O
, O
amygdala O
and O
hippocampus O
. O

The O
decrease O
in O
NGF O
content O
in O
the O
hippocampus O
in O
response O
to O
folate B-Medicinal food
deficiency O
in O
Ung O
( O
- O
/ O
- O
) O
mice O
may O
contribute O
to O
their O
phenotype O
of O
enhanced O
anxiety B-Symptom_WorkedFor
and O
despair-like B-Symptom_WorkedFor
behavior I-Symptom_WorkedFor
as O
well O
as O
to O
selective O
hippocampal O
neurodegeneration O
. O

Subfertility O
affects O
one O
in O
seven O
couples O
in O
the O
United O
Kingdom O
and O
is O
associated O
with O
considerable O
patient O
stress B-Symptom_TestedFor
and O
anxiety B-Symptom_TestedFor
. O

The O
RCOG O
, O
with O
the O
publication O
of O
the O
evidence-based O
guidelines O
, O
gives O
us O
clear O
recommendations O
on O
the O
initial O
investigation O
of O
the O
infertile O
couple O
. O

Against O
these O
guidelines O
we O
audited O
patient O
care O
over O
a O
period O
of O
5 B-Duration
months I-Duration
in O
a O
dedicated O
consultant-led O
infertility O
clinic O
. O

Our O
results O
show O
that O
a O
considerable O
number O
of O
patients O
failed O
to O
have O
the O
correct O
advice O
clearly O
documented O
, O
and O
the O
initial O
primary O
care O
investigations O
of O
mid-luteal O
progesterone O
and O
semen O
analysis O
were O
performed O
correctly O
with O
results O
available O
in O
only O
33% O
and O
2% O
of O
occasions O
, O
respectively O
. O

There O
were O
, O
however O
, O
areas O
where O
the O
guidelines O
were O
adhered O
to O
very O
efficiently O
. O

To O
improve O
care O
we O
recommend O
the O
use O
of O
an O
infertility O
referral O
form O
for O
use O
in O
primary O
care O
upon O
which O
the O
practitioners O
can O
fill O
in O
the O
appropriate O
details O
and O
be O
guided O
on O
the O
necessary O
investigations O
. O

Depression B-Symptom_WorkedFor
, O
a O
mental O
illness O
characterized O
by O
persistent O
feeling O
of O
sadness O
and O
loss O
of O
interest O
, O
has O
been O
a O
serious O
health O
problem O
worldwide O
. O

Manipulation O
of O
the O
microbiota O
by O
probiotics O
and O
prebiotics O
represents O
a O
novel O
emerging O
strategy O
for O
the O
treatment O
of O
various O
psychiatric O
disorders O
such O
as O
major O
depressive B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

Here O
, O
we O
show O
that O
one O
water-soluble O
polysaccharide O
from O
Ginkgo B-Medicinal food
biloba I-Medicinal food
leaves O
( O
GPS O
) O
reduced O
stress-induced B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
and O
reversed O
gut O
dysbiosis O
. O

Similar O
to O
the O
antidepressant O
paroxetine O
, O
GPS B-Medicinal food
significantly O
reduced O
the O
immobility O
times O
in O
the O
tail O
suspension O
test O
( O
TST O
) O
and O
forced O
swimming O
test O
( O
FST O
) O
and O
anxiety-like O
behavior O
in O
the O
open O
field O
test O
( O
OFT O
) O
. O

Consistent O
with O
the O
improvement O
of O
depression-like O
behavior O
above O
, O
GPS B-Medicinal food
mice O
had O
elevated O
serotonin O
and O
dopamine O
levels O
in O
multiple O
brain O
regions O
including O
the O
hippocampus O
, O
cerebral O
cortex O
and O
olfactory O
bulb O
, O
relative O
to O
unpredictable O
chronic O
mild O
stress B-Symptom_WorkedFor
( O
UCMS O
) O
treatment O
mice O
. O

GPS O
treatment O
could O
alleviate O
the O
stress-induced O
reduction O
in O
the O
density O
of O
serotonin-positive O
and O
dopamine-positive O
cells O
. O

Fecal O
microbiome O
transplant O
( O
FMT O
) O
combined O
with O
antibiotic O
treatment O
showed O
that O
the O
anti-depressant O
activity O
of O
GPS O
had O
a O
causal O
relationship O
with O
intestinal O
microbes O
. O

By O
performing O
a O
pyrosequencing-based O
analysis O
of O
bacterial O
16S O
rRNA O
( O
V3 O
+ O
V4 O
region O
) O
in O
fecal O
of O
the O
mice O
, O
the O
results O
showed O
that O
GPS O
reversed O
depression-associated O
gut O
dysbiosis O
and O
increased O
the O
richness O
of O
Lactobacillus O
species O
which O
has O
been O
proven O
to O
be O
a O
path O
to O
relieve O
depression B-Symptom_WorkedFor
. O

Our O
results O
demonstrated O
that O
the O
polysaccharide B-Drug/Scientific name
from O
Ginkgo B-Medicinal food
biloba I-Medicinal food
leaves O
might O
be O
a O
promising O
pharmacotherapeutic O
candidate O
for O
treating O
depression B-Symptom_WorkedFor
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety B-Symptom_WorkedFor
and O
specific O
anxiety B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based O
anxiolytics O
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based O
medicines O
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic O
activity O
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal O
medicines O
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic O
activity O
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic O
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety O
disorders O
in O
human O
clinical O
trials O
: O
Piper O
methysticum O
, O
Matricaria O
recutita O
, O
Ginkgo O
biloba O
, O
Scutellaria O
lateriflora O
, O
Silybum O
marianum O
, O
Passiflora O
incarnata O
, O
Withania O
somniferum O
, O
Galphimia O
glauca O
, O
Centella O
asiatica O
, O
Rhodiola O
rosea O
, O
Echinacea O
spp O
. O
, O
Melissa O
officinalis O
and O
Echium O
amoenum O
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum O
perforatum O
or O
Valeriana O
spp O
. O
for O
any O
anxiety O
disorder O
. O

Acute O
anxiolytic O
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa O
monnieri O
has O
shown O
anxiolytic O
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety O
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria O
viridis O
and O
Banisteriopsis O
caarti O
( O
ayahuasca O
) O
, O
Psilocybe O
spp O
. O
and O
cannabidiol-enriched O
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis O
spp O
. O

Exposure O
to O
chronic O
restraint O
stress O
in O
rats O
and O
psychosocial O
stress O
in O
humans O
has O
been O
shown O
to O
alter O
cognitive O
functions O
such O
as O
learning O
and O
memory O
and O
has O
been O
linked O
to O
the O
pathophysiology O
of O
mood O
and O
anxiety O
disorders O
. O

Antianxiety O
or O
sedative O
agents O
used O
in O
the O
management O
of O
stress O
have O
several O
disadvantages O
and O
undesired O
effects O
. O

Therefore O
, O
in O
this O
study O
, O
we O
investigated O
efficacy O
of O
a O
natural O
medicine O
, O
the O
extract O
of O
Ginkgo B-Medicinal food
biloba I-Medicinal food
( O
EGB B-Medicinal food
761 I-Medicinal food
) O
, O
in O
prevention O
and O
treatment O
of O
the O
post-stress B-Symptom_WorkedFor
memory I-Symptom_WorkedFor
dysfunctions I-Symptom_WorkedFor
. O

The O
results O
showed O
that O
chronic O
restraint O
stress O
( O
2 O
h O
for O
21 O
days O
) O
or O
an O
' O
equivalent O
' O
dose O
of O
exogenous B-Other_ingredients
corticosterone I-Other_ingredients
( O
5 B-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
) O
impaired O
nonspatial O
memory O
as O
measured O
by O
an O
object O
recognition O
test O
. O

In O
control O
rats O
, O
EGB B-Medicinal food
761 I-Medicinal food
improved O
spatial O
and O
nonspatial O
memory O
in O
Morris O
water O
maze O
and O
object O
recognition O
tests O
. O

Preventive O
doses O
of O
EGB O
761 O
( O
100 O
mg O
/ O
kg O
) O
normalized O
cognitive O
deficits O
, O
seen O
in O
rats O
chronically O
stressed O
or O
treated O
with O
corticosterone O
in O
object O
recognition O
test O
, O
and O
improved O
memory O
processes O
in O
these O
rats O
measured O
by O
Morris O
water O
maze O
test O
. O

There O
was O
no O
influence O
of O
our O
treatments O
on O
locomotor O
exploratory O
activity O
and O
anxiety O
measured O
in O
open O
field O
and O
elevated O
' O
plus O
' O
maze O
tests O
, O
making O
a O
contribution O
of O
unspecific O
motor O
and O
emotional O
effects O
of O
the O
used O
drugs O
to O
their O
performance O
in O
the O
memory O
tests O
improbable O
. O

Aims O
: O
To O
assess O
the O
effect O
of O
a O
real O
life O
mental O
stress B-Medicinal food
situation O
on O
blood O
pressure O
( O
BP O
) O
and O
heart O
rate O
( O
HR O
) O
in O
students O
undergoing O
a O
medical O
licensing O
examination O
. O

Method O
: O
Prospective O
observational O
study O
of O
121 B-#Participants
medical O
students O
taking O
the O
final O
licensing O
exam O
. O

BP O
and O
HR O
were O
taken O
before O
and O
after O
the O
exam O
. O

Additionally O
, O
BP O
was O
measured O
by O
ambulatory O
BP O
monitoring O
device O
and O
HR O
was O
recorded O
continuously O
by O
an O
HR O
monitor O
belt O
in O
25 O
students O
throughout O
the O
examination O
. O

Major O
findings O
: O
Diastolic O
BP O
( O
DBP O
) O
increased O
from O
81 O
+ O
/ O
- O
10 O
mmHg O
before O
the O
exam O
to O
86 O
+ O
/ O
- O
9 O
mmHg O
( O
p O
= O
0.008 O
) O
during O
the O
exam O
and O
to O
88 O
+ O
/ O
- O
11 O
mmHg O
, O
( O
p O
= O
0.007 O
) O
15 O
min O
after O
the O
exam O
. O

Systolic O
BP O
( O
SBP O
) O
did O
not O
increase O
significantly O
during O
( O
from O
131 O
+ O
/ O
- O
14 O
before O
the O
exam O
to O
136 O
+ O
/ O
- O
18 O
mmHg O
) O
and O
after O
the O
exam O
( O
135 O
+ O
/ O
- O
16 O
mmHg O
) O
. O

HR O
decreased O
during O
( O
to O
100 O
+ O
/ O
- O
18 O
beats O
/ O
min O
, O
p O
< O
0.001 O
) O
, O
and O
after O
the O
exam O
( O
to O
95 O
+ O
/ O
- O
19 O
beats O
/ O
min O
, O
p O
< O
0.001 O
) O
compared O
to O
values O
before O
the O
exam O
( O
114 O
+ O
/ O
- O
19 O
beats O
/ O
min O
) O
. O

SBP O
was O
higher O
in O
male O
students O
compared O
to O
female O
students O
before O
( O
138 O
+ O
/ O
- O
10 O
vs O
125 O
+ O
/ O
- O
18 O
mmHg O
) O
and O
after O
( O
126 O
+ O
/ O
- O
18 O
vs O
115 O
+ O
/ O
- O
17 O
mmHg O
) O
the O
exam O
( O
p O
< O
0.01 O
) O
. O

Conclusion O
: O
Only O
DBP O
increased O
during O
medical O
licensing O
examination O
, O
albeit O
within O
a O
small O
range O
. O

SBP O
did O
not O
change O
significantly O
and O
HR O
decreased O
during O
the O
exam O
. O

Male O
students O
showed O
a O
higher O
SBP O
compared O
to O
female O
students O
. O

Background O
: O
Due O
to O
an O
ageing O
population O
in O
Australia O
there O
has O
been O
an O
increase O
in O
the O
number O
of O
older O
adults O
with O
subjective B-participant_health
cognitive I-participant_health
impairment I-participant_health
( O
SCI B-participant_health
) O
, O
a O
self-reported O
decline O
in O
cognitive O
function O
associated O
with O
an O
increased O
risk O
of O
mild O
cognitive O
impairment O
and O
dementia O
. O

There O
is O
no O
current O
, O
recommended O
treatment O
for O
SCI O
; O
therefore O
, O
the O
effectiveness O
of O
a O
supplement O
approved O
by O
the O
Therapeutic O
Goods O
Association O
that O
has O
the O
potential O
to O
enhance O
cognitive O
function O
in O
an O
at-risk O
cohort O
should O
be O
tested O
. O

The O
primary O
aim O
of O
this O
proposed O
research O
is O
to O
determine O
the O
efficacy O
of O
6 B-Duration
months I-Duration
of O
treatment O
with O
BioCeuticals O
Cognition O
Support O
Formula O
® O
( O
containing O
Bacopa B-Medicinal food
monniera I-Medicinal food
( O
brahmi B-Medicinal food
) O
, O
Ginkgo B-Medicinal food
biloba I-Medicinal food
, O
Panax B-Medicinal food
ginseng I-Medicinal food
and O
alpha-lipoic B-Medicinal food
acid I-Medicinal food
) O
on O
cognition O
in O
older O
adults O
with O
SCI B-participant_health
( O
utilising O
the O
CogState O
® O
one O
card O
learning O
and O
identification O
tests O
as O
co-primary O
outcome O
measures O
of O
visual O
short-term O
memory O
and O
attention O
; O
mean O
speed O
( O
ms O
) O
, O
accuracy O
( O
% O
) O
, O
and O
total O
number O
of O
hits O
, O
misses O
, O
and O
anticipations O
) O
compared O
with O
placebo O
. O

The O
secondary O
aims O
are O
to O
assess O
an O
improvement O
in O
other O
cognitive O
domains O
( O
executive O
functioning O
, O
processing O
speed O
, O
and O
working O
memory O
) O
, O
evaluate O
safety O
, O
adverse O
effects O
, O
and O
determine O
efficacy O
on O
mood O
, O
fatigue O
, O
and O
neurocognition O
. O

It O
is O
expected O
that O
improvements O
across O
the O
study O
timepoints O
in O
the O
co-primary O
outcomes O
in O
the O
active O
treatment O
group O
( O
compared O
with O
placebo O
) O
will O
be O
evident O
. O

Method O
: O
One-hundred B-#Participants
and I-#Participants
twenty I-#Participants
participants O
will O
be O
recruited O
for O
the O
randomised O
, O
double-blind O
, O
placebo-controlled O
study O
. O

Participants O
will O
be O
randomly O
assigned O
to O
one O
of O
the O
treatment O
groups O
( O
active O
or O
placebo O
) O
at O
a O
1 O
: O
1 O
ratio O
, O
and O
will O
be O
required O
to O
complete O
a O
series O
of O
cognitive O
( O
using O
CogState O
® O
) O
, O
mood B-Symptom_WorkedFor
( O
using O
the O
Depression B-Metric
, I-Metric
Anxiety I-Metric
, I-Metric
Stress I-Metric
Scale I-Metric
( O
DASS O
- O
42 O
) O
and O
Short B-Metric
Health I-Metric
Anxiety I-Metric
Inventory I-Metric
( O
SHAI O
) O
) O
, O
and O
fatigue B-Symptom_WorkedFor
( O
using O
the O
Functional B-Metric
Assessment I-Metric
of I-Metric
Chronic I-Metric
Illness I-Metric
Therapy I-Metric
Fatigue I-Metric
Scale I-Metric
( O
FACIT-F O
) O
) O
tasks O
at O
baseline O
( O
0 O
months O
) O
, O
the O
midpoint O
( O
3 O
months O
) O
, O
and O
the O
endpoint O
( O
6 O
months O
) O
. O

These O
tasks O
will O
be O
evaluated O
between O
timepoints O
( O
baseline O
vs O
. O
midpoint O
, O
midpoint O
vs O
. O
endpoint O
, O
and O
baseline O
vs O
. O
endpoint O
) O
. O

Neurocognition O
will O
be O
measured O
by O
electroencephalography O
at O
baseline O
and O
at O
the O
endpoint O
in O
half O
of O
the O
participants O
. O

Adverse O
effects O
will O
be O
documented O
over O
the O
6 B-Duration
- I-Duration
month I-Duration
trial O
period O
. O

Discussion O
: O
This O
is O
the O
first O
study O
to O
test O
the O
efficacy O
of O
Cognition O
Support O
Formula O
® O
on O
cognition O
in O
older O
adults O
with O
SCI O
. O

As O
people O
with O
SCI O
have O
an O
increased O
risk O
of O
dementia O
, O
and O
there O
are O
limited O
treatments O
options O
for O
this O
population O
, O
it O
is O
important O
to O
assess O
a O
supplement O
that O
has O
the O
potential O
to O
enhance O
cognitive O
function O
. O

Trial O
registration O
: O
Universal O
Trial O
Number O
( O
UTN O
) O
, O
U1111 O
- O
1196 O
- O
9548 O
. O

Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
, O
ACTRN12617000945325 O
. O

Registered O
on O
30 O
June O
2017 O
. O

Mental O
stress B-Symptom_WorkedFor
, O
such O
as O
anxiety B-Symptom_WorkedFor
and O
conflict O
, O
causes O
physiological O
changes O
, O
such O
as O
changes O
in O
autonomic O
nervous O
activity O
and O
gastric O
ulcers O
. O

In O
addition O
, O
stress B-Symptom_WorkedFor
induces O
glucocorticoids O
and O
changes O
the O
hippocampal O
brain-derived B-Metric
neurotrophic I-Metric
factor I-Metric
( O
BDNF O
) O
expression O
levels O
. O

We O
previously O
reported O
that O
Acanthopanax B-Medicinal food
senticosus I-Medicinal food
HARM I-Medicinal food
( O
ASH B-Medicinal food
) O
prevents O
stress-induced O
gastric O
ulcers O
. O

Thus O
, O
we O
investigated O
the O
potential O
anxiolytic O
effect O
and O
influence O
of O
ASH B-Medicinal food
on O
the O
hippocampus O
BDNF-related B-Metric
protein O
in O
male O
Sprague-Dawley O
rats O
fed O
1% O
and O
5% O
ASH B-Medicinal food
extract-containing O
food O
for O
one O
week O
using O
novelty O
suppressed O
feeding O
( O
NSF O
) O
and O
improved O
elevated O
beam O
walking O
( O
IEBW O
) O
tests O
. O

ASH B-Medicinal food
treatment O
significantly O
decreased O
latency O
to O
eat O
in O
the O
NSF O
test O
and O
increased O
the O
time O
spent O
on O
the O
open O
arm O
in O
the O
IEBW O
test O
. O

ASH5% O
treatment O
showed O
a O
significant O
decrease O
in O
LFnu O
, O
indicative O
of O
sympathetic O
nervous O
activity O
, O
and O
a O
significant O
increase O
in O
HFnu O
, O
indicative O
of O
parasympathetic O
nervous O
activity O
, O
in O
the O
NSF O
test O
. O

In O
addition O
, O
ASH1% O
and O
ASH5% O
treatments O
significantly O
decreased O
LFnu O
and O
significantly O
increased O
HFnu O
in O
the O
IEBW O
test O
. O

ASH5% O
treatment O
significantly O
increased O
hippocampal O
BDNF O
protein O
expression O
in O
both O
Western O
blotting O
and O
immunohistochemistry O
experiments O
. O

Our O
findings O
suggest O
that O
anxiolytic O
effects O
of O
ASH O
occur O
via O
the O
regulation O
of O
autonomic O
function O
and O
increased O
hippocampal O
BDNF O
signaling O
. O

Catechin B-Drug/Scientific name
is O
an O
active O
ingredient O
of O
green B-Medicinal food
tea I-Medicinal food
. O

It O
is O
reported O
to O
inhibit O
corticosteroid-induced O
anxiety B-Symptom_WorkedFor
and O
depression-like B-Symptom_WorkedFor
symptoms O
. O

Considering O
the O
complex O
nature O
of O
depression O
, O
effects O
of O
catechin B-Drug/Scientific name
need O
to O
be O
studied O
in O
a O
clinically O
relevant O
depression O
model O
. O

The O
present O
study O
was O
designed O
to O
explore O
the O
antidepressant O
effect O
of O
catechin O
in O
Sprague O
Dawley O
rats O
subjected O
to O
chronic O
unpredictable O
mild O
stress O
( O
CUMS O
) O
. O

Animals O
were O
subjected O
to O
CUMS O
and O
treated O
with O
( O
+ O
) O
- O
catechin B-Drug/Scientific name
( O
50 O
mg O
/ O
kg O
) O
or O
escitalopram B-Other_ingredients
( O
10 O
mg O
/ O
kg O
) O
orally O
; O
a O
CUMS O
control O
and O
a O
vehicle O
control O
that O
was O
not O
exposed O
to O
CUMS O
were O
also O
established O
. O

Various O
stressors O
were O
applied O
daily O
in O
an O
unpredictable O
manner O
for O
8 O
weeks O
achieve O
CUMS O
. O

Sucrose O
preference O
test O
were O
performed O
after O
4 O
and O
8 O
weeks O
and O
forced O
swim O
tests O
( O
FSTs O
) O
were O
conducted O
at O
weeks O
4 O
, O
6 O
and O
8 O
. O

At O
the O
end O
of O
week O
8 O
, O
animals O
were O
sacrificed O
and O
the O
brain O
homogenate O
was O
studied O
for O
antioxidant O
parameters O
. O

Compared O
with O
the O
vehicle O
control O
, O
animals O
of O
the O
CUMS O
control O
group O
showed O
a O
significant O
decrease O
in O
sucrose O
intake O
. O

Catechin B-Drug/Scientific name
and O
escitalopram B-Other_ingredients
treatment O
significantly O
improved O
the O
sucrose O
intake O
compared O
with O
the O
CUMS O
control O
. O

A O
similar O
trend O
was O
observed O
in O
the O
FSTs O
, O
where O
catechin B-Drug/Scientific name
and O
escitalopram B-Other_ingredients
treatment O
significantly O
reduced O
the O
immobility O
time O
, O
and O
antioxidant O
parameters O
, O
including O
catalase O
, O
glutathione O
and O
superoxide O
dismutase O
levels O
were O
recovered O
in O
treated O
animals O
compared O
with O
the O
CUMS O
control O
. O

Thus O
, O
it O
was O
concluded O
that O
catechin B-Drug/Scientific name
reverses O
CUMS-induced O
depression O
in O
rats O
by O
ameliorating O
oxidative O
stress O
, O
which O
may O
help O
to O
develop O
a O
novel O
treatment O
for O
major O
depressive B-Symptom_WorkedFor
disorder I-Symptom_WorkedFor
. O

L-theanine B-Drug/Scientific name
( O
γ-glutamylethylamide B-Drug/Scientific name
) O
is O
an O
amino O
acid O
found O
primarily O
in O
the O
green B-Medicinal food
tea I-Medicinal food
plant O
. O

This O
study O
explored O
the O
effects O
of O
an O
L-theanine-based B-Medicinal food
nutrient O
drink O
on O
mood O
responses O
to O
a O
cognitive O
stressor O
. O

Additional O
measures O
included O
an O
assessment O
of O
cognitive O
performance O
and O
resting O
state O
alpha O
oscillatory O
activity O
using O
magnetoencephalography O
( O
MEG O
) O
. O

Thirty-four B-#Participants
healthy O
adults O
aged O
18 O
- O
40 O
participated O
in O
this O
double-blind O
, O
placebo-controlled O
, O
balanced O
crossover O
study O
. O

The O
primary O
outcome O
measure O
, O
subjective O
stress B-Symptom_WorkedFor
response O
to O
a O
multitasking O
cognitive O
stressor O
, O
was O
significantly O
reduced O
one O
hour O
after O
administration O
of O
the O
L-theanine B-Drug/Scientific name
drink O
when O
compared O
to O
placebo O
. O

The O
salivary O
cortisol O
response O
to O
the O
stressor O
was O
reduced O
three O
hours O
post-dose O
following O
active O
treatment O
. O

No O
treatment-related O
cognitive O
performance O
changes O
were O
observed O
. O

Resting O
state O
alpha O
oscillatory O
activity O
was O
significantly O
greater O
in O
posterior O
MEG O
sensors O
after O
active O
treatment O
compared O
to O
placebo O
two O
hours O
post-dose O
; O
however O
, O
this O
effect O
was O
only O
apparent O
for O
those O
higher O
in O
trait O
anxiety O
. O

This O
change O
in O
resting O
state O
alpha O
oscillatory O
activity O
was O
not O
correlated O
with O
the O
change O
in O
subjective O
stress B-Symptom_WorkedFor
response O
or O
the O
cortisol O
response O
, O
suggesting O
further O
research O
is O
required O
to O
assess O
the O
functional O
relevance O
of O
these O
treatment-related O
changes O
in O
resting O
alpha O
activity O
. O

These O
findings O
further O
support O
the O
anti-stress B-Symptom_WorkedFor
effects O
of O
L-theanine B-Drug/Scientific name
. O

Purpose O
of O
review O
: O
We O
review O
the O
influence O
of O
nutrition O
and O
lifestyle O
on O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
and O
recurrence O
and O
summarize O
food O
items O
, O
diets O
and O
lifestyle O
practices O
that O
physicians O
may O
wish O
to O
prioritize O
for O
discussion O
with O
their O
patients O
. O

Recent O
findings O
: O
Recent O
study O
results O
suggest O
an O
association O
between O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
and O
several O
food O
items O
including O
meat B-Medicinal food
, O
fruit B-Medicinal food
, O
vegetables B-Medicinal food
, O
milk B-Medicinal food
products I-Medicinal food
and O
oil B-Medicinal food
. O

Micronutrient O
deficiency O
is O
associated O
with O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
risk O
; O
however O
, O
it O
remains O
unclear O
if O
micronutrient O
supplementation O
can O
modify O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
. O

Furthermore O
, O
total O
fluid O
intake O
, O
alcohol O
, O
coffee B-Medicinal food
and O
tea B-Medicinal food
seem O
to O
have O
no O
influence O
on O
bladder O
cancer O
incidence O
. O

There O
is O
weak O
evidence O
that O
stress B-Symptom_TestedFor
, O
anxiety B-Symptom_TestedFor
and O
lack O
of O
sleep B-Symptom_TestedFor
may O
increase O
the O
risk O
of O
developing O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
, O
whereas O
exercise O
may O
reduce O
the O
risk O
of O
dying O
from O
it O
. O

Summary O
: O
Several O
dietary O
items O
and O
life O
styles O
are O
associated O
with O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
and O
recurrence O
. O

However O
, O
besides O
smoking O
cessation O
, O
there O
is O
no O
evidence O
that O
a O
certain O
diet O
or O
lifestyle O
can O
decrease O
bladder B-Symptom_TestedFor
cancer I-Symptom_TestedFor
incidence O
. O

P001 O
- O
Sepsis O
impairs O
the O
capillary O
response O
within O
hypoxic O
capillaries O
and O
decreases O
erythrocyte O
oxygen-dependent O
ATP O
efflux O
R O
. O

M O
. O

Bateman O
, O
M O
. O

D O
. O

Sharpe O
, O
J O
. O

E O
. O

Jagger O
, O
C O
. O

G O
. O

Ellis O
P002 O
- O
Lower O
serum O
immunoglobulin O
G2 O
level O
does O
not O
predispose O
to O
severe O
flu O
. O

J O
. O

Solé-Violán O
, O
M O
. O

López-Rodríguez O
, O
E O
. O

Herrera-Ramos O
, O
J O
. O

Ruíz-Hernández O
, O
L O
. O

Borderías O
, O
J O
. O

Horcajada O
, O
N O
. O

González-Quevedo O
, O
O O
. O

Rajas O
, O
M O
. O

Briones O
, O
F O
. O

Rodríguez O
de O
Castro O
, O
C O
. O

Rodríguez O
Gallego O
P003 O
- O
Brain O
protective O
effects O
of O
intravenous O
immunoglobulin O
through O
inhibition O
of O
complement O
activation O
and O
apoptosis O
in O
a O
rat O
model O
of O
sepsis O
F O
. O

Esen O
, O
G O
. O

Orhun O
, O
P O
. O

Ergin O
Ozcan O
, O
E O
. O

Senturk O
, O
C O
. O

Ugur O
Yilmaz O
, O
N O
. O

Orhan O
, O
N O
. O

Arican O
, O
M O
. O

Kaya O
, O
M O
. O

Kucukerden O
, O
M O
. O

Giris O
, O
U O
. O

Akcan O
, O
S O
. O

Bilgic O
Gazioglu O
, O
E O
. O

Tuzun O
P004 O
- O
Adenosine O
a1 O
receptor O
dysfunction O
is O
associated O
with O
leukopenia O
: O
A O
possible O
mechanism O
for O
sepsis-induced O
leukopenia O
R O
. O

Riff O
, O
O O
. O

Naamani O
, O
A O
. O

Douvdevani O
P005 O
- O
Analysis O
of O
neutrophil O
by O
hyper O
spectral O
imaging O
- O
A O
preliminary O
report O
R O
. O

Takegawa O
, O
H O
. O

Yoshida O
, O
T O
. O

Hirose O
, O
N O
. O

Yamamoto O
, O
H O
. O

Hagiya O
, O
M O
. O

Ojima O
, O
Y O
. O

Akeda O
, O
O O
. O

Tasaki O
, O
K O
. O

Tomono O
, O
T O
. O

Shimazu O
P006 O
- O
Chemiluminescent O
intensity O
assessed O
by O
eaa O
predicts O
the O
incidence O
of O
postoperative O
infectious O
complications O
following O
gastrointestinal O
surgery O
S O
. O

Ono O
, O
T O
. O

Kubo O
, O
S O
. O

Suda O
, O
T O
. O

Ueno O
, O
T O
. O

Ikeda O
P007 O
- O
Serial O
change O
of O
c1 O
inhibitor O
in O
patients O
with O
sepsis O
– O
A O
prospective O
observational O
study O
T O
. O

Hirose O
, O
H O
. O

Ogura O
, O
H O
. O

Takahashi O
, O
M O
. O

Ojima O
, O
J O
. O

Kang O
, O
Y O
. O

Nakamura O
, O
T O
. O

Kojima O
, O
T O
. O

Shimazu O
P008 O
- O
Comparison O
of O
bacteremia O
and O
sepsis O
on O
sepsis O
related O
biomarkers O
T O
. O

Ikeda O
, O
S O
. O

Suda O
, O
Y O
. O

Izutani O
, O
T O
. O

Ueno O
, O
S O
. O

Ono O
P009 O
- O
The O
changes O
of O
procalcitonin O
levels O
in O
critical O
patients O
with O
abdominal O
septic O
shock O
during O
blood O
purification O
T O
. O

Taniguchi O
, O
M O
. O

O O
P010 O
- O
Validation O
of O
a O
new O
sensitive O
point O
of O
care O
device O
for O
rapid O
measurement O
of O
procalcitonin O
C O
. O

Dinter O
, O
J O
. O

Lotz O
, O
B O
. O

Eilers O
, O
C O
. O

Wissmann O
, O
R O
. O

Lott O
P011 O
- O
Infection O
biomarkers O
in O
primary O
care O
patients O
with O
acute O
respiratory O
tract O
infections O
– O
Comparison O
of O
procalcitonin O
and O
C-reactive O
protein O
M O
. O

M O
. O

Meili O
, O
P O
. O

S O
. O

Schuetz O
P012 O
- O
Do O
we O
need O
a O
lower O
procalcitonin O
cut O
off O
? O

H O
. O

Hawa O
, O
M O
. O

Sharshir O
, O
M O
. O

Aburageila O
, O
N O
. O

Salahuddin O
P013 O
- O
The O
predictive O
role O
of O
C-reactive O
protein O
and O
procalcitonin O
biomarkers O
in O
central O
nervous O
system O
infections O
with O
extensively O
drug O
resistant O
bacteria O
V O
. O

Chantziara O
, O
S O
. O

Georgiou O
, O
A O
. O

Tsimogianni O
, O
P O
. O

Alexandropoulos O
, O
A O
. O

Vassi O
, O
F O
. O

Lagiou O
, O
M O
. O

Valta O
, O
G O
. O

Micha O
, O
E O
. O

Chinou O
, O
G O
. O

Michaloudis O
P014 O
- O
Changes O
in O
endotoxin O
activity O
assay O
and O
procalcitonin O
levels O
after O
direct O
hemoperfusion O
with O
polymyxin-b O
immobilized O
fiber O
A O
. O

Kodaira O
, O
T O
. O

Ikeda O
, O
S O
. O

Ono O
, O
T O
. O

Ueno O
, O
S O
. O

Suda O
, O
Y O
. O

Izutani O
, O
H O
. O

Imaizumi O
P015 O
- O
Diagnostic O
usefullness O
of O
combination O
biomarkers O
on O
ICU O
admission O
M O
. O

V O
. O

De O
la O
Torre-Prados O
, O
A O
. O

Garcia-De O
la O
Torre O
, O
A O
. O

Enguix-Armada O
, O
A O
. O

Puerto-Morlan O
, O
V O
. O

Perez-Valero O
, O
A O
. O

Garcia-Alcantara O
P016 O
- O
Platelet O
function O
analysis O
utilising O
the O
PFA O
- O
100 O
does O
not O
predict O
infection O
, O
bacteraemia O
, O
sepsis O
or O
outcome O
in O
critically O
ill O
patients O
N O
. O

Bolton O
, O
J O
. O

Dudziak O
, O
S O
. O

Bonney O
, O
A O
. O

Tridente O
, O
P O
. O

Nee O
P017 O
- O
Extracellular O
histone O
H3 O
levels O
are O
inversely O
correlated O
with O
antithrombin O
levels O
and O
platelet O
counts O
and O
are O
associated O
with O
mortality O
in O
sepsis O
patients O
G O
. O

Nicolaes O
, O
M O
. O

Wiewel O
, O
M O
. O

Schultz O
, O
K O
. O

Wildhagen O
, O
J O
. O

Horn O
, O
R O
. O

Schrijver O
, O
T O
. O

Van O
der O
Poll O
, O
C O
. O

Reutelingsperger O
P018 O
- O
Il O
- O
8 O
: O
is O
this O
a O
more O
reliable O
biomarker O
for O
sepsis O
severity O
than O
CRP O
, O
Procalcitonin O
, O
E-selectin O
, O
IL O
- O
6 O
and O
TNF O
- O
[ O
alpha O
] O
S O
. O

Pillai O
, O
G O
. O

Davies O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P019 O
- O
Relation O
between O
adrenomedullin O
and O
short-term O
outcome O
in O
ICU O
patients O
: O
Results O
from O
the O
frog O
ICU O
study O
E O
. O

G O
. O

Gayat O
, O
J O
. O

Struck O
, O
A O
. O

Cariou O
, O
N O
. O

Deye O
, O
B O
. O

Guidet O
, O
S O
. O

Jabert O
, O
J O
. O

Launay O
, O
M O
. O

Legrand O
, O
M O
. O

Léone O
, O
M O
. O

Resche-Rigon O
, O
E O
. O

Vicaut O
, O
A O
. O

Vieillard-Baron O
, O
A O
. O

Mebazaa O
P020 O
- O
Impact O
of O
disease O
severity O
assessment O
on O
performance O
of O
heparin-binding O
protein O
for O
the O
prediction O
of O
septic O
shock O
R O
. O

Arnold O
, O
M O
. O

Capan O
, O
A O
. O

Linder O
, O
P O
. O

Akesson O
P021 O
- O
Kinetics O
and O
prognostic O
value O
of O
presepsin O
( O
sCD14 O
) O
in O
septic O
patients O
. O

A O
pilot O
study O
M O
. O

Popescu O
, O
D O
. O

Tomescu O
P022 O
- O
Comparison O
of O
CD64 O
levels O
performed O
by O
the O
facs O
and O
accellix O
systems O
C O
. O

L O
. O

Sprung O
, O
R O
. O

Calderon O
Morales O
, O
G O
. O

Munteanu O
, O
E O
. O

Orenbuch-Harroch O
, O
P O
. O

Levin O
, O
H O
. O

Kasdan O
, O
A O
. O

Reiter O
, O
T O
. O

Volker O
, O
Y O
. O

Himmel O
, O
Y O
. O

Cohen O
, O
J O
. O

Meissonnier O
P023 O
- O
Diagnosing O
sepsis O
in O
5 O
minutes O
: O
Nanofluidic O
technology O
study O
with O
pancreatic-stone O
protein O
( O
PSP O
/ O
reg O
) O
L O
. O

Girard O
, O
F O
. O

Rebeaud O
P024 O
- O
How O
nanotechnology-based O
approaches O
could O
contribute O
to O
sepsis O
prevention O
, O
diagnosis O
and O
treatment O
I O
. O

Herrmann O
P025 O
- O
Il7r O
transcriptional O
expression O
analysis O
during O
septic O
shock O
B O
. O

Delwarde O
, O
E O
. O

Peronnet O
, O
E O
. O

Cerrato O
, O
F O
. O

Venet O
, O
A O
. O

Lepape O
, O
T O
. O

Rimmelé O
, O
G O
. O

Monneret O
, O
J O
. O

Textoris O
P026 O
- O
Disbalance O
of O
microbial O
metabolites O
of O
aromatic O
acids O
affects O
the O
severity O
in O
critically O
ill O
patients O
N O
. O

Beloborodova O
, O
V O
. O

Moroz O
, O
A O
. O

Osipov O
, O
A O
. O

Bedova O
, O
Y O
. O

Sarshor O
, O
A O
. O

Pautova O
, O
A O
. O

Sergeev O
, O
E O
. O

Chernevskaya O
P027 O
- O
Copeptin O
predicts O
10 O
- O
year O
all-cause O
mortality O
in O
community O
patients O
J O
. O

Odermatt O
, O
R O
. O

Bolliger O
, O
L O
. O

Hersberger O
, O
M O
. O

Ottiger O
, O
M O
. O

Christ-Crain O
, O
B O
. O

Mueller O
, O
P O
. O

Schuetz O
P028 O
- O
Identification O
of O
differential O
proteomic O
response O
in O
septic O
patients O
secondary O
to O
community O
and O
hospital O
acquired O
pneumonia O
N O
. O

K O
. O

Sharma O
, O
A O
. O

K O
. O

Tashima O
, O
M O
. O

K O
. O

Brunialti O
, O
F O
. O

R O
. O

Machado O
, O
M O
. O

Assuncao O
, O
O O
. O

Rigato O
, O
R O
. O

Salomao O
P029 O
- O
Monocyte O
HLA-DR O
expression O
in O
community-acquired O
bacteremic O
sepsis O
- O
dynamics O
associated O
to O
aetiology O
and O
prediction O
of O
secondary O
sepsis O
S O
. O

C O
. O

Cajander O
, O
G O
. O

Rasmussen O
, O
E O
. O

Tina O
, O
B O
. O

Söderquist O
, O
J O
. O

Källman O
, O
K O
. O

Strålin O
P030 O
- O
Soluble O
B O
- O
and O
T-lymphocyte O
attenuator O
: O
A O
possible O
prognostic O
marker O
in O
sepsis O
A O
. O

L O
. O

Lange O
, O
J O
. O

S O
. O

Sundén-Cullberg O
, O
A O
. O

M O
. O

Magnuson O
, O
O O
. O

H O
. O

Hultgren O
P031 O
- O
Fractal O
dimension O
: O
A O
new O
biomarker O
for O
quantifying O
clot O
microstructure O
in O
patients O
across O
the O
sepsis O
spectrum O
G O
. O

Davies O
, O
S O
. O

Pillai O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P032 O
- O
Comparison O
between O
the O
new O
biomarker O
for O
coagulation O
, O
clot O
microstructure O
( O
Df O
) O
with O
rotational O
thromboelastometry O
( O
ROTEM O
) O
in O
patients O
across O
the O
sepsis O
spectrum O
S O
. O

Pillai O
, O
G O
. O

Davies O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P033 O
- O
Changes O
in O
fibrinolysis O
across O
the O
sepsis O
spectrum O
: O
The O
use O
of O
rotational O
thromboelastometry O
( O
ROTEM O
) O
lysis O
index O
( O
LI60 O
) O
and O
D-Dimer O
concentration O
S O
. O

Pillai O
, O
G O
. O

Davies O
, O
G O
. O

Mills O
, O
R O
. O

Aubrey O
, O
K O
. O

Morris O
, O
P O
. O

Williams O
, O
P O
. O

Evans O
P034 O
- O
The O
intensive O
care O
infection O
score O
– O
a O
promising O
marker O
for O
the O
prediction O
of O
infection O
and O
its O
severity O
. O

P O
. O

Van O
der O
Geest O
, O
M O
. O

Mohseni O
, O
J O
. O

Linssen O
, O
R O
. O

De O
Jonge O
, O
S O
. O

Duran O
, O
J O
. O

Groeneveld O
P035 O
- O
Challenges O
in O
the O
clinical O
diagnosis O
of O
sepsis O
R O
. O

Miller O
III O
, O
B O
. O

K O
. O

Lopansri O
, O
L O
. O

C O
. O

McHugh O
, O
A O
. O

Seldon O
, O
J O
. O

P O
. O

Burke O
P036 O
- O
Does O
zero O
heat O
flux O
thermometry O
more O
accurately O
identify O
sepsis O
on O
intensive O
care O
? O

J O
. O

Johnston O
, O
R O
. O

Reece-Anthony O
, O
A O
. O

Bond O
, O
A O
. O

Molokhia O
P037 O
- O
Advancing O
quality O
( O
AQ O
) O
sepsis O
programme O
: O
Improving O
early O
identification O
& O
treatment O
of O
sepsis O
in O
North O
West O
England O
. O

C O
. O

Mcgrath O
, O
E O
. O

Nsutebu O
P038 O
- O
Prehospital O
transport O
of O
acute O
septic O
patients O
P O
. O

Bank O
Pedersen O
, O
D O
. O

Pilsgaard O
Henriksen O
, O
S O
. O

Mikkelsen O
, O
A O
. O

Touborg O
Lassen O
P039 O
- O
Vasodilatory O
plant O
extracts O
gel O
as O
an O
alternative O
treatment O
for O
fever O
in O
critically O
ill O
patients O
R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P040 O
- O
Host O
response O
and O
outcome O
of O
hypothermic O
sepsis O
M O
. O

A O
. O

Wiewel O
, O
M O
. O

B O
. O

Harmon O
, O
L O
. O

A O
. O

Van O
Vught O
, O
B O
. O

P O
. O

Scicluna O
, O
A O
. O

J O
. O

Hoogendijk O
, O
J O
. O

Horn O
, O
A O
. O

H O
. O

Zwinderman O
, O
O O
. O

L O
. O

Cremer O
, O
M O
. O

J O
. O

Bonten O
, O
M O
. O

J O
. O

Schultz O
, O
T O
. O

Van O
der O
Poll O
, O
N O
. O

P O
. O

Juffermans O
, O
W O
. O

J O
. O

Wiersinga O
P041 O
- O
Septic O
shock O
alert O
over O
SIRS O
criteria O
has O
an O
impact O
on O
outcome O
but O
needs O
to O
be O
revised O
G O
. O

Eren O
, O
Y O
Tekdos O
, O
M O
. O

Dogan O
, O
O O
. O

Acicbe O
, O
E O
. O

Kaya O
, O
O O
. O

Hergunsel O
P042 O
- O
Association O
between O
previous O
prescription O
of O
βblockers O
and O
mortality O
rate O
among O
septic O
patients O
: O
A O
retrospective O
observational O
study O
S O
. O

Alsolamy O
, O
G O
. O

Ghamdi O
, O
L O
. O

Alswaidan O
, O
S O
. O

Alharbi O
, O
F O
. O

Alenezi O
, O
Y O
. O

Arabi O
P043 O
- O
Recognition O
and O
treatment O
of O
sepsis O
on O
labour O
ward O
– O
teaching O
& O
information O
resources O
can O
improve O
knowledge O
J O
. O

Heaton O
, O
A O
. O

Boyce O
, O
L O
. O

Nolan O
, O
J O
. O

Johnston O
, O
A O
. O

Dukoff-Gordon O
, O
A O
. O

Dean O
, O
A O
. O

Molokhia O
P044 O
- O
Culture O
negative O
sepsis O
in O
the O
ICU O
– O
what O
is O
unique O
to O
this O
patient O
population O
? O

T O
. O

Mann O
Ben O
Yehudah O
P045 O
- O
Organ O
dysfunction O
in O
severe O
sepsis O
patients O
identified O
in O
administrative O
data O
in O
Germany O
, O
2007 O
- O
2013 O
C O
. O

Fleischmann O
, O
D O
. O

Thomas-Rueddel O
, O
C O
. O

Haas O
, O
U O
. O

Dennler O
, O
K O
. O

Reinhart O
P046 O
- O
A O
comparison O
of O
residents O
’ O
knowledge O
regarding O
; O
the O
Surviving O
Sepsis O
Campaign O
2012 O
guideline O
O O
. O

Suntornlohanakul O
, O
B O
. O

Khwannimit O
P047 O
- O
Effectiveness O
of O
a O
septic O
shock O
bundle O
to O
improve O
outcomes O
in O
the O
ICU O
F O
. O

Breckenridge O
, O
A O
. O

Puxty O
P048 O
- O
Dose O
of O
norepinephrine O
in O
the O
first O
24 O
hours O
as O
a O
parameter O
evaluating O
the O
effectiveness O
of O
treatment O
in O
patients O
with O
severe O
sepsis O
and O
septic O
shock O
P O
. O

Szturz O
, O
P O
. O

Folwarzcny O
, O
J O
. O

Svancara O
, O
R O
. O

Kula O
, O
P O
. O

Sevcik O
P049 O
- O
Norepinephrine O
or O
vasopressin O
+ O
norepinephrine O
in O
septic O
shock O
. O

A O
retrospective O
series O
of O
39 O
patients O
L O
. O

Caneva O
, O
A O
. O

Casazza O
, O
E O
. O

Bellazzi O
, O
S O
. O

Marra O
, O
L O
. O

Pagani O
, O
M O
. O

Vetere O
, O
R O
. O

Vanzino O
, O
D O
. O

Ciprandi O
, O
R O
. O

Preda O
, O
R O
. O

Boschi O
, O
L O
. O

Carnevale O
P050 O
- O
Methylene O
blue O
effectiveness O
as O
contributory O
treatment O
in O
patients O
with O
septic O
shock O
V O
. O

Lopez O
, O
M O
. O

Aguilar O
Arzapalo O
, O
L O
. O

Barradas O
, O
A O
. O

Escalante O
, O
J O
. O

Gongora O
, O
M O
. O

Cetina O
P051 O
- O
Coagulation O
disorders O
in O
patients O
with O
severe O
sepsis O
and O
DIC O
evaluated O
with O
thromboelastometry O
. O

B O
Adamik O
, O
D O
Jakubczyk O
, O
A O
Kübler O
P052 O
- O
Frequency O
and O
outcome O
of O
early O
sepsis-associated O
coagulopathy O
A O
. O

Radford O
, O
T O
. O

Lee O
, O
J O
. O

Singer O
, O
J O
. O

Boyd O
, O
D O
. O

Fineberg O
, O
M O
. O

Williams O
, O
J O
. O

Russell O
P053 O
- O
Assessment O
of O
coagulopathy O
in O
cancer O
patients O
with O
severe O
sepsis O
or O
septic O
shock O
. O

A O
case-control O
pilot O
study O
E O
. O

Scarlatescu O
, O
D O
. O

Tomescu O
, O
G O
. O

Droc O
, O
S O
. O

Arama O
P054 O
- O
Thromboelastometry O
in O
critically O
ill O
patients O
with O
disseminated O
intravascular O
coagulation O
M O
. O

Müller O
, O
M O
. O

Straat O
, O
S O
. O

S O
. O

Zeerleder O
, O
N O
. O

P O
. O

Juffermans O
P055 O
- O
Cessation O
of O
a O
preexisting O
chronic O
antiplatelet O
therapy O
is O
associated O
with O
increased O
mortality O
rates O
in O
severe O
sepsis O
and O
septic O
shock O
C O
. O

F O
. O

Fuchs O
, O
C O
. O

S O
. O

Scheer O
, O
S O
. O

W O
. O

Wauschkuhn O
, O
M O
. O

V O
. O

Vollmer O
, O
K O
. O

M O
. O

Meissner O
, O
S O
. O

K O
. O

Kuhn O
, O
K O
. O

H O
. O

Hahnenkamp O
, O
S O
. O

R O
. O

Rehberg O
, O
M O
. O

G O
. O

Gründling O
P056 O
- O
Neutrophil O
Extracellular O
Traps O
( O
NETs O
) O
production O
under O
hypoxic O
condition O
N O
. O

Yamamoto O
, O
M O
. O

Ojima O
, O
S O
. O

Hamaguchi O
, O
T O
. O

Hirose O
, O
Y O
. O

Akeda O
, O
R O
. O

Takegawa O
, O
O O
. O

Tasaki O
, O
T O
. O

Shimazu O
, O
K O
. O

Tomono O
P057 O
- O
Impact O
of O
ultraviolet O
air O
sterilizer O
in O
intensive O
care O
unit O
room O
, O
and O
clinical O
outcomes O
of O
patients O
E O
. O

Gómez-Sánchez O
, O
M O
. O

Heredia-Rodríguez O
, O
E O
. O

Álvarez-Fuente O
, O
M O
. O

Lorenzo-López O
, O
E O
. O

Gómez-Pesquera O
, O
M O
. O

Aragón-Camino O
, O
P O
. O

Liu-Zhu O
, O
A O
. O

Sánchez-López O
, O
A O
. O

Hernández-Lozano O
, O
M O
. O

T O
. O

Peláez-Jareño O
, O
E O
. O

Tamayo O
P058 O
- O
Focus O
of O
infection O
in O
severe O
sepsis O
- O
comparison O
of O
administrative O
data O
and O
prospective O
cohorts O
from O
Germany O
D O
. O

O O
. O

Thomas-Rüddel O
, O
C O
. O

Fleischmann O
, O
C O
. O

Haas O
, O
U O
. O

Dennler O
, O
K O
. O

Reinhart O
P059 O
- O
“ O
Zero O
CLABSI O
” O
– O
can O
we O
get O
there O
? O

Obstacles O
on O
the O
4 O
year O
journey O
and O
our O
strategies O
to O
overcome O
them O
– O
experience O
from O
an O
Indian O
ICU O
V O
. O

Adora O
, O
A O
. O

Kar O
, O
A O
. O

Chakraborty O
, O
S O
. O

Roy O
, O
A O
. O

Bandyopadhyay O
, O
M O
. O

Das O
P060 O
- O
Novel O
molecular O
techniques O
to O
identify O
central O
venous O
catheter O
( O
CVC O
) O
associated O
blood O
stream O
infections O
( O
BSIs O
) O
T O
. O

Mann O
Ben O
Yehudah O
, O
G O
. O

Ben O
Yehudah O
, O
M O
. O

Salim O
, O
N O
. O

Kumar O
, O
L O
. O

Arabi O
, O
T O
. O

Burger O
, O
P O
. O

Lephart O
, O
E O
. O

Toth-martin O
P061 O
- O
Zero O
clabsi O
” O
– O
can O
we O
get O
there O
? O

Obstacles O
on O
the O
4 O
year O
journey O
and O
our O
strategies O
to O
overcome O
them O
– O
experience O
from O
an O
Indian O
ICU O
R O
. O

Rao O
, O
A O
. O

Kar O
, O
A O
. O

Chakraborty O
P062 O
- O
Prevention O
of O
central O
line-associated O
bloodstream O
infections O
in O
intensive O
care O
units O
: O
An O
international O
online O
survey O
C O
. O

Valencia O
, O
N O
. O

Hammami O
, O
S O
. O

Blot O
, O
J O
. O

L O
. O

Vincent O
, O
M O
. O

L O
. O

Lambert O
P063 O
- O
30 O
days O
antimicrobial O
efficacy O
of O
non-leaching O
central O
venous O
catheters O
J O
. O

Brunke O
, O
T O
. O

Riemann O
, O
I O
. O

Roschke O
P064 O
- O
Efficacy O
of O
noble O
metal O
alloy-coated O
catheter O
in O
prevention O
of O
bacteriuria O
R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P065 O
- O
Predicting O
bacteremic O
urinary O
tract O
infection O
in O
community O
setting O
: O
A O
prospective O
observational O
study O
S O
. O

Nimitvilai O
, O
K O
. O

Jintanapramote O
, O
S O
. O

Jarupongprapa O
P066 O
- O
Eight-year O
analysis O
of O
acinetobacter O
spp O
. O
monobacteremia O
in O
surgical O
and O
medical O
intensive O
care O
units O
at O
university O
hospital O
in O
Lithuania O
D O
. O

Adukauskiene O
, O
D O
. O

Valanciene O
P067 O
- O
Group O
A O
and O
group O
B O
streptococcal O
infections O
in O
intensive O
care O
unit O
– O
our O
experience O
in O
a O
tertiary O
centre O
G O
. O

Bose O
, O
V O
. O

Lostarakos O
, O
B O
. O

Carr O
P068 O
- O
Improved O
detection O
of O
spontaneous O
bacterial O
peritonitis O
by O
uritop O
+ O
tm O
strip O
test O
and O
inoculation O
of O
blood O
culture O
bottles O
with O
ascitic O
fluid O
S O
. O

Khedher O
, O
A O
. O

Maaoui O
, O
A O
. O

Ezzamouri O
, O
M O
. O

Salem O
P069 O
- O
Increased O
risk O
of O
cellulitis O
in O
patients O
with O
congestive O
heart O
failure O
: O
a O
population O
based O
cohort O
study O
J O
. O

Chen O
P070 O
- O
Outcomes O
of O
severe O
cellulitis O
and O
necrotizing O
fasciitis O
in O
the O
critically O
ill O
D O
. O

R O
. O

Cranendonk O
, O
L O
. O

A O
. O

Van O
Vught O
, O
M O
. O

A O
. O

Wiewel O
, O
O O
. O

L O
. O

Cremer O
, O
J O
. O

Horn O
, O
M O
. O

J O
. O

Bonten O
, O
M O
. O

J O
. O

Schultz O
, O
T O
. O

Van O
der O
Poll O
, O
W O
. O

J O
. O

Wiersinga O
P071 O
- O
Botulism O
outbreak O
associated O
with O
people O
who O
inject O
drugs O
( O
PWIDs O
) O
in O
Scotland O
. O

M O
. O

Day O
, O
G O
. O

Penrice O
, O
K O
. O

Roy O
, O
P O
. O

Robertson O
, O
G O
. O

Godbole O
, O
B O
. O

Jones O
, O
M O
. O

Booth O
, O
L O
. O

Donaldson O
P072 O
- O
Surveillance O
of O
ESBL-producing O
enterobacteriaceae O
fecal O
carriers O
in O
the O
ICU O
Y O
. O

Kawano O
, O
H O
. O

Ishikura O
P073 O
- O
Prevalence O
of O
ESBL O
and O
carbapenemase O
producing O
uropathogens O
in O
a O
newly O
opened O
hospital O
in O
south O
India O
S O
. O

Sreevidya O
, O
N O
. O

Brahmananda O
Reddy O
, O
P O
. O

Muraray O
Govind O
, O
R O
. O

Pratheema O
, O
J O
. O

Devachandran O
Apollo O
Speciality O
Hospital O
- O
OMR O
, O
Chennai O
, O
India O
P074 O
- O
Prevalence O
, O
risk O
factors O
and O
outcomes O
of O
methicillin-resistant O
staphylococcus O
aureus O
nasal O
colonization O
in O
critically O
ill O
patients O
H O
. O

Al-Dorzi O
, O
M O
. O

Almutairi O
, O
B O
. O

Alhamadi O
, O
A O
. O

Crizaldo O
Toledo O
, O
R O
. O

Khan O
, O
B O
. O

Al O
Raiy O
, O
Y O
. O

Arabi O
P075 O
- O
Multidrug-resistant O
Acinetobacter O
baumannii O
infection O
in O
intensive O
care O
unit O
patients O
in O
a O
hospital O
with O
building O
construction O
: O
Is O
there O
an O
association O
? O

H O
. O

Talaie O
P076 O
- O
Multidrug-resistant O
organisms O
in O
a O
Dutch O
ICU O
J O
. O

A O
. O

Van O
Oers O
, O
A O
. O

Harts O
, O
E O
. O

Nieuwkoop O
, O
P O
. O

Vos O
P077 O
- O
Epidemiology O
and O
risk O
factors O
of O
ICU O
acquired O
infections O
caused O
by O
multidrug-resistant O
gram O
negative O
bacilli O
Y O
. O

Boussarsar O
, O
F O
. O

Boutouta O
, O
S O
. O

Kamoun O
, O
I O
. O

Mezghani O
, O
S O
. O

Koubaji O
, O
A O
. O

Ben O
Souissi O
, O
A O
. O

Riahi O
, O
M O
. O

S O
. O

Mebazaa O
P078 O
- O
Improving O
outcomes O
of O
severe O
infections O
by O
multidrug-resistant O
pathogens O
with O
polyclonal O
IgM-enriched O
immunoglobulins O
E O
. O

Giamarellos-Bourboulis O
, O
N O
. O

Tziolos O
, O
C O
. O

Routsi O
, O
C O
. O

Katsenos O
, O
I O
. O

Tsangaris O
, O
I O
. O

Pneumatikos O
, O
G O
. O

Vlachogiannis O
, O
V O
. O

Theodorou O
, O
A O
. O

Prekates O
, O
E O
. O

Antypa O
, O
V O
. O

Koulouras O
, O
N O
. O

Kapravelos O
, O
C O
. O

Gogos O
, O
E O
. O

Antoniadou O
, O
K O
. O

Mandragos O
, O
A O
. O

Armaganidis O
P079 O
- O
Must O
change O
the O
medical O
practice O
in O
ICU O
? O

A O
. O

R O
. O

Robles O
Caballero O
, O
B O
. O

Civantos O
, O
J O
. O

C O
. O

Figueira O
, O
J O
. O

López O
P080 O
- O
Mediterranean O
spotted O
fever O
in O
an O
infectious O
diseases O
intensive O
care O
unit O
A O
. O

Silva-Pinto O
, O
F O
. O

Ceia O
, O
A O
. O

Sarmento O
, O
L O
. O

Santos O
P081 O
- O
Clinical O
features O
and O
outcomes O
of O
patients O
with O
Middle O
East O
respiratory O
syndrome O
requiring O
admission O
to O
a O
saudi O
intensive O
care O
unit O
: O
A O
retrospective O
analysis O
of O
31 O
cases O
G O
. O

Almekhlafi O
, O
Y O
. O

Sakr O
P082 O
- O
The O
ICU O
response O
to O
a O
hospital O
outbreak O
of O
Middle O
East O
respiratory O
syndrome O
coronavirus O
infection O
H O
. O

Al-Dorzi O
, O
R O
. O

Khan O
, O
S O
. O

Baharoon O
, O
A O
. O

Aldawood O
, O
A O
. O

Matroud O
, O
J O
. O

Alchin O
, O
S O
. O

Al O
Johani O
, O
H O
. O

Balkhy O
, O
Y O
. O

Arabi O
P083 O
- O
Middle O
East O
respiratory O
syndrome O
: O
Surveillance O
data O
analysis O
S O
. O

Alsolamy O
, O
S O
. O

Y O
. O

Yousif O
, O
B O
. O

O O
. O

Alotabi O
, O
A O
. O

S O
. O

Alsaawi O
P085 O
- O
Use O
of O
Taqman O
array O
card O
molecular O
diagnostics O
in O
severe O
pneumonia O
: O
A O
case O
series O
J O
. O

Ang O
, O
MD O
Curran O
, O
D O
. O

Enoch O
, O
V O
. O

Navapurkar O
, O
A O
. O

Conway O
Morris O
P086 O
- O
‘ O
BUNS O
’ O
: O
An O
investigation O
protocol O
improves O
the O
ICU O
management O
of O
pneumonia O
R O
. O

Sharvill O
, O
J O
. O

Astin O
P087 O
- O
Pneumonia O
in O
patients O
following O
secondary O
peritonitis O
: O
epidemiological O
features O
and O
impact O
on O
mortality O
M O
. O

Heredia-Rodríguez O
, O
E O
. O

Gómez-Sánchez O
, O
M O
. O

T O
. O

Peláez-Jareño O
, O
E O
. O

Gómez-Pesquera O
, O
M O
. O

Lorenzo-López O
, O
P O
. O

Liu-Zhu O
, O
M O
. O

Aragón-Camino O
, O
A O
. O

Hernández-Lozano O
, O
A O
. O

Sánchez-López O
, O
E O
. O

Álvarez-Fuente O
, O
E O
. O

Tamayo O
P088 O
- O
The O
use O
of O
the O
“ O
CURB O
- O
65 O
score O
” O
by O
emergency O
room O
clinicians O
in O
a O
large O
teaching O
hospital O
J O
. O

Patel O
, O
C O
. O

Kruger O
P089 O
- O
Incidence O
of O
community O
acquired O
pneumonia O
with O
viral O
infection O
in O
mechanically O
ventilated O
patients O
in O
the O
medical O
intensive O
care O
unit O
J O
. O

O O
’ O
Neal O
, O
H O
. O

Rhodes O
, O
J O
. O

Jancik O
P090 O
- O
The O
SAATELLITE O
Study O
: O
Prevention O
of O
S O
aureus O
Nosocomial O
Pneumonia O
( O
NP O
) O
with O
MEDI4893 O
, O
a O
Human O
Monoclonal O
Antibody O
( O
mAb O
) O
Against O
S O
aureus O
B O
. O

François O
, O
P O
. O

F O
. O

Laterre O
, O
P O
. O

Eggimann O
, O
A O
. O

Torres O
, O
M O
. O

Sánchez O
, O
P O
. O

F O
. O

Dequin O
, O
G O
. O

L O
. O

Bassi O
, O
J O
. O

Chastre O
, O
H O
. O

S O
. O

Jafri O
P091 O
- O
Risk O
factors O
and O
microbiological O
profile O
for O
nosocomial O
infections O
in O
trauma O
patients O
M O
. O

Ben O
Romdhane O
, O
Z O
. O

Douira O
, O
S O
. O

Kamoun O
, O
M O
. O

Bousselmi O
, O
A O
. O

Ben O
Souissi O
, O
Y O
. O

Boussarsar O
, O
A O
. O

Riahi O
, O
M.S O
. O

Mebazaa O
P092 O
- O
Correlation O
between O
percentages O
of O
ventilated O
patients O
developed O
vap O
and O
use O
of O
antimicrobial O
agents O
in O
ICU O
patients O
. O

A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P093 O
- O
A O
comparison O
of O
two O
ventilator O
associated O
pneumonia O
surveillance O
techniques O
T O
. O

H O
. O

Craven O
, O
G O
. O

Wojcik O
, O
K O
. O

Kefala O
, O
J O
. O

McCoubrey O
, O
J O
. O

Reilly O
, O
R O
. O

Paterson O
, O
D O
. O

Inverarity O
, O
I O
. O

Laurenson O
, O
T O
. O

S O
. O

Walsh O
P094 O
- O
Lung O
ultrasound O
before O
and O
after O
fiberbronchoscopy O
- O
modifications O
may O
improve O
ventilator-associated O
pneumonia O
diagnosis O
S O
. O

Mongodi O
, O
B O
. O

Bouhemad O
, O
A O
. O

Orlando O
, O
A O
. O

Stella O
, O
G O
. O

Via O
, O
G O
. O

Iotti O
, O
A O
. O

Braschi O
, O
F O
. O

Mojoli O
P095 O
- O
Comparing O
the O
accuracy O
of O
predictors O
of O
mortality O
in O
ventilator-associated O
pneumonia O
M O
. O

Haliloglu O
, O
B O
. O

Bilgili O
, O
U O
. O

Kasapoglu O
, O
I O
. O

Sayan O
, O
M O
. O

Süzer O
Aslan O
, O
A O
. O

Yalcın O
, O
I O
. O

Cinel O
P096 O
- O
Impact O
of O
pRBCs O
transfusion O
on O
percentage O
of O
ventilated O
patients O
developed O
VAP O
in O
ICU O
patients O
A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P097 O
- O
The O
impact O
of O
a O
series O
of O
interventions O
on O
the O
rate O
of O
ventilator O
associated O
pneumonia O
in O
a O
large O
teaching O
hospital O
H O
. O

E O
. O

Ellis O
, O
K O
. O

Bauchmuller O
, O
D O
. O

Miller O
, O
A O
Temple O
P098 O
- O
The O
EVADE O
study O
: O
Prevention O
of O
Nosocomial O
Pneumonia O
( O
NP O
) O
caused O
by O
P O
aeruginosa O
with O
MEDI3902 O
, O
a O
Novel O
Bispecific O
Monoclonal O
Antibody O
, O
against O
P O
aeruginosa O
virulence O
factors O
J O
. O

Chastre O
, O
B O
. O

François O
, O
A O
. O

Torres O
, O
C O
. O

E O
. O

Luyt O
, O
M O
. O

Sánchez O
, O
M O
. O

Singer O
, O
H O
. O

S O
. O

Jafri O
P099 O
- O
Short-term O
inhaled O
colistin O
adjunctive O
therapy O
for O
ventilator-associated O
pneumonia O
Y O
. O

Nassar O
, O
M O
. O

S O
. O

Ayad O
P100 O
- O
Effect O
of O
aerosolised O
colistin O
on O
weaning O
from O
mechanical O
ventilation O
A O
. O

Trifi O
, O
S O
. O

Abdellatif O
, O
F O
. O

Daly O
, O
R O
. O

Nasri O
, O
S O
. O

Ben O
Lakhal O
P101 O
- O
Septic O
shock O
is O
an O
independent O
risk O
factor O
for O
colistin-induced O
severe O
acute O
kidney O
injury O
: O
a O
retrospective O
cohort O
study O
B O
. O

Bilgili O
, O
M O
. O

Haliloglu O
, O
F O
. O

Gul O
, O
I O
. O

Cinel O
P102 O
- O
Nosocomial O
pneumonia O
- O
emphasis O
on O
inhaled O
tobramycin O
A O
. O

Kuzovlev O
, O
A O
. O

Shabanov O
, O
S O
. O

Polovnikov O
, O
V O
. O

Moroz O
P103 O
- O
In O
vitro O
evaluation O
of O
amikacin O
inhale O
and O
commercial O
nebulizers O
in O
a O
mechanical O
ventilator O
N O
. O

Kadrichu O
, O
T O
. O

Dang O
, O
K O
. O

Corkery O
, O
P O
. O

Challoner O
P104 O
- O
The O
effects O
of O
nebulized O
amikacin O
/ O
fosfomycin O
and O
systemic O
meropenem O
on O
severe O
amikacin-resistant O
meropenem-susceptible O
P.aeruginosa O
pneumonia O
G O
. O

Li O
Bassi O
, O
E O
. O

Aguilera O
, O
C O
. O

Chiurazzi O
, O
C O
. O

Travierso O
, O
A O
. O

Motos O
, O
L O
. O

Fernandez O
, O
R O
. O

Amaro O
, O
T O
. O

Senussi O
, O
F O
. O

Idone O
, O
J O
. O

Bobi O
, O
M O
. O

Rigol O
, O
A O
. O

Torres O
P105 O
- O
Optimization O
of O
gentamicin O
peak O
concentrations O
in O
critically O
ill O
patients O
C O
. O

J O
. O

Hodiamont O
, O
N O
. O

P O
. O

Juffermans O
, O
J O
. O

M O
. O

Janssen O
, O
C O
. O

S O
. O

Bouman O
, O
R O
. O

A O
. O

Mathôt O
, O
M O
. O

D O
. O

De O
Jong O
, O
R O
. O

M O
. O

Van O
Hest O
P106 O
- O
Systematic O
review O
of O
cefepime O
induced O
neurotoxicity O
L O
. O

Payne O
, O
G O
. O

L O
. O

Fraser O
P107 O
- O
Unasyn O
® O
causes O
QT O
prolongation O
during O
treatment O
of O
intensive O
care O
patients O
B O
. O

Tudor O
, O
M O
. O

Lahner O
, O
G O
. O

Roth O
, O
C O
. O

Krenn O
P108 O
- O
Comparative O
study O
between O
teicoplanin O
and O
vancomycin O
in O
methicillin-resistant O
staphylococcus O
aureus O
( O
mrsa O
) O
infectious O
of O
toxicological O
intensive O
care O
unit O
( O
ticu O
) O
patients O
– O
Tehran O
, O
Iran O
H O
. O

Talaie O
P109 O
- O
Phage O
therapy O
against O
antimicrobial O
resistance O
, O
design O
of O
the O
first O
clinical O
study O
phagoburn O
P O
. O

Jault O
, O
J O
. O

Gabard O
, O
T O
. O

Leclerc O
, O
S O
. O

Jennes O
, O
Y O
. O

Que O
, O
A O
. O

Rousseau O
, O
F O
. O

Ravat O
P110 O
- O
Antibiotic O
dosing O
errors O
in O
critically O
ill O
patients O
with O
severe O
sepsis O
or O
septic O
shock O
H O
. O

Al-Dorzi O
, O
A O
. O

Eissa O
, O
S O
. O

Al-Harbi O
, O
T O
. O

Aldabbagh O
, O
R O
. O

Khan O
, O
Y O
. O

Arabi O
P111 O
- O
Does O
empiric O
antifungal O
therapy O
improve O
survival O
in O
septic O
critically O
ill O
patients O
? O

( O
immunocompromised O
excluded O
) O
A O
. O

Trifi O
, O
S O
. O

Abdellatif O
, O
F O
. O

Daly O
, O
R O
. O

Nasri O
, O
S O
. O

Ben O
Lakhal O
P112 O
- O
Neurocysticercosis-Qatar O
experience O
F O
. O

Paramba O
, O
N O
. O

Purayil O
, O
V O
. O

Naushad O
, O
O O
. O

Mohammad O
, O
V O
. O

Negi O
, O
P O
. O

Chandra O
P113 O
- O
Early O
indicators O
in O
acute O
haemorrhagic O
shock O
A O
. O

Kleinsasser O
P114 O
- O
Filtering O
of O
red O
blood O
cells O
reduces O
the O
inflammatory O
response O
of O
pulmonary O
cells O
in O
an O
in O
vitro O
model O
of O
mechanical O
ventilation O
M O
. O

R O
. O

Witrz O
, O
J O
. O

F O
. O

Buchner-Doeven O
, O
A O
. O

M O
. O

Tuip-de O
Boer O
, O
J O
. O

C O
. O

Goslings O
, O
N O
. O

P O
. O

Juffermans O
P115 O
- O
Microparticles O
from O
red O
blood O
cell O
transfusion O
induce O
a O
pro-coagulant O
and O
pro-inflammatory O
endothelial O
cell O
response O
M O
. O

Van O
Hezel O
, O
M O
. O

Straat O
, O
A O
Boing O
, O
R O
Van O
Bruggen O
, O
N O
Juffermans O
P116 O
- O
The O
contribution O
of O
cytokines O
on O
thrombosis O
development O
during O
hospitalization O
in O
ICU O
D O
. O

Markopoulou O
, O
K O
. O

Venetsanou O
, O
V O
. O

Kaldis O
, O
D O
. O

Koutete O
, O
D O
. O

Chroni O
, O
I O
. O

Alamanos O
P117 O
- O
Prophylactic O
enoxaparin O
dosing O
and O
adjustment O
through O
anti-xa O
monitoring O
in O
an O
inpatient O
burn O
unit O
L O
. O

Koch O
, O
J O
. O

Jancik O
, O
H O
. O

Rhodes O
, O
E O
. O

Walter O
P118 O
- O
Determination O
of O
optimal O
cut-off O
values O
of O
haemoglobin O
, O
platelet O
count O
and O
fibrinogen O
at O
24 O
hours O
after O
injury O
associated O
with O
mortality O
in O
trauma O
patients O
K O
. O

Maekawa O
, O
M O
. O

Hayakawa O
, O
S O
. O

Kushimoto O
, O
A O
. O

Shiraishi O
, O
H O
. O

Kato O
, O
J O
. O

Sasaki O
, O
H O
. O

Ogura O
, O
T O
. O

Matauoka O
, O
T O
. O

Uejima O
, O
N O
. O

Morimura O
, O
H O
. O

Ishikura O
, O
A O
. O

Hagiwara O
, O
M O
. O

Takeda O
P119 O
- O
Trauma-induced O
coagulopathy O
- O
prothrombin O
complex O
concentrate O
vs O
fresh O
frozen O
plasma O
O O
. O

Tarabrin O
, O
S O
. O

Shcherbakow O
, O
D O
. O

Gavrychenko O
, O
G O
. O

Mazurenko O
, O
V O
. O

Ivanova O
, O
O O
. O

Chystikov O
P120 O
- O
First O
study O
to O
prove O
the O
superiority O
of O
prothrombin O
complex O
concentrates O
on O
mortality O
rate O
over O
fresh O
frozen O
plasma O
in O
patients O
with O
acute O
bleeding O
C O
. O

Plourde O
, O
J O
. O

Lessard O
, O
J O
. O

Chauny O
, O
R O
. O

Daoust O
P121 O
- O
Prothrombin O
complex O
concentrate O
vs O
fresh O
frozen O
plasma O
in O
obstetric O
massive O
bleeding O
S O
. O

Shcherbakow O
, O
O O
. O

Tarabrin O
, O
D O
. O

Gavrychenko O
, O
G O
. O

Mazurenko O
, O
O O
. O

Chystikov O
P122 O
- O
Impact O
of O
FFP O
transfusion O
on O
VAP O
in O
ICU O
patients O
A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P123 O
- O
Preoperative O
platelet O
function O
test O
and O
the O
thrombin O
generation O
assay O
are O
predictive O
for O
blood O
loss O
after O
cardiac O
surgery O
L O
. O

Kropman O
, O
L O
. O

In O
het O
Panhuis O
, O
J O
. O

Konings O
, O
D O
. O

Huskens O
, O
E O
. O

Schurgers O
, O
M O
. O

Roest O
, O
B O
. O

De O
Laat O
, O
M O
. O

Lance O
P124 O
- O
Rotational O
thromboelastometry O
versus O
standard O
coagulation O
tests O
before O
surgical O
interventions O
M O
. O

Durila O
, O
P O
. O

Lukas O
, O
M O
. O

Astraverkhava O
, O
J O
. O

Jonas O
P125 O
- O
Correction O
of O
impaired O
clot O
quality O
and O
stability O
by O
fibrinogen O
and O
activated O
prothrombin O
complex O
concentrate O
in O
a O
model O
of O
severe O
thrombocytopenia O
I O
. O

Budnik O
, O
B O
. O

Shenkman O
P126 O
- O
Assessment O
of O
point-of-care O
prothrombin O
time O
analyzer O
as O
a O
monitor O
after O
cardiopulmonary O
bypass O
H O
. O

Hayami O
, O
Y O
. O

Koide O
, O
T O
. O

Goto O
P127 O
- O
Disseminated O
intravascular O
coagulation O
( O
dic O
) O
is O
underdiagnosed O
in O
critically O
ill O
patients O
: O
do O
we O
need O
d-dimer O
measurements O
? O

R O
. O

Iqbal O
, O
Y O
. O

Alhamdi O
, O
N O
. O

Venugopal O
, O
S O
. O

Abrams O
, O
C O
. O

Downey O
, O
C O
. O

H O
. O

Toh O
, O
I O
. O

D O
. O

Welters O
P128 O
- O
Validity O
of O
the O
age-adjusted O
d-dimer O
cutoff O
in O
patients O
with O
COPD O
B O
. O

Bombay O
, O
J O
. O

M O
. O

Chauny O
, O
R O
. O

D O
. O

Daoust O
, O
J O
. O

L O
. O

Lessard O
, O
M O
. O

M O
. O

Marquis O
, O
J O
. O

P O
. O

Paquet O
P129 O
- O
A O
scoping O
review O
of O
strategies O
for O
prevention O
and O
management O
of O
bleeding O
following O
paediatric O
cardiopulmonary O
bypass O
surgery O
K O
. O

Siemens O
, O
D O
. O

Sangaran O
, O
B O
. O

J O
. O

Hunt O
, O
A O
. O

Durward O
, O
A O
. O

Nyman O
, O
I O
. O

A O
. O

Murdoch O
, O
S O
. O

M O
. O

Tibby O
P130 O
- O
Nadir O
hemoglobulin O
during O
cardiopulmonary O
bypass O
: O
impact O
on O
postoperative O
morbidity O
and O
mortality O
F O
. O

Ampatzidou O
, O
D O
. O

Moisidou O
, O
E O
. O

Dalampini O
, O
M O
. O

Nastou O
, O
E O
. O

Vasilarou O
, O
V O
. O

Kalaizi O
, O
H O
. O

Chatzikostenoglou O
, O
G O
. O

Drossos O
P131 O
- O
Red O
blood O
cell O
transfusion O
do O
not O
influence O
the O
prognostic O
value O
of O
RDW O
in O
critically O
ill O
patients O
S O
. O

Spadaro O
, O
A O
. O

Fogagnolo O
, O
T O
. O

Fiore O
, O
A O
. O

Schiavi O
, O
V O
. O

Fontana O
, O
F O
. O

Taccone O
, O
C O
. O

Volta O
P132 O
- O
Reasons O
for O
admission O
in O
the O
paediatric O
intensive O
care O
unit O
and O
the O
need O
for O
blood O
and O
blood O
products O
transfusions O
E O
. O

Chochliourou O
, O
E O
. O

Volakli O
, O
A O
. O

Violaki O
, O
E O
. O

Samkinidou O
, O
G O
. O

Evlavis O
, O
V O
. O

Panagiotidou O
, O
M O
. O

Sdougka O
P133 O
- O
The O
implementation O
of O
a O
massive O
haemorrhage O
protocol O
( O
mhp O
) O
for O
the O
management O
of O
major O
trauma O
: O
a O
ten O
year O
, O
single-centre O
study O
R O
. O

Mothukuri O
, O
C O
. O

Battle O
, O
K O
. O

Guy O
, O
G O
. O

Mills O
, O
P O
. O

Evans O
P134 O
- O
An O
integrated O
major O
haemorrhage O
protocol O
for O
pre-hospital O
and O
retrieval O
medical O
teams O
J O
. O

Wijesuriya O
, O
S O
. O

Keogh O
P135 O
- O
The O
impact O
of O
transfusion O
thresholds O
on O
mortality O
and O
cardiovascular O
events O
in O
patients O
with O
cardiovascular O
disease O
( O
non-cardiac O
surgery O
) O
: O
a O
systematic O
review O
and O
meta-analysis O
A O
. O

Docherty O
, O
R O
. O

O O
’ O
Donnell O
, O
S O
. O

Brunskill O
, O
M O
. O

Trivella O
, O
C O
. O

Doree O
, O
L O
. O

Holst O
, O
M O
. O

Parker O
, O
M O
. O

Gregersen O
, O
J O
. O

Almeida O
, O
T O
. O

Walsh O
, O
S O
. O

Stanworth O
P136 O
- O
The O
relationship O
between O
poor O
pre-operative O
immune O
status O
and O
outcome O
from O
cardiac O
surgery O
is O
specific O
to O
the O
peri-operative O
antigenic O
threat O
S O
. O

Moravcova O
, O
J O
. O

Mansell O
, O
A O
. O

Rogers O
, O
R O
. O

A O
. O

Smith O
, O
C O
. O

Hamilton-Davies O
P137 O
- O
Impact O
of O
simple O
clinical O
practice O
guidelines O
for O
reducing O
post-operative O
atrial O
fibrillation O
after O
cardiac O
surgery O
. O

A O
. O

Omar O
, O
M O
. O

Allam O
, O
O O
. O

Bilala O
, O
A O
. O

Kindawi O
, O
H O
. O

Ewila O
P138 O
- O
Dexamethasone O
administration O
during O
cardiopulmonary O
bypass O
has O
no O
beneficial O
effects O
on O
elective O
postoperative O
cardiac O
surgery O
patients O
F O
. O

Ampatzidou O
, O
D O
. O

Moisidou O
, O
M O
. O

Nastou O
, O
E O
. O

Dalampini O
, O
A O
. O

Malamas O
, O
E O
. O

Vasilarou O
, O
G O
. O

Drossos O
P139 O
- O
Intra-aortic O
balloon O
counterpulsation O
in O
patients O
undergoing O
cardiac O
surgery O
( O
IABCS O
) O
: O
preliminary O
results O
G O
. O

Ferreira O
, O
J O
. O

Caldas O
, O
J O
. O

Fukushima O
, O
E O
. O

A O
. O

Osawa O
, O
E O
. O

Arita O
, O
L O
. O

Camara O
, O
S O
. O

Zeferino O
, O
J O
. O

Jardim O
, O
F O
. O

Gaioto O
, O
L O
. O

Dallan O
, O
F O
. O

B O
. O

Jatene O
, O
R O
. O

Kalil O
Filho O
, O
. O
F O
Galas O
, O
L O
. O

A O
. O

Hajjar O
P140 O
- O
Effects O
of O
low-dose O
atrial O
natriuretic O
peptide O
infusion O
on O
cardiac O
surgery-associated O
acute O
kidney O
injury O
C O
. O

Mitaka O
, O
T O
. O

Ohnuma O
, O
T O
. O

Murayama O
, O
F O
. O

Kunimoto O
, O
M O
. O

Nagashima O
, O
T O
. O

Takei O
, O
M O
. O

Tomita O
P141 O
- O
Acute O
kidney O
injury O
influence O
on O
high O
sensitive O
troponin O
measurements O
after O
cardiac O
surgery O
A O
. O

Omar O
, O
K O
. O

Mahmoud O
, O
S O
. O

Hanoura O
, O
S O
. O

Sudarsanan O
, O
P O
. O

Sivadasan O
, O
H O
. O

Othamn O
, O
Y O
. O

Shouman O
, O
R O
. O

Singh O
, O
A O
. O

Al O
Khulaifi O
P142 O
- O
Complex O
evaluation O
of O
endothelial O
dysfunction O
markers O
for O
prognosis O
of O
outcomes O
in O
patients O
undergoing O
cardiac O
surgery O
I O
. O

Mandel O
, O
S O
. O

Mikheev O
, O
I O
. O

Suhodolo O
, O
V O
. O

Kiselev O
, O
Y O
. O

Svirko O
, O
Y O
. O

Podoksenov O
P143 O
- O
New-onset O
atrial O
fibrillation O
in O
intensive O
care O
: O
incidence O
, O
management O
and O
outcome O
S O
. O

A O
. O

Jenkins O
, O
R O
. O

Griffin O
P144 O
- O
One O
single O
spot O
measurement O
of O
the O
sublingual O
microcirculation O
during O
acute O
pulmonary O
hypertension O
in O
a O
pig O
model O
of O
shock O
M O
. O

S O
. O

Tovar O
Doncel O
, O
A O
. O

Lima O
, O
C O
. O

Aldecoa O
, O
C O
. O

Ince O
P145 O
- O
Assessment O
of O
levosimendan O
as O
a O
therapeutic O
option O
to O
recruit O
the O
microcirculation O
in O
cardiogenic O
shock O
– O
initial O
experience O
in O
cardiac O
ICU O
A O
. O

Taha O
, O
A O
. O

Shafie O
, O
M O
. O

Mostafa O
, O
N O
. O

Syed O
, O
H O
. O

Hon O
P146 O
- O
Terlipressin O
vs O
. O
norepinephrine O
in O
the O
Potential O
Multiorgan O
Donor O
( O
PMD O
) O
F O
. O

Righetti O
, O
E O
. O

Colombaroli O
, O
G O
. O

Castellano O
P147 O
- O
Echocardiography O
in O
the O
potential O
heart O
donor O
exposed O
to O
substitution O
hormonotherapy O
F O
. O

Righetti O
, O
E O
. O

Colombaroli O
P148 O
- O
Machine O
learning O
can O
reduce O
rate O
of O
monitor O
alarms O
M O
. O

Hravnak O
, O
L O
. O

C O
. O

Chen O
, O
A O
. O

D O
. O

Dubrawski O
, O
G O
. O

C O
. O

Clermont O
, O
M O
. O

R O
. O

Pinsky O
P149 O
- O
Peripherally O
inserted O
central O
catheters O
placed O
in O
the O
ICU O
S O
. O

Gonzalez O
, O
D O
. O

Macias O
, O
J O
. O

Acosta O
, O
P O
. O

Jimenez O
, O
A O
. O

Loza O
, O
A O
. O

Lesmes O
, O
F O
. O

Lucena O
, O
C O
. O

Leon O
P150 O
- O
Recordings O
of O
abnormal O
central O
venous O
pressure O
waveform O
morphology O
during O
an O
episode O
of O
pulmonary O
hypertension O
in O
a O
porcine O
shock O
model O
M O
. O

S O
. O

Tovar O
Doncel O
, O
C O
. O

Ince O
, O
C O
. O

Aldecoa O
, O
A O
. O

Lima O
P151 O
- O
Ultrasound O
guided O
central O
venous O
access O
technique O
among O
French O
intensivists O
M O
. O

Bastide O
, O
J O
. O

Richecoeur O
, O
E O
. O

Frenoy O
, O
C O
. O

Lemaire O
, O
B O
. O

Sauneuf O
, O
F O
. O

Tamion O
, O
S O
. O

Nseir O
, O
D O
. O

Du O
Cheyron O
, O
H O
. O

Dupont O
, O
J O
. O

Maizel O
P152 O
- O
Predictive O
ability O
of O
the O
Pv-aCO2 O
gap O
in O
patients O
with O
shock O
M O
. O

Shaban O
, O
R O
. O

Kolko O
, O
N O
. O

Salahuddin O
, O
M O
. O

Sharshir O
, O
M O
. O

AbuRageila O
, O
A O
. O

AlHussain O
P153 O
- O
Comparison O
of O
echocardiography O
and O
pulmonary O
artery O
catheter O
measurements O
of O
hemodynamic O
parameters O
in O
critical O
ill O
patients O
P O
. O

Mercado O
, O
J O
. O

Maizel O
, O
L O
. O

Kontar O
, O
D O
. O

Titeca O
, O
F O
. O

Brazier O
, O
A O
. O

Riviere O
, O
M O
. O

Joris O
, O
T O
. O

Soupison O
, O
B O
. O

De O
Cagny O
, O
M O
. O

Slama O
P154 O
- O
The O
volume O
clamp O
method O
for O
noninvasive O
cardiac O
output O
measurement O
in O
postoperative O
cardiothoracic O
surgery O
patients O
: O
a O
comparison O
with O
intermittent O
pulmonary O
artery O
thermodilution O
J O
. O

Wagner O
, O
A O
. O

Körner O
, O
M O
. O

Kubik O
, O
S O
. O

Kluge O
, O
D O
. O

Reuter O
, O
B O
. O

Saugel O
P155 O
- O
Hemodynamic O
monitoring O
in O
patients O
with O
septic O
shock O
( O
SS O
) O
– O
CPCCO O
( O
continuous O
pulse O
contour O
cardiac O
output O
) O
vs O
. O

TEE O
( O
transesophageal O
echocardiography O
) O
E O
. O

Colombaroli O
, O
F O
. O

Righetti O
, O
G O
. O

Castellano O
P156 O
- O
Cardiac O
output O
measurement O
with O
transthoracic O
echocardiography O
in O
critically O
ill O
patients O
: O
a O
pragmatic O
clinical O
study O
T O
. O

Tran O
, O
D O
. O

De O
Bels O
, O
A O
. O

Cudia O
, O
M O
. O

Strachinaru O
, O
P O
. O

Ghottignies O
, O
J O
. O

Devriendt O
, O
C O
. O

Pierrakos O
P157 O
- O
Left O
ventricular O
outflow O
tract O
velocity O
time O
integral O
correlates O
with O
stroke O
volume O
index O
in O
mechanically O
ventilated O
patients O
Ó O
. O

Martínez O
González O
, O
R O
. O

Blancas O
, O
J O
. O

Luján O
, O
D O
. O

Ballesteros O
, O
C O
. O

Martínez O
Díaz O
, O
A O
. O

Núñez O
, O
C O
. O

Martín O
Parra O
, O
B O
. O

López O
Matamala O
, O
M O
. O

Alonso O
Fernández O
, O
M O
. O

Chana O
P158 O
- O
Transpulmonary O
thermodilution O
( O
TPTD O
) O
derived O
from O
femoral O
vs O
. O
jugular O
central O
venous O
catheter O
: O
validation O
of O
a O
previously O
published O
correction O
formula O
and O
a O
proprietary O
correction O
formula O
for O
global O
end-diastolic O
volume O
index O
( O
GEDVI O
) O
W O
. O

Huber O
, O
M O
. O

Eckmann O
, O
F O
. O

Elkmann O
, O
A O
. O

Gruber O
, O
I O
. O

Klein O
, O
R O
. O

M O
. O

Schmid O
, O
T O
. O

Lahmer O
P160 O
- O
Dynamic O
arterial O
elastance O
calculated O
with O
lidcoplus O
monitor O
does O
not O
predict O
changes O
in O
arterial O
pressure O
after O
a O
fluid O
challenge O
in O
postsurgical O
patients O
D O
. O

Bastoni O
, O
H O
. O

Aya O
, O
L O
. O

Toscani O
, O
L O
. O

Pigozzi O
, O
A O
. O

Rhodes O
, O
M O
. O

Cecconi O
P159 O
- O
Venous O
return O
driving O
pressure O
and O
resistance O
in O
acute O
blood O
volume O
changes O
P O
. O

W O
. O

Moller O
, O
S O
. O

Sondergaard O
, O
S O
. O

M O
. O

Jakob O
, O
J O
. O

Takala O
, O
D O
. O

Berger O
P160 O
- O
Dynamic O
arterial O
elastance O
calculated O
with O
lidcoplus O
monitor O
does O
not O
predict O
changes O
in O
arterial O
pressure O
after O
a O
fluid O
challenge O
in O
postsurgical O
patients O
D O
. O

Bastoni O
, O
H O
. O

Aya O
, O
L O
. O

Toscani O
, O
L O
. O

Pigozzi O
, O
A O
. O

Rhodes O
, O
M O
. O

Cecconi O
P161 O
- O
Analysis O
of O
duration O
of O
post-operative O
goal-directed O
therapy O
protocol O
C O
. O

Ostrowska O
, O
H O
. O

Aya O
, O
A O
. O

Abbas O
, O
J O
. O

Mellinghoff O
, O
C O
. O

Ryan O
, O
D O
. O

Dawson O
, O
A O
. O

Rhodes O
, O
M O
. O

Cecconi O
P162 O
- O
Hemodynamic O
optimization O
– O
back O
to O
square O
one O
? O

M O
. O

Cronhjort O
, O
O O
. O

Wall O
, O
E O
. O

Nyberg O
, O
R O
. O

Zeng O
, O
C O
. O

Svensen O
, O
J O
. O

Mårtensson O
, O
E O
. O

Joelsson-Alm O
P163 O
- O
Effectiveness O
of O
fluid O
thoracic O
content O
measurement O
by O
bioimpedance O
guiding O
intravascular O
volume O
optimization O
in O
patients O
with O
septic O
shock O
M O
. O

Aguilar O
Arzapalo O
, O
L O
. O

Barradas O
, O
V O
. O

Lopez O
, O
M O
. O

Cetina O
P164 O
- O
A O
systematic O
review O
on O
the O
role O
of O
internal O
jugular O
vein O
ultrasound O
measurements O
in O
assessment O
of O
volume O
status O
in O
critical O
shock O
patients O
N O
. O

Parenti O
, O
C O
. O

Palazzi O
, O
L O
. O

A O
. O

Amidei O
, O
F O
. O

B O
. O

Borrelli O
, O
S O
. O

C O
. O

Campanale O
, O
F O
. O

T O
. O

Tagliazucchi O
, O
G O
. O

S O
. O

Sedoni O
, O
D O
. O

L O
. O

Lucchesi O
, O
E O
. O

C O
. O

Carella O
, O
A O
. O

L O
Luciani O
P165 O
- O
Importance O
of O
recognizing O
dehydration O
in O
medical O
Intensive O
Care O
Unit O
M O
. O

Mackovic O
, O
N O
. O

Maric O
, O
M O
. O

Bakula O
P166 O
- O
Effect O
of O
volume O
for O
a O
fluid O
challenge O
in O
septic O
patients O
H O
. O

Aya O
, O
A O
. O

Rhodes O
, O
R O
. O

M O
. O

Grounds O
, O
N O
. O

Fletcher O
, O
M O
. O

Cecconi O
P167 O
- O
Fluid O
bolus O
practices O
in O
a O
large O
Australian O
intensive O
care O
unit O
B O
. O

Avard O
, O
P O
. O

Zhang O
P168 O
- O
Liberal O
late O
fluid O
management O
is O
associated O
with O
longer O
ventilation O
duration O
and O
worst O
outcome O
in O
severe O
trauma O
patients O
: O
a O
retrospective O
cohort O
of O
294 O
patients O
M O
. O

Mezidi O
, O
J O
. O

Charbit O
, O
M O
. O

Ould-Chikh O
, O
P O
. O

Deras O
, O
C O
. O

Maury O
, O
O O
. O

Martinez O
, O
X O
. O

Capdevila O
P169 O
- O
Association O
of O
fluids O
and O
outcomes O
in O
emergency O
department O
patients O
hospitalized O
with O
community-acquired O
pneumonia O
P O
. O

Hou O
, O
W O
. O

Z O
. O

Linde-Zwirble O
, O
I O
. O

D O
. O

Douglas O
, O
N O
. O

S O
. O

Shapiro O
P170 O
- O
Association O
of O
positive O
fluid O
balance O
with O
poor O
outcome O
in O
medicosurgical O
ICU O
patients O
A O
. O

Ben O
Souissi O
, O
I O
. O

Mezghani O
, O
Y O
. O

Ben O
Aicha O
, O
S O
. O

Kamoun O
, O
B O
. O

Laribi O
, O
B O
. O

Jeribi O
, O
A O
. O

Riahi O
, O
M O
. O

S O
. O

Mebazaa O
P171 O
- O
Impact O
of O
fluid O
balance O
to O
organ O
dysfunction O
in O
critically O
ill O
patients O
C O
. O

Pereira O
, O
R O
. O

Marinho O
, O
R O
. O

Antunes O
, O
A O
. O

Marinho O
P172 O
- O
Volume O
bolus O
in O
ICU O
patients O
: O
do O
we O
need O
to O
balance O
our O
crystalloids O
? O

M O
. O

Crivits O
, O
M O
. O

Raes O
, O
J O
. O

Decruyenaere O
, O
E O
. O

Hoste O
P173 O
- O
The O
use O
of O
6 O
% O
HES O
solution O
do O
not O
reduce O
total O
fluid O
requirement O
in O
the O
therapy O
of O
patients O
with O
burn O
shock O
V O
. O

Bagin O
, O
V O
. O

Rudnov O
, O
A O
. O

Savitsky O
, O
M O
. O

Astafyeva O
, O
I O
. O

Korobko O
, O
V O
. O

Vein O
P174 O
- O
Electron O
microscopic O
assessment O
of O
acute O
kidney O
injury O
in O
septic O
sheep O
resuscitated O
with O
crystalloids O
or O
different O
colloids O
T O
. O

Kampmeier O
, O
P O
. O

Arnemann O
, O
M O
. O

Hessler O
, O
A O
. O

Wald O
, O
K O
. O

Bockbreder O
, O
A O
. O

Morelli O
, O
H O
. O

Van O
Aken O
, O
S O
. O

Rehberg O
, O
C O
. O

Ertmer O
P175 O
- O
Alterations O
of O
conjunctival O
microcirculation O
in O
a O
sheep O
model O
of O
haemorrhagic O
shock O
and O
resuscitation O
with O
0.9 O
% O
saline O
or O
balanced O
tetrastarch O
P O
. O

Arnemann O
, O
M O
. O

Hessler O
, O
T O
. O

Kampmeier O
, O
S O
. O

Rehberg O
, O
H O
. O

Van O
Aken O
, O
C O
. O

Ince O
, O
C O
. O

Ertmer O
P176 O
- O
A O
single O
centre O
nested O
pilot O
study O
investigating O
the O
effect O
of O
using O
0.9 O
% O
saline O
or O
Plasma-Lyte O
148 O
® O
as O
crystalloid O
fluid O
therapy O
on O
gastrointestinal O
feeding O
intolerance O
in O
mechanically O
ventilated O
patients O
receiving O
nasogastric O
enteral O
nutrition O
S O
. O

Reddy O
, O
M O
. O

Bailey O
, O
R O
. O

Beasley O
, O
R O
. O

Bellomo O
, O
D O
. O

Mackle O
, O
A O
. O

Psirides O
, O
P O
. O

Young O
P177 O
- O
A O
single O
centre O
nested O
pilot O
study O
investigating O
the O
effect O
on O
post-operative O
bleeding O
of O
using O
0.9 O
% O
saline O
or O
Plasma-Lyte O
® O
148 O
as O
crystalloid O
fluid O
therapy O
in O
adults O
in O
ICU O
after O
heart O
surgery O
S O
. O

Reddy O
, O
M O
. O

Bailey O
, O
R O
. O

Beasley O
, O
R O
. O

Bellomo O
, O
D O
. O

Mackle O
, O
P O
. O

Young O
P178 O
- O
Extreme O
hypernatremia O
and O
sepsis O
in O
a O
patient O
with O
Huntington O
’ O
s O
dementia O
: O
a O
conundrum O
in O
fluid O
management O
H O
. O

Venkatesh O
, O
S O
. O

Ramachandran O
, O
A O
. O

Basu O
, O
H O
. O

Nair O
P179 O
- O
Diagnosis O
and O
management O
of O
severe O
hypernatraemia O
in O
the O
critical O
care O
setting O
S O
. O

Egan O
, O
J O
. O

Bates O
P180 O
- O
Correlation O
between O
arterial O
blood O
gas O
and O
electrolyte O
disturbances O
during O
hospitalization O
and O
outcome O
in O
critically O
ill O
patients O
S O
. O

Oliveira O
, O
N O
. O

R O
. O

Rangel O
Neto O
, O
F O
. O

Q O
. O

Reis O
P181 O
- O
Missing O
the O
“ O
I O
” O
in O
MUDPILES O
– O
a O
rare O
cause O
of O
high O
anion O
gap O
metabolic O
acidosis O
( O
HAGMA O
) O
C O
. O

P O
. O

Lee O
, O
X O
. O

L O
. O

Lin O
, O
C O
. O

Choong O
, O
K O
. O

M O
. O

Eu O
, O
W O
. O

Y O
. O

Sim O
, O
K O
. O

S O
. O

Tee O
, O
J O
. O

Pau O
, O
J O
. O

Abisheganaden O
P182 O
- O
Plasma O
NGAL O
and O
urinary O
output O
: O
potential O
parameters O
for O
early O
initiation O
of O
renal O
replacement O
therapy O
K O
. O

Maas O
, O
H O
. O

De O
Geus O
P183 O
- O
Renal O
replacement O
therapy O
for O
critically O
ill O
patients O
: O
an O
intermittent O
continuity O
E O
. O

Lafuente O
, O
R O
. O

Marinho O
, O
J O
. O

Moura O
, O
R O
. O

Antunes O
, O
A O
. O

Marinho O
P184 O
- O
A O
survey O
of O
practices O
related O
to O
renal O
replacement O
therapy O
in O
critically O
ill O
patients O
in O
the O
north O
of O
England O
. O

T O
. O

E O
. O

Doris O
, O
D O
. O

Monkhouse O
, O
T O
. O

Shipley O
, O
S O
. O

Kardasz O
, O
I O
Gonzalez O
P185 O
- O
High O
initiation O
creatinine O
associated O
with O
lower O
28 O
- O
day O
mortality O
in O
critically O
ill O
patients O
necessitating O
continuous O
renal O
replacement O
therapy O
S O
. O

Stads O
, O
A O
. O

J O
. O

Groeneveld O
P186 O
- O
The O
impact O
of O
Karnofsky O
performance O
scale O
on O
outcomes O
in O
acute O
kidney O
injury O
patients O
receiving O
renal O
replacement O
therapy O
on O
the O
intensive O
care O
unit O
I O
. O

Elsayed O
, O
N O
. O

Ward O
, O
A O
. O

Tridente O
, O
A O
. O

Raithatha O
P187 O
- O
Severe O
hypophosphatemia O
during O
citrate-anticoagulated O
CRRT O
A O
. O

Steuber O
, O
C O
. O

Pelletier O
, O
S O
. O

Schroeder O
, O
E O
. O

Michael O
, O
T O
. O

Slowinski O
, O
D O
. O

Kindgen-Milles O
P188 O
- O
Citrate O
regional O
anticoagulation O
for O
post O
dilution O
continuous O
renal O
replacement O
therapy O
S O
. O

Ghabina O
P189 O
- O
Citrate O
18 O
mmol O
/ O
l O
improves O
anticoagulation O
during O
RRT O
with O
adsorbing O
filters O
F O
. O

Turani O
, O
A O
. O

Belli O
, O
S O
. O

Busatti O
, O
G O
. O

Barettin O
, O
F O
. O

Candidi O
, O
F O
. O

Gargano O
, O
R O
. O

Barchetta O
, O
M O
. O

Falco O
P190 O
- O
Calcium O
gluconate O
instead O
of O
calcium O
chloride O
in O
citrate-anticoagulated O
CVVHD O
O O
. O

Demirkiran O
, O
M O
. O

Kosuk O
, O
S O
. O

Bozbay O
P191 O
- O
Enhanced O
clearance O
of O
interleukin O
- O
6 O
with O
continuous O
veno-venous O
haemodialysis O
( O
CVVHD O
) O
using O
Ultraflux O
EMiC2 O
vs O
. O

Ultraflux O
AV1000S O
V O
. O

Weber O
, O
J O
. O

Hartmann O
, O
S O
. O

Harm O
, O
I O
. O

Linsberger O
, O
T O
. O

Eichhorn O
, O
G O
. O

Valicek O
, O
G O
. O

Miestinger O
, O
C O
. O

Hoermann O
P192 O
- O
Removal O
of O
bilirubin O
with O
a O
new O
adsorbent O
system O
: O
in O
vitro O
kinetics O
S O
. O

Faenza O
, O
D O
. O

Ricci O
, O
E O
. O

Mancini O
, O
C O
. O

Gemelli O
, O
A O
. O

Cuoghi O
, O
S O
. O

Magnani O
, O
M O
. O

Atti O
P193 O
- O
Case O
series O
of O
patients O
with O
severe O
sepsis O
and O
septic O
shock O
treated O
with O
a O
new O
extracorporeal O
sorbent O
T O
. O

Laddomada O
, O
A O
. O

Doronzio O
, O
B O
. O

Balicco O
P194 O
- O
In O
vitro O
adsorption O
of O
a O
broad O
spectrum O
of O
inflammatory O
mediators O
with O
CytoSorb O
® O
hemoadsorbent O
polymer O
beads O
M O
. O

C O
. O

Gruda O
, O
P O
. O

O O
’ O
Sullivan O
, O
V O
. O

P O
. O

Dan O
, O
T O
. O

Guliashvili O
, O
A O
. O

Scheirer O
, O
T O
. O

D O
. O

Golobish O
, O
V O
. O

J O
. O

Capponi O
, O
P O
. O

P O
. O

Chan O
P195 O
- O
Observations O
in O
early O
vs O
. O
late O
use O
of O
cytosorb O
therapy O
in O
critically O
ill O
patients O
K O
. O

Kogelmann O
, O
M O
. O

Drüner O
, O
D O
. O

Jarczak O
P196 O
- O
Oxiris O
membrane O
decreases O
endotoxin O
during O
rrt O
in O
septic O
patients O
with O
basal O
EAA O
> O
0,6 O
F O
. O

Turani O
, O
A O
. O

B O
. O

Belli O
, O
S O
. O

M O
. O

Martni O
, O
V O
. O

C O
. O

Cotticelli O
, O
F O
. O

Mounajergi O
, O
R O
. O

Barchetta O
P197 O
- O
An O
observational O
prospective O
study O
on O
the O
onset O
of O
augmented O
renal O
clearance O
: O
the O
first O
report O
S O
. O

Morimoto O
, O
H O
. O

Ishikura O
P198 O
- O
An O
ultrasound O
- O
guided O
algorithm O
for O
the O
management O
of O
oliguria O
in O
severe O
sepsis O
I O
. O

Hussain O
, O
N O
. O

Salahuddin O
, O
A O
. O

Nadeem O
, O
K O
. O

Ghorab O
, O
K O
. O

Maghrabi O
P199 O
- O
Ultrasound O
in O
acute O
kidney O
injury O
( O
aki O
) O
. O

First O
findings O
of O
farius O
, O
an O
education-programme O
in O
structural O
ultrasonography O
S O
. O

K O
. O

Kloesel O
, O
C O
. O

Goldfuss O
, O
A O
. O

Stieglitz O
, O
A O
. O

S O
. O

Stieglitz O
, O
L O
. O

Krstevska O
, O
G O
. O

Albuszies O
P200 O
- O
Effectiveness O
of O
renal O
angina O
index O
score O
predicting O
acute O
kidney O
injury O
on O
critically O
ill O
patients O
M O
. O

Aguilar O
Arzapalo O
, O
L O
. O

Barradas O
, O
V O
. O

Lopez O
, O
A O
. O

Escalante O
, O
G O
. O

Jimmy O
, O
M O
. O

Cetina O
P201 O
- O
Time O
length O
below O
blood O
pressure O
thresholds O
and O
progression O
of O
acute O
kidney O
injury O
in O
critically O
ill O
patients O
with O
or O
without O
sepsis O
: O
a O
retrospective O
, O
exploratory O
cohort O
study O
J O
. O

Izawa O
, O
T O
. O

Iwami O
, O
S O
. O

Uchino O
, O
M O
. O

Takinami O
, O
T O
. O

Kitamura O
, O
T O
. O

Kawamura O
P202 O
- O
Anaemia O
does O
not O
affect O
renal O
recovery O
in O
acute O
kidney O
injury O
J O
. O

G O
. O

Powell-Tuck O
, O
S O
. O

Crichton O
, O
M O
. O

Raimundo O
, O
L O
. O

Camporota O
, O
D O
. O

Wyncoll O
, O
M O
. O

Ostermann O
P203 O
- O
Estimated O
glomerular O
filtration O
rate O
based O
on O
serum O
creatinine O
: O
actual O
practice O
in O
Dutch O
ICU O
’ O
s O
A O
. O

Hana O
, O
H O
. O

R O
. O

De O
Geus O
P204 O
- O
Comparison O
of O
estimated O
glomerular O
filtration O
rate O
calculated O
by O
mdrd O
, O
ckd-epi-serum-creatinine O
and O
ckd-epi-cystatin-c O
in O
adult O
critically O
ill O
patients O
H O
. O

R O
. O

De O
Geus O
, O
A O
. O

Hana O
P205 O
- O
Early O
diagnosis O
of O
septic O
acute O
kidney O
injury O
in O
medical O
critical O
care O
patients O
with O
a O
urine O
cell O
cycle O
arrest O
marker O
: O
insulin O
like O
growth O
factor O
binding O
protein O
- O
7 O
( O
IGFBP O
- O
7 O
) O
M O
. O

Aydogdu O
, O
N O
. O

Boyaci O
, O
S O
. O

Yuksel O
, O
G O
. O

Gursel O
, O
A O
. O

B O
. O

Cayci O
Sivri O
P206 O
- O
Urinary O
neutrophil O
gelatinase-associated O
lipocalin O
as O
early O
biomarker O
of O
severe O
acute O
kidney O
injury O
in O
intensive O
care O
J O
. O

Meza-Márquez O
, O
J O
. O

Nava-López O
, O
R O
. O

Carrillo-Esper O
P207 O
- O
Shrunken O
pore O
syndrome O
is O
associated O
with O
a O
sharp O
rise O
in O
mortality O
in O
patients O
undergoing O
elective O
coronary O
artery O
bypass O
grafting O
A O
. O

Dardashti O
, O
A O
. O

Grubb O
P208 O
- O
The O
biomarker O
nephrocheck O
™ O
can O
discriminate O
the O
septic O
shock O
patients O
with O
an O
akin O
1 O
or O
2 O
acute O
renal O
failure O
who O
will O
not O
progress O
toward O
the O
akin O
3 O
level O
J O
. O

Maizel O
, O
M O
. O

Wetzstein O
, O
D O
. O

Titeca O
, O
L O
. O

Kontar O
, O
F O
. O

Brazier O
, O
B O
. O

De O
Cagny O
, O
A O
. O

Riviere O
, O
T O
. O

Soupison O
, O
M O
. O

Joris O
, O
M O
. O

Slama O
P209 O
- O
A O
worldwide O
multicentre O
evaluation O
of O
acute O
kidney O
injury O
in O
septic O
and O
non-septic O
critically O
ill O
patients O
: O
the O
intensive O
care O
over O
nations O
( O
icon O
) O
audit O
E O
. O

Peters O
, O
H O
. O

Njimi O
, O
P O
. O

Pickkers O
, O
J O
. O

L O
. O

Vincent O
P210 O
- O
Does O
enhanced O
recovery O
after O
surgery O
reduce O
the O
incidence O
of O
acute O
kidney O
injury O
in O
those O
undergoing O
major O
gynae-oncological O
surgery O
? O

M O
. O

Waraich O
, O
J O
. O

Doyle O
, O
T O
. O

Samuels O
, O
L O
. O

Forni O
P211 O
- O
Identification O
of O
risk O
factors O
for O
the O
development O
of O
acute O
kidney O
injury O
after O
lower O
limb O
arthroplasty O
N O
. O

Desai O
, O
R O
. O

Baumber O
, O
P O
. O

Gunning O
, O
A O
. O

Sell O
P212 O
- O
Incidences O
and O
associations O
of O
acute O
kidney O
injury O
after O
major O
trauma O
S O
. O

Lin O
, O
H O
. O

Torrence O
, O
M O
. O

O O
’ O
Dwyer O
, O
C O
. O

Kirwan O
, O
J O
. O

Prowle O
P213 O
- O
Acute O
kidney O
injury O
of O
major O
trauma O
patients O
T O
Kim O
P214 O
- O
Trajectory O
of O
serum O
creatinine O
after O
major O
surgery O
and O
the O
diagnosis O
of O
acute O
kidney O
injury O
M O
. O

E O
. O

O O
’ O
Connor O
, O
R O
. O

W O
. O

Hewson O
, O
C O
. O

J O
. O

Kirwan O
, O
R O
. O

M O
. O

Pearse O
, O
J O
. O

Prowle O
P215 O
- O
Epidemiology O
of O
acute O
kidney O
injury O
after O
cardiac O
surgery O
. O

A O
single O
center O
retrospective O
study O
S O
. O

Hanoura O
, O
A O
. O

Omar O
, O
H O
. O

Othamn O
, O
S O
. O

Sudarsanan O
, O
M O
. O

Allam O
, O
M O
. O

Maksoud O
, O
R O
. O

Singh O
, O
A O
. O

Al O
Khulaifi O
P216 O
- O
Post-operative O
acute O
kidney O
injury O
after O
major O
non-cardiac O
surgery O
and O
its O
association O
with O
death O
in O
the O
following O
year O
M O
. O

E O
. O

O O
’ O
Connor O
, O
R O
. O

W O
. O

Hewson O
, O
C O
. O

J O
. O

Kirwan O
, O
R O
. O

M O
. O

Pearse O
, O
J O
. O

Prowle O
P217 O
- O
Factors O
affecting O
acute O
renal O
failure O
in O
intensive O
care O
unit O
and O
effect O
of O
these O
factors O
on O
mortality O
O O
. O

Uzundere O
, O
D O
. O

Memis O
, O
M O
. O

Ýnal O
, O
A O
. O
, O
N O
. O

Turan O
P218 O
- O
Results O
of O
the O
live O
kidney O
transplantations O
according O
to O
national O
data O
of O
turkish O
organ O
and O
tissue O
information O
system O
M O
. O

A O
. O

Aydin O
, O
H O
. O

Basar O
, O
I O
. O

Sencan O
, O
A O
. O

Kapuagasi O
, O
M O
. O

Ozturk O
, O
Z O
. O

Uzundurukan O
, O
D O
. O

Gokmen O
, O
A O
. O

Ozcan O
, O
C O
. O

Kaymak O
P219 O
- O
Anaesthesia O
procedure O
and O
intensive O
therapy O
in O
patients O
with O
neck O
phlegmon O
V O
. O

A O
. O

Artemenko O
, O
A O
. O

Budnyuk O
P220 O
- O
Nasal O
high O
flow O
oygen O
for O
acute O
respiratory O
failure O
: O
a O
systematic O
review O
R O
. O

Pugh O
, O
S O
. O

Bhandari O
P221 O
- O
Setting O
optimal O
flow O
rate O
during O
high O
flow O
nasal O
cannula O
support O
: O
preliminary O
results O
T O
. O

Mauri O
, O
C O
. O

Turrini O
, O
T O
. O

Langer O
, O
P O
. O

Taccone O
, O
C O
. O

A O
. O

Volta O
, O
C O
. O

Marenghi O
, O
L O
. O

Gattinoni O
, O
A O
. O

Pesenti O
P222 O
- O
Dose O
to O
dose O
consistency O
across O
two O
different O
gas O
flow O
rates O
using O
cystic O
fibrosis O
and O
normal O
adult O
breathing O
profiles O
during O
nasal O
high O
flow O
oxygen O
therapy O
L O
. O

Sweeney O
, O
A O
. O

O O
’ O
Sullivan O
, O
P O
. O

Kelly O
, O
E O
. O

Mukeria O
, O
R O
. O

MacLoughlin O
P223 O
- O
Final O
results O
of O
an O
evaluation O
of O
airway O
medix O
closed O
suction O
system O
compared O
to O
a O
standard O
closed O
suction O
system O
M O
. O

Pfeffer O
, O
J O
. O

T O
. O

Thomas O
, O
G O
. O

B O
. O

Bregman O
, O
G O
. O

K O
. O

Karp O
, O
E O
. O

K O
. O

Kishinevsky O
, O
D O
. O

S O
. O

Stavi O
, O
N O
. O

A O
. O

Adi O
P224 O
- O
Different O
cuff O
materials O
and O
different O
leak O
tests O
- O
one O
size O
does O
not O
fit O
all O
T O
. O

Poropat O
, O
R O
. O

Knafelj O
P225 O
- O
Observational O
study O
on O
the O
value O
of O
the O
cuff-leak O
test O
and O
the O
onset O
of O
upper O
airway O
obstruction O
after O
extubation O
E O
. O

Llopart O
, O
M O
. O

Batlle O
, O
C O
. O

De O
Haro O
, O
J O
. O

Mesquida O
, O
A O
. O

Artigas O
P226 O
- O
A O
device O
for O
emergency O
transtracheal O
lung O
ventilation O
D O
. O

Pavlovic O
, O
L O
. O

Lewerentz O
, O
A O
. O

Spassov O
, O
R O
. O

Schneider O
P227 O
- O
Long-term O
outcome O
and O
health-related O
quality O
of O
life O
in O
patients O
discharged O
from O
the O
intensive O
care O
unit O
with O
a O
tracheostomy O
and O
with O
or O
without O
prolonged O
mechanical O
ventilation O
S O
. O

De O
Smet O
, O
S O
. O

De O
Raedt O
, O
E O
. O

Derom O
, O
P O
Depuydt O
, O
S O
. O

Oeyen O
, O
D O
. O

Benoit O
, O
J O
. O

Decruyenaere O
P228 O
- O
Ultrasound-guided O
percutaneous O
dilational O
tracheostomy O
versus O
bronchoscopy-guided O
percutaneous O
dilational O
tracheostomy O
in O
critically O
ill O
patients O
( O
trachus O
) O
: O
a O
randomized O
clinical O
trial O
A O
. O

Gobatto O
, O
B O
. O

Bese O
, O
P O
. O

Tierno O
, O
L O
. O

Melro O
, O
P O
. O

Mendes O
, O
F O
. O

Cadamuro O
, O
M O
. O

Park O
, O
L O
. O

M O
. O

Malbouisson O
P229 O
- O
Is O
it O
safe O
to O
discharge O
patients O
with O
tracheostomy O
from O
the O
ICU O
to O
the O
ward O
? O

B O
. O

C O
. O

Civanto O
, O
J O
. O

L O
. O

Lopez O
, O
A O
. O

Robles O
, O
J O
. O

Figueira O
, O
S O
. O

Yus O
, O
A O
. O

Garcia O
P230 O
- O
The O
application O
of O
tracheostomy O
in O
children O
in O
ICU O
A O
. O

Oglinda O
, O
G O
. O

Ciobanu O
, O
C O
. O

Oglinda O
, O
L O
. O

Schirca O
, O
T O
. O

Sertinean O
, O
V O
. O

Lupu O
P231 O
- O
The O
impact O
of O
passive O
humidifiers O
on O
aerosol O
drug O
delivery O
during O
mechanical O
ventilation O
P O
. O

Kelly O
, O
A O
. O

O O
’ O
Sullivan O
, O
L O
. O

Sweeney O
, O
R O
. O

MacLoughlin O
P232 O
- O
Evaluation O
of O
vibrating O
mesh O
and O
jet O
nebuliser O
performance O
at O
two O
different O
attachment O
setups O
in O
line O
with O
a O
humidifier O
nebuliser O
system O
A O
. O

O O
’ O
Sullivan O
, O
P O
. O

Kelly O
, O
L O
. O

Sweeney O
, O
E O
. O

Mukeria O
, O
M O
. O

Wolny O
, O
R O
. O

MacLoughlin O
P233 O
- O
Psv-niv O
versus O
cpap O
in O
the O
treatment O
of O
acute O
cardiogenic O
pulmonary O
edema O
A O
. O

Pagano O
, O
F O
. O

Numis O
, O
G O
. O

Vison O
, O
L O
. O

Saldamarco O
, O
T O
. O

Russo O
, O
G O
. O

Porta O
, O
F O
. O

Paladino O
P234 O
- O
Noninvasive O
ventilation O
in O
patients O
with O
haematologic O
malignancy O
: O
a O
retrospective O
review O
C O
. O

Bell O
, O
J O
. O

Liu O
, O
J O
. O

Debacker O
, O
C O
. O

Lee O
, O
E O
. O

Tamberg O
, O
V O
. O

Campbell O
, O
S O
. O

Mehta O
P235 O
- O
Use O
of O
non-invasive O
ventilation O
in O
infectious O
diseases O
besides O
classical O
indications O
A O
. O

Silva-Pinto O
, O
A O
. O

Sarmento O
, O
L O
. O

Santos O
P236 O
- O
The O
impact O
of O
fragility O
on O
noninvasive O
mechanical O
ventilation O
application O
and O
results O
in O
the O
ICU O
Ý O
. O

Kara O
, O
F O
. O

Yýldýrým O
, O
A O
. O

Zerman O
, O
Z O
. O

Güllü O
, O
N O
. O

Boyacý O
, O
B O
. O

Basarýk O
Aydogan O
, O
Ü O
. O

Gaygýsýz O
, O
K O
. O

Gönderen O
, O
G O
. O

Arýk O
, O
M O
. O

Turkoglu O
, O
M O
. O

Aydogdu O
, O
G O
. O

Aygencel O
, O
Z O
. O

Ülger O
, O
G O
. O

Gursel O
P237 O
- O
Effects O
of O
metabolic O
alkalosis O
on O
noninvasive O
ventilation O
success O
and O
ICU O
outcome O
in O
patients O
with O
hypercapnic O
respiratory O
failure O
N O
. O

Boyacý O
, O
Z O
. O

Isýkdogan O
, O
Ö O
. O

Özdedeoglu O
, O
Z O
. O

Güllü O
, O
M O
. O

Badoglu O
, O
U O
. O

Gaygýsýz O
, O
M O
. O

Aydogdu O
, O
G O
. O

Gursel O
P238 O
- O
Asynchrony O
index O
and O
breathing O
patterns O
of O
acute O
exacerbation O
copd O
patients O
assisted O
with O
noninvasive O
pressure O
support O
ventilation O
and O
neurally O
adjusted O
ventilatory O
assist O
N O
. O

Kongpolprom O
, O
C O
. O

Sittipunt O
P239 O
- O
High O
frequency O
jet O
ventilation O
for O
severe O
acute O
hypoxemia O
A O
. O

Eden O
, O
Y O
. O

Kokhanovsky O
, O
S O
. O

Bursztein O
– O
De O
Myttenaere O
, O
R O
. O

Pizov O
P240 O
- O
HFOV O
revisited O
: O
a O
7 O
year O
retrospective O
analysis O
of O
patients O
receiving O
HFOV O
who O
met O
oscillate O
trial O
entry O
criteria O
L O
. O

Neilans O
, O
N O
. O

MacIntyre O
P241 O
- O
Implementation O
of O
a O
goal-directed O
mechanical O
ventilation O
order O
set O
driven O
by O
respiratory O
therapists O
can O
improve O
compliance O
with O
best O
practices O
for O
mechanical O
ventilation O
M O
. O

Radosevich O
, O
B O
. O

Wanta O
, O
V O
. O

Weber O
, O
T O
. O

Meyer O
, O
N O
. O

Smischney O
, O
D O
. O

Brown O
, O
D O
. O

Diedrich O
P242 O
- O
A O
reduction O
in O
tidal O
volumes O
for O
ventilated O
patients O
on O
ICU O
calculated O
from O
IBW O
. O
can O
it O
minimise O
mortality O
in O
comparison O
to O
traditional O
strategies O
? O

A O
. O

Fuller O
, O
P O
. O

McLindon O
, O
K O
. O

Sim O
P243 O
- O
Predictive O
value O
of O
lung O
aeration O
scoring O
using O
lung O
ultrasound O
in O
weaning O
failure O
M O
. O

Shoaeir O
, O
K O
. O

Noeam O
, O
A O
. O

Mahrous O
, O
R O
. O

Matsa O
, O
A O
. O

Ali O
P244 O
- O
Conventional O
versus O
automated O
weaning O
from O
mechanical O
ventilation O
using O
SmartCare O
™ O
C O
. O

Dridi O
, O
S O
. O

Koubaji O
, O
S O
. O

Kamoun O
, O
F O
. O

Haddad O
, O
A O
. O

Ben O
Souissi O
, O
B O
. O

Laribi O
, O
A O
. O

Riahi O
, O
M O
. O

S O
. O

Mebazaa O
P245 O
- O
Ultrasonographic O
evaluation O
protocol O
for O
weaning O
from O
mechanichal O
ventilation O
A O
. O

Pérez-Calatayud O
, O
R O
. O

Carrillo-Esper O
, O
A O
. O

Zepeda-Mendoza O
, O
M O
. O

Diaz-Carrillo O
, O
E O
. O

Arch-Tirado O
P246 O
- O
Diaphragm O
ultrasonography O
: O
a O
method O
for O
weaning O
patients O
from O
mechanical O
ventilation O
S O
. O

Carbognin O
, O
L O
. O

Pelacani O
, O
F O
. O

Zannoni O
, O
A O
. O

Agnoli O
, O
G O
. O

Gagliardi O
P247 O
- O
Dorsal O
diaphragmatic O
excursion O
tracks O
transpulmonary O
pressure O
in O
ventilated O
ARDS O
patients O
: O
a O
potential O
non-invasive O
indicator O
of O
lung O
recruitment O
? O

R O
. O

Cho O
, O
A O
. O

Adams O
, O
S O
. O

Lunos O
, O
S O
. O

Ambur O
, O
R O
. O

Shapiro O
, O
M O
. O

Prekker O
P248 O
- O
Pulse O
oximetry O
in O
the O
icu O
patient O
: O
is O
the O
perfusion O
index O
of O
any O
value O
? O

M O
. O

Thijssen O
, O
L O
. O

Janssen O
, O
N O
. O

Foudraine O
P249 O
- O
Ventilation O
is O
a O
better O
assessment O
of O
respiratory O
status O
than O
EtCO2 O
C O
. O

J O
. O

Voscopoulos O
, O
J O
. O

Freeman O
P250 O
- O
Evaluation O
of O
the O
relationship O
between O
non-invasive O
minute O
ventilation O
and O
end-tidal O
CO2 O
in O
patients O
undergoing O
general O
vs O
spinal O
anesthesia O
C O
. O

J O
. O

Voscopoulos O
, O
J O
. O

Freeman O
, O
E O
. O

George O
P251 O
- O
Respiratory O
volume O
monitoring O
provides O
early O
warning O
of O
respiratory O
depression O
and O
can O
be O
used O
to O
reduce O
false O
alarms O
in O
non-intubated O
patients O
C O
. O

J O
. O

Voscopoulos O
, O
D O
. O

Eversole O
, O
J O
. O

Freeman O
, O
E O
. O

George O
P252 O
- O
P O
/ O
i O
index O
: O
a O
predictive O
edi-derived O
weaning O
index O
during O
nava O
S O
. O

Muttini O
, O
R O
. O

Bigi O
, O
G O
. O

Villani O
, O
N O
. O

Patroniti O
P253 O
- O
Adequacy O
of O
ventilation O
in O
patients O
receiving O
opioids O
in O
the O
post O
anesthesia O
care O
unit O
: O
minute O
ventilation O
versus O
respiratory O
rate O
G O
. O

Williams O
, O
C O
. O

J O
. O

Voscopoulos O
, O
J O
. O

Freeman O
, O
E O
. O

George O
P254 O
- O
Comparison O
of O
regional O
and O
global O
expiratory O
time O
constants O
measured O
by O
electrical O
impedance O
tomography O
( O
EIT O
) O
A O
. O

Waldmann O
, O
S O
. O

Böhm O
, O
W O
. O

Windisch O
, O
S O
. O

Strassmann O
, O
C O
. O

Karagiannidis O
P255 O
- O
Electrical O
impedance O
tomography O
: O
robustness O
of O
a O
new O
pixel O
wise O
regional O
expiratory O
time O
constant O
calculation O
A O
. O

Waldmann O
, O
S O
. O

Böhm O
, O
W O
. O

Windisch O
, O
S O
. O

Strassmann O
, O
C O
. O

Karagiannidis O
P256 O
- O
Validation O
of O
regional O
and O
global O
expiratory O
time O
constant O
measurement O
by O
electrical O
impedance O
tomography O
in O
ards O
and O
obstructive O
pulmonary O
diseases O
C O
. O

K O
. O

Karagiannidis O
, O
A O
. O

W O
. O

Waldmann O
, O
S O
. O

B O
. O

Böhm O
, O
S O
. O

Strassmann O
, O
W O
. O

W O
. O

Windisch O
P257 O
- O
Transpulmonary O
pressure O
in O
a O
model O
with O
elastic O
recoiling O
lung O
and O
expanding O
chest O
wall O
P O
. O

Persson O
, O
S O
. O

Lundin O
, O
O O
. O

Stenqvist O
P258 O
- O
Lactate O
in O
pleural O
and O
abdominal O
effusion O
G O
. O

Porta O
, O
F O
. O

Numis O
, O
C O
. O

S O
. O

Serra O
, O
A O
. O

P O
. O

Pagano O
, O
M O
. O

M O
. O

Masarone O
, O
L O
. O

R O
. O

Rinaldi O
, O
A O
. O

A O
. O

Amelia O
, O
M O
. O

F O
. O

Fascione O
, O
L O
. O

A O
. O

Adinolfi O
, O
E O
. O

R O
. O

Ruggiero O
P259 O
- O
Outcome O
of O
patients O
admitted O
to O
the O
intensive O
care O
with O
pulmonary O
fibrosis O
F O
. O

Asota O
, O
K O
. O

O O
’ O
Rourke O
, O
S O
. O

Ranjan O
, O
P O
. O

Morgan O
P260 O
- O
Sedation O
and O
analgesia O
practice O
in O
extra-corporeal O
membrane O
oxygenation O
( O
ECMO O
) O
- O
treated O
patients O
with O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
: O
a O
retrospective O
study O
J O
. O

W O
. O

DeBacker O
, O
E O
. O

Tamberg O
, O
L O
. O

O O
’ O
Neill O
, O
L O
. O

Munshi O
, O
L O
. O

Burry O
, O
E O
. O

Fan O
, O
S O
. O

Mehta O
P261 O
- O
Characteristics O
and O
outcomes O
of O
patients O
deemed O
not O
eligible O
when O
referred O
for O
veno-venous O
extracorporeal O
membrane O
oxygenation O
( O
vv-ECMO O
) O
S O
. O

Poo O
, O
K O
. O

Mahendran O
, O
J O
. O

Fowles O
, O
C O
. O

Gerrard O
, O
A O
. O

Vuylsteke O
P262 O
- O
The O
SAVE O
SMR O
for O
veno-arterial O
ECMO O
R O
. O

Loveridge O
, O
C O
. O

Chaddock O
, O
S O
. O

Patel O
, O
V O
. O

Kakar O
, O
C O
. O

Willars O
, O
T O
. O

Hurst O
, O
C O
. O

Park O
, O
T O
. O

Best O
, O
A O
. O

Vercueil O
, O
G O
. O

Auzinger O
P263 O
- O
A O
simplified O
score O
to O
predict O
early O
( O
48 O
h O
) O
mortality O
in O
patients O
being O
considered O
for O
VA-ECMO O
A O
. O

Borgman O
, O
A O
. O

G O
. O

Proudfoot O
, O
E O
. O

Grins O
, O
K O
. O

E O
. O

Emiley O
, O
J O
. O

Schuitema O
, O
S O
. O

J O
. O

Fitch O
, O
G O
. O

Marco O
, O
J O
. O

Sturgill O
, O
M O
. O

G O
. O

Dickinson O
, O
M O
. O

Strueber O
, O
A O
. O

Khaghani O
, O
P O
. O

Wilton O
, O
S O
. O

M O
. O

Jovinge O
P264 O
- O
Lung O
function O
six O
months O
post O
extra O
corporeal O
membrane O
oxygenation O
( O
ECMO O
) O
for O
severe O
acute O
respiratory O
failure O
in O
adult O
survivors O
C O
. O

Sampson O
, O
S O
. O

Harris-Fox O
P265 O
- O
Bicarbonate O
dialysis O
removes O
carbon O
dioxide O
in O
hypoventilated O
rodents O
. O

M O
. O

E O
. O

Cove O
, O
L O
. O

H O
. O

Vu O
, O
A O
. O

Sen O
, O
W O
. O

J O
. O

Federspiel O
, O
J O
. O

A O
. O

Kellum O
P266 O
- O
Procalcitonin O
as O
predictor O
of O
primary O
graft O
dysfunction O
and O
mortality O
in O
post-lung O
transplantation O
C O
. O

Mazo O
Torre O
, O
J O
. O

Riera O
, O
S O
. O

Ramirez O
, O
B O
. O

Borgatta O
, O
L O
. O

Lagunes O
, O
J O
. O

Rello O
P267 O
- O
New O
molecular O
biomarkers O
of O
acute O
respiratory O
distress O
syndrome O
in O
abdominal O
sepsis O
A O
. O

K O
. O

Kuzovlev O
, O
V O
. O

Moroz O
, O
A O
. O

Goloubev O
, O
S O
. O

Polovnikov O
, O
S O
. O

Nenchuk O
P268 O
- O
Tight O
junction O
’ O
s O
proteins O
claudin O
- O
5 O
and O
regulation O
by O
tnf O
in O
experimental O
murine O
lung O
injury O
model O
of O
ali O
/ O
ards O
V O
. O

Karavana O
, O
C O
. O

Glynos O
, O
A O
. O

Asimakos O
, O
K O
. O

Pappas O
, O
C O
. O

Vrettou O
, O
M O
. O

Magkou O
, O
E O
. O

Ischaki O
, O
G O
. O

Stathopoulos O
, O
S O
. O

Zakynthinos O
P269 O
- O
Cell O
counts O
in O
endobronchial O
aspirate O
to O
assess O
airway O
inflammation O
in O
ARDS O
patients O
: O
a O
pilot O
study O
S O
. O

Spadaro O
, O
I O
. O

Kozhevnikova O
, O
F O
. O

Dalla O
Corte O
, O
S O
. O

Grasso O
, O
P O
. O

Casolari O
, O
G O
. O

Caramori O
, O
C O
. O

Volta O
P270 O
- O
Epidemiological O
and O
clinical O
profile O
of O
patients O
with O
acute O
respiratory O
distress O
syndrome O
in O
the O
surgical O
intensive O
care O
unit O
surgical O
, O
hospital O
JRA O
, O
Antananarivo O
T O
. O

Andrianjafiarinoa O
, O
T O
. O

Randriamandrato O
, O
T O
. O

Rajaonera O
P271 O
- O
Effect O
of O
high O
PEEP O
after O
recruitment O
maneuver O
on O
right O
ventricular O
function O
in O
ARDS O
. O

Is O
it O
good O
for O
the O
lung O
and O
for O
the O
heart O
? O

S O
. O

El-Dash O
, O
ELV O
Costa O
, O
MR O
Tucci O
, O
F O
Leleu O
, O
L O
Kontar O
, O
B O
. O

De O
Cagny O
, O
F O
. O

Brazier O
, O
D O
. O

Titeca O
, O
G O
. O

Bacari-Risal O
, O
J O
. O

Maizel O
, O
M O
. O

Amato O
, O
M O
. O

Slama O
P272 O
- O
Effect O
of O
recruitment O
maneuver O
on O
left O
ventricular O
systolic O
strain O
P O
. O

Mercado O
, O
J O
. O

Maizel O
, O
L O
. O

Kontar O
, O
D O
. O

Titeca O
, O
F O
. O

Brazier O
, O
A O
. O

Riviere O
, O
M O
. O

Joris O
, O
T O
. O

Soupison O
, O
B O
. O

De O
Cagny O
, O
S O
. O

El O
Dash O
, O
M O
. O

Slama O
P273 O
- O
Inhaled O
nitric O
oxide O
– O
is O
switching O
supplier O
cost O
effective O
? O

Remmington O
, O
A O
. O

Fischer O
, O
S O
. O

Squire O
, O
M O
. O

Boichat O
P274 O
- O
Epidemiological O
study O
of O
severe O
acute O
pancreatitis O
in O
Japan O
, O
comparison O
of O
the O
etiology O
and O
the O
patient O
outcomes O
on O
1159 O
patients O
. O

H O
. O

Honzawa O
, O
H O
. O

Yasuda O
, O
T O
. O

Adati O
, O
S O
. O

Suzaki O
, O
M O
. O

Horibe O
, O
M O
. O

Sasaki O
, O
M O
. O

Sanui O
P275 O
- O
Extracorporeal O
liver O
support O
therapy O
. O

Experience O
in O
an O
intensive O
care O
unit O
R O
. O

Marinho O
, O
J O
. O

Daniel O
, O
H O
. O

Miranda O
, O
A O
. O

Marinho O
P276 O
- O
Accuracy O
of O
mortality O
prediction O
models O
in O
acute O
versus O
acute-on-chronic O
liver O
failure O
in O
the O
intensive O
care O
setting O
K O
. O

Milinis O
, O
M O
. O

Cooper O
, O
G O
. O

R O
. O

Williams O
, O
E O
. O

McCarron O
, O
S O
. O

Simants O
, O
I O
. O

Patanwala O
, O
I O
. O

Welters O
P277 O
- O
Risk O
of O
coronary O
artery O
disease O
in O
patients O
with O
chronic O
liver O
disease O
: O
a O
population O
based O
cohort O
study O
Y O
. O

Su O
P278 O
- O
20 O
years O
of O
liver O
transplantation O
in O
Santiago O
de O
Compostela O
( O
Spain O
) O
. O

Experience O
review O
J O
. O

Fernández O
Villanueva O
, O
R O
. O

Fernández O
Garda O
, O
A O
. O

López O
Lago O
, O
E O
. O

Rodríguez O
Ruíz O
, O
R O
. O

Hernández O
Vaquero O
, O
S O
. O

Tomé O
Martínez O
de O
Rituerto O
, O
E O
. O

Varo O
Pérez O
P279 O
- O
Diarrhea O
is O
a O
risk O
factor O
for O
liver O
injury O
and O
may O
lead O
to O
intestinal O
failure O
associated O
liver O
disease O
in O
critical O
illness O
N O
. O

Lefel O
, O
F O
. O

Schaap O
, O
D O
. O

Bergmans O
, O
S O
. O

Olde O
Damink O
, O
M O
. O

Van O
de O
Poll O
P280 O
- O
Bowel O
care O
on O
the O
intensive O
care O
unit O
: O
constipation O
guideline O
compliance O
and O
complications O
K O
. O

Tizard O
, O
C O
. O

Lister O
, O
L O
. O

Poole O
P281 O
- O
Malnutrition O
assessed O
by O
phase O
angle O
determines O
outcomes O
in O
low O
risk O
cardiac O
surgery O
patients O
D O
. O

Ringaitiene O
, O
D O
. O

Gineityte O
, O
V O
. O

Vicka O
, O
I O
. O

Norkiene O
, O
J O
. O

Sipylaite O
P282 O
- O
Preoperative O
fasting O
times O
in O
an O
irish O
hospital O
A O
. O

O O
’ O
Loughlin O
, O
V O
. O

Maraj O
, O
J O
. O

Dowling O
P283 O
- O
Costs O
and O
final O
outcome O
of O
early O
x O
delayed O
feeding O
in O
a O
private O
Brazil O
ICU O
M O
. O

B O
. O

Velasco O
, O
D O
. O

M O
. O

Dalcomune O
, O
E O
. O

B O
. O

Dias O
, O
S O
. O

L O
. O

Fernandes O
P284 O
- O
Can O
ventilator O
derived O
energy O
expenditure O
measurements O
replace O
indirect O
calorimetry O
? O

T O
. O

Oshima O
, O
S O
. O

Graf O
, O
C O
. O

Heidegger O
, O
L O
. O

Genton O
, O
V O
. O

Karsegard O
, O
Y O
. O

Dupertuis O
, O
C O
. O

Pichard O
P285 O
- O
Revisiting O
the O
refeeding O
syndrome O
: O
results O
of O
a O
systematic O
review O
N O
. O

Friedli O
, O
Z O
. O

Stanga O
, O
B O
. O

Mueller O
, O
P O
. O

Schuetz O
P286 O
- O
Compliance O
with O
the O
new O
protocol O
for O
parenteral O
nutrition O
in O
our O
ICU O
L O
. O

Vandersteen O
, O
B O
. O

Stessel O
, O
S O
. O

Evers O
, O
A O
. O

Van O
Assche O
, O
L O
. O

Jamaer O
, O
J O
. O

Dubois O
P287 O
- O
Nutrition O
may O
be O
another O
treatment O
in O
the O
intensive O
care O
unit O
where O
less O
is O
more O
? O

R O
. O

Marinho O
, O
H O
. O

Castro O
, O
J O
. O

Moura O
, O
J O
. O

Valente O
, O
P O
. O

Martins O
, O
P O
. O

Casteloes O
, O
C O
. O

Magalhaes O
, O
S O
. O

Cabral O
, O
M O
. O

Santos O
, O
B O
. O

Oliveira O
, O
A O
. O

Salgueiro O
, O
A O
. O

Marinho O
P288 O
- O
Should O
we O
provide O
more O
protein O
to O
critically O
ill O
patients O
? O

R O
. O

Marinho O
, O
M O
. O

Santos O
, O
E O
. O

Lafuente O
, O
H O
. O

Castro O
, O
S O
. O

Cabral O
, O
J O
. O

Moura O
, O
P O
. O

Martins O
, O
B O
. O

Oliveira O
, O
A O
. O

Salgueiro O
, O
S O
. O

Duarte O
, O
S O
. O

Castro O
, O
M O
. O

Melo O
, O
P O
. O

Casteloes O
, O
A O
. O

Marinho O
P289 O
Protein O
provision O
in O
an O
adult O
intensive O
care O
unit O
S O
. O

Gray O
P290 O
- O
Prevalence O
and O
clinical O
outcomes O
of O
vitamin O
d O
deficiency O
in O
the O
medical O
critically O
ill O
patients O
in O
Songklanagarind O
hospital O
K O
. O

Maipang O
, O
R O
. O

Bhurayanontachai O
P291 O
- O
Vitamin O
d O
deficiency O
strongly O
predicts O
adverse O
medical O
outcome O
across O
different O
medical O
inpatient O
populations O
: O
results O
from O
a O
prospective O
study O
L O
. O

G O
. O

Grädel O
, O
P O
. O

Schütz O
P292 O
- O
Omega O
- O
3 O
fatty O
acids O
in O
patients O
undergoing O
cardiac O
surgery O
: O
a O
systematic O
review O
and O
meta-analysis O
P O
. O

Langlois O
, O
W O
. O

Manzanares O
P293 O
- O
Can O
5 O
- O
hydroxytriptophan O
prevent O
post-traumatic O
stress O
disorder O
in O
critically O
ill O
patients O
? O

R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P294 O
- O
Parenteral O
selenium O
in O
the O
critically O
ill O
: O
an O
updated O
systematic O
review O
and O
meta-analysis O
W O
. O

Manzanares O
, O
P O
. O

Langlois O
, O
M O
. O

Lemieux O
, O
G O
. O

Elke O
, O
F O
. O

Bloos O
, O
K O
. O

Reinhart O
, O
D O
. O

Heyland O
P295 O
- O
Probiotics O
in O
the O
critically O
ill O
: O
an O
updated O
systematic O
review O
and O
meta-analysis O
P O
. O

Langlois O
, O
M O
. O

Lemieux O
, O
I O
. O

Aramendi O
, O
D O
. O

Heyland O
, O
W O
. O

Manzanares O
P296 O
- O
Diabetes O
with O
hyperglycemic O
crisis O
episodes O
may O
be O
associated O
with O
higher O
risk O
of O
pancreatic O
cancer O
: O
a O
population-based O
cohort O
study O
Y O
. O

Su O
P297 O
- O
Incidence O
of O
hypoglycemia O
in O
an O
intensive O
care O
unit O
depending O
on O
insulin O
protocol O
R O
. O

Marinho O
, O
N O
. O

Babo O
, O
A O
. O

Marinho O
P298 O
- O
Severity O
of O
the O
diseases O
is O
two-dimensionally O
correlated O
to O
blood O
glucose O
, O
including O
blood O
glucose O
variability O
, O
especially O
in O
moderately O
to O
severely O
ill O
patients O
with O
glucose O
intolerance O
. O

M O
. O

Hoshino O
, O
Y O
. O

Haraguchi O
, O
S O
. O

Kajiwara O
, O
T O
. O

Mitsuhashi O
, O
T O
. O

Tsubata O
, O
M O
. O

Aida O
P299 O
- O
A O
study O
of O
glycemic O
control O
by O
subcutaneous O
glargine O
injection O
transition O
from O
continuous O
regular O
insulin O
infusion O
in O
critically O
ill O
patients O
T O
. O

Rattanapraphat O
, O
R O
. O

Bhurayanontachai O
, O
C O
. O

Kongkamol O
, O
B O
. O

Khwannimit O
P300 O
- O
Glycemic O
control O
in O
Portuguese O
intensive O
care O
unit O
R O
. O

Marinho O
, O
M O
. O

Santos O
, O
H O
. O

Castro O
, O
E O
. O

Lafuente O
, O
A O
. O

Salgueiro O
, O
S O
. O

Cabral O
, O
P O
. O

Martins O
, O
J O
. O

Moura O
, O
B O
. O

Oliveira O
, O
M O
. O

Melo O
, O
B O
. O

Xavier O
, O
J O
. O

Valente O
, O
C O
. O

Magalhaes O
, O
P O
. O

Casteloes O
, O
A O
. O

Marinho O
P301 O
- O
Impact O
of O
hyperglycemia O
duration O
on O
the O
day O
of O
operation O
on O
short-term O
outcome O
of O
cardiac O
surgery O
patients O
D O
. O

Moisidou O
, O
F O
. O

Ampatzidou O
, O
C O
. O

Koutsogiannidis O
, O
M O
. O

Moschopoulou O
, O
G O
. O

Drossos O
P302 O
- O
Lactate O
levels O
in O
diabetic O
ketoacidosis O
patients O
at O
ICU O
admissions O
G O
. O

Taskin O
, O
M O
. O

Çakir O
, O
AK O
Güler O
, O
A O
. O

Taskin O
, O
N O
. O

Öcal O
, O
S O
. O

Özer O
, O
L O
. O

Yamanel O
P303 O
- O
Intensive O
care O
implications O
of O
merging O
heart O
attack O
centre O
units O
in O
London O
J O
. O

M O
. O

Wong O
, O
C O
. O

Fitton O
, O
S O
. O

Anwar O
, O
S O
. O

Stacey O
P304 O
- O
Special O
characteristics O
of O
in-hospital O
cardiac O
arrests O
M O
. O

Aggou O
, O
B O
. O

Fyntanidou O
, O
S O
. O

Patsatzakis O
, O
E O
. O

Oloktsidou O
, O
K O
. O

Lolakos O
, O
E O
. O

Papapostolou O
, O
V O
. O

Grosomanidis O
P305 O
- O
Clinical O
evaluation O
of O
ICU-admitted O
patients O
who O
were O
resuscitated O
in O
the O
general O
medicine O
ward O
S O
. O

Suda O
, O
T O
. O

Ikeda O
, O
S O
. O

Ono O
, O
T O
. O

Ueno O
, O
Y O
. O

Izutani O
P306 O
- O
Serious O
game O
evaluation O
of O
a O
one-hour O
training O
basic O
life O
support O
session O
for O
secondary O
school O
students O
: O
new O
tools O
for O
future O
bystanders O
S O
. O

Gaudry O
, O
V O
. O

Desailly O
, O
P O
. O

Pasquier O
, O
PB O
Brun O
, O
AT O
Tesnieres O
, O
JD O
Ricard O
, O
D O
. O

Dreyfuss O
, O
A O
. O

Mignon O
P307 O
- O
Public O
and O
clinical O
staff O
perceptions O
and O
knowledge O
of O
CPR O
compared O
to O
local O
and O
national O
data O
J O
. O

C O
White O
, O
A O
. O

Molokhia O
, O
A O
. O

Dean O
, O
A O
. O

Stilwell O
, O
G O
. O

Friedlaender O
P308 O
Dispatcher-assisted O
telephone O
cardiopulmonary O
resuscitation O
using O
a O
French-language O
compression-ventilation O
pediatric O
protocol O
M O
. O

Peters O
, O
S O
. O

Stipulante O
, O
A O
. O

Delfosse O
, O
AF O
Donneau O
, O
A O
. O

Ghuysen O
P309 O
Dantrolene O
versus O
amiodarone O
for O
resuscitation O
– O
an O
experimental O
study O
C O
. O

Feldmann O
, O
D O
. O

Freitag O
, O
W O
. O

Dersch O
, O
M O
. O

Irqsusi O
, O
D O
. O

Eschbach O
, O
T O
. O

Steinfeldt O
, O
H O
. O

Wulf O
, O
T O
. O

Wiesmann O
P310 O
Long O
term O
survival O
and O
functional O
neurological O
outcome O
in O
comatose O
survivors O
undergoing O
therapeutic O
hypothermia O
N O
. O

Kongpolprom O
, O
J O
. O

Cholkraisuwat O
P311 O
Impact O
of O
kidney O
disease O
on O
mortality O
and O
neurological O
outcome O
in O
out-of-hospital O
cardiac O
arrest O
: O
a O
prospective O
observational O
study O
S O
. O

Beitland O
, O
E O
. O

Nakstad O
, O
H O
. O

Stær-Jensen O
, O
T O
. O

Drægni O
, O
G O
. O

Andersen O
, O
D O
. O

Jacobsen O
, O
C O
. O

Brunborg O
, O
B O
. O

Waldum-Grevbo O
, O
K O
. O

Sunde O
P312 O
ICU O
dependency O
of O
patients O
admitted O
after O
primary O
percutaneous O
coronary O
intervention O
( O
PPCI O
) O
following O
out O
of O
the O
hospital O
cardiac O
arrest O
K O
. O

Hoyland O
, O
D O
. O

Pandit O
P313 O
Prognostic O
indicators O
and O
outcome O
prediction O
model O
for O
patients O
with O
return O
of O
spontaneous O
circulation O
from O
cardiopulmonary O
arrest O
: O
comprehensive O
registry O
of O
in-hospital O
intensive O
care O
on O
OHCA O
survival O
( O
critical O
) O
study O
in O
Osaka O
, O
Japan O
K O
. O

Hayakawa O
P314 O
Cerebral O
oxygen O
saturation O
during O
resuscitation O
in O
a O
porcine O
model O
of O
cardiac O
arrest O
E O
. O

Oloktsidou O
, O
K O
. O

Kotzampassi O
, O
B O
. O

Fyntanidou O
, O
S O
. O

Patsatzakis O
, O
L O
. O

Loukipoudi O
, O
E O
. O

Doumaki O
, O
V O
. O

Grosomanidis O
P315 O
Presumption O
of O
cardiopulmonary O
resuscitation O
for O
sustaining O
cerebral O
oxidation O
using O
regional O
cerebral O
saturation O
of O
oxygen O
: O
observational O
cohort O
study O
( O
press O
study O
) O
H O
. O

Yasuda O
P316 O
EEG O
reactivity O
in O
patients O
after O
cardiac O
arrest O
: O
a O
close O
look O
at O
stimuli O
MM O
Admiraal O
, O
M O
. O

Van O
Assen O
, O
MJ O
Van O
Putten O
, O
M O
. O

Tjepkema-Cloostermans O
, O
AF O
Van O
Rootselaar O
, O
J O
. O

Horn O
P317 O
Prognostic O
value O
of O
neuron-specific O
enolase O
after O
cardiac O
arrest O
F O
. O

Ragusa O
, O
A O
. O

Marudi O
, O
S O
. O

Baroni O
, O
A O
. O

Gaspari O
, O
E O
. O

Bertellini O
P318 O
Correlation O
between O
electroencephalographic O
findings O
and O
serum O
neuron O
specific O
enolase O
with O
outcome O
of O
post O
cardiac O
arrest O
patients O
A O
. O

Taha O
, O
T O
. O

Abdullah O
, O
S O
. O

Abdel O
Monem O
P319 O
Introduction O
of O
a O
targeted O
temperature O
management O
strategy O
following O
cardiac O
arrest O
in O
a O
district O
general O
hospital O
intensive O
care O
unit O
. O

S O
. O

Alcorn O
, O
S O
. O

McNeill O
, O
S O
. O

Russell O
P320 O
The O
evolution O
of O
cerebral O
oxygen O
saturation O
in O
post-cardiac O
arrest O
patients O
treated O
with O
therapeutic O
hypothermia O
W O
. O

Eertmans O
, O
C O
. O

Genbrugge O
, O
I O
. O

Meex O
, O
J O
. O

Dens O
, O
F O
. O

Jans O
, O
C O
. O

De O
Deyne O
P321 O
Prognostic O
factors O
and O
neurological O
outcomes O
of O
therapeutic O
hypothermia O
in O
comatose O
survivors O
from O
cardiac O
arrest O
: O
8 O
- O
year O
single O
center O
experience O
J O
. O

Cholkraisuwat O
, O
N O
. O

Kongpolprom O
P322 O
Adherence O
to O
targeted O
temperature O
management O
after O
out O
of O
hospital O
cardiac O
arrest O
B O
. O

Avard O
, O
R O
. O

Burns O
P323 O
Implementation O
of O
a O
therapeutic O
hypothermia O
protocol O
for O
comatose O
survivors O
of O
out-of-hospital O
cardiac O
arrest O
. O

A O
. O

Patarchi O
, O
T O
. O

Spina O
P324 O
Factors O
associated O
with O
ventilator O
weaning O
after O
targeted O
temperature O
management O
for O
cardiac O
arrest O
patients O
in O
japan O
H O
. O

Tanaka O
, O
N O
. O

Otani O
, O
S O
. O

Ode O
, O
S O
. O

Ishimatsu O
P325 O
Differential O
activation O
of O
c-fos O
in O
paraventricular O
nuclei O
of O
the O
hypothalamus O
and O
thalamus O
of O
the O
rat O
following O
myocardial O
infarction O
J O
. O

Cho O
, O
J O
. O

B O
. O

Moon O
, O
C O
. O

W O
. O

Park O
, O
T O
. O

G O
. O

Ohk O
, O
M O
. O

C O
. O

Shin O
, O
M O
. O

H O
. O

Won O
P326 O
Monitoring O
of O
cTroponin O
I O
in O
patients O
with O
acute O
ischemic O
stroke O
- O
predictor O
of O
inhospital O
mortality O
S O
. O

Dakova O
, O
Z O
. O

Ramsheva O
, O
K O
. O

Ramshev O
P327 O
Hyperthermic O
preconditioning O
severely O
accelerates O
neuronal O
damage O
in O
the O
gerbil O
ischemic O
hippocampal O
dentate O
gyrus O
via O
decreasing O
sods O
expressions O
J O
. O

Cho O
, O
J O
. O

B O
. O

Moon O
, O
C O
. O

W O
. O

Park O
, O
T O
. O

G O
. O

Ohk O
, O
M O
. O

C O
. O

Shin O
P328 O
Failure O
in O
neuroprotection O
of O
remote O
limb O
ischemic O
post O
conditioning O
in O
the O
hippocampus O
of O
a O
gerbil O
model O
of O
transient O
cerebral O
ischemia O
J O
. O

Cho O
, O
J O
. O

B O
. O

Moon O
, O
C O
. O

W O
. O

Park O
, O
T O
. O

G O
. O

Ohk O
, O
M O
. O

C O
. O

Shin O
P329 O
Brain O
death O
and O
admission O
diagnosis O
in O
neurologic O
intensive O
care O
unit O
, O
a O
correlation O
? O

A O
Marudi O
, O
S O
Baroni O
, O
A O
Gaspari O
, O
E O
Bertellini O
P330 O
Brain O
magnetic O
resonance O
imaging O
findings O
in O
patients O
with O
septic O
shock O
G O
. O

Orhun O
, O
E O
. O

Senturk O
, O
P O
. O

E O
. O

Ozcan O
, O
S O
. O

Sencer O
, O
C O
. O

Ulusoy O
, O
E O
. O

Tuzun O
, O
F O
. O

Esen O
P331 O
Benefits O
of O
L-carnitine O
in O
valproic O
acid O
induced O
encephalopathy O
R O
. O

Tincu O
, O
C O
. O

Cobilinschi O
, O
D O
. O

Tomescu O
, O
Z O
. O

Ghiorghiu O
, O
R O
. O

Macovei O
P332Automatic O
analysis O
of O
EEG O
reactivity O
in O
comatose O
patients O
M O
. O

Van O
Assen O
, O
M O
. O

M O
. O

Admiraal O
, O
M O
. O

J O
. O

Van O
Putten O
, O
M O
. O

Tjepkema-Cloostermans O
, O
A O
. O

F O
. O

Van O
Rootselaar O
, O
J O
. O

Horn O
P333 O
Usefulness O
of O
common O
ICU O
severity O
scoring O
systems O
in O
predicting O
outcome O
after O
spontaneous O
intracerebral O
hemorrhage O
M O
. O

Fallenius O
, O
M O
. O

B O
. O

Skrifvars O
, O
M O
. O

Reinikainen O
, O
S O
. O

Bendel O
, O
R O
. O

Raj O
P334 O
Evalution O
of O
patients O
with O
suspected O
subarachnoid O
haemorrhage O
and O
negative O
ct O
imaging O
M O
. O

Abu-Habsa O
, O
C O
. O

Hymers O
, O
A O
. O

Borowska O
, O
H O
. O

Sivadhas O
, O
S O
. O

Sahiba O
, O
S O
. O

Perkins O
P335 O
Timing O
of O
endovascular O
and O
surgical O
treatment O
for O
aneurysmal O
subarachnoid O
haemorrhage O
: O
early O
but O
not O
so O
fast O
. O

J O
. O

Rubio O
, O
J O
. O

A O
. O

Rubio O
, O
R O
. O

Sierra O
P336 O
Red O
blood O
cell O
transfusion O
in O
aneurysmal O
subarachnoid O
hemorrhage O
– O
the O
Sahara O
cohort O
study O
S O
. O

English O
, O
M O
. O

Chasse O
, O
A O
. O

Turgeon O
, O
F O
. O

Lauzier O
, O
D O
. O

Griesdale O
, O
A O
. O

Garland O
, O
D O
. O

Fergusson O
, O
R O
. O

Zarychanski O
, O
A O
. O

Tinmouth O
, O
C O
. O

Van O
Walraven O
, O
K O
. O

Montroy O
, O
J O
. O

Ziegler O
, O
R O
. O

Dupont O
Chouinard O
, O
R O
. O

Carignan O
, O
A O
. O

Dhaliwal O
, O
C O
. O

Lum O
, O
J O
. O

Sinclair O
, O
G O
. O

Pagliarello O
, O
L O
. O

McIntyre O
P337 O
- O
Aneurysmal O
subarachnoid O
hemorrhage O
and O
anemia O
: O
a O
canadian O
multi-centre O
retrospective O
cohort O
study O
S O
. O

English O
, O
M O
. O

Chasse O
, O
A O
. O

Turgeon O
, O
F O
. O

Lauzier O
, O
D O
. O

Griesdale O
, O
A O
. O

Garland O
, O
D O
. O

Fergusson O
, O
R O
. O

Zarychanski O
, O
A O
. O

Tinmouth O
, O
C O
. O

Van O
Walraven O
, O
K O
. O

Montroy O
, O
J O
. O

Ziegler O
, O
R O
. O

Dupont O
Chouinard O
, O
R O
. O

Carignan O
, O
A O
. O

Dhaliwal O
, O
C O
. O

Lum O
, O
J O
. O

Sinclair O
, O
G O
. O

Pagliarello O
, O
L O
. O

McIntyre O
P338 O
- O
Does O
the O
neutrophil-to-lymphocyte O
( O
NLR O
) O
ratio O
predict O
symptomatic O
vasospasm O
or O
delayed O
cerebral O
ischemia O
( O
DCI O
) O
after O
aneurysmal O
subarachnoid O
haemorrhage O
( O
SAH O
) O
? O

T O
. O

Groza O
, O
N O
. O

Moreau O
, O
D O
. O

Castanares-Zapatero O
, O
P O
. O

Hantson O
P339 O
- O
ICU-acquired O
infections O
in O
aneurysmal O
subarachnoid O
hemorrhage O
patients O
: O
impact O
on O
ICU O
and O
hospital O
length O
of O
stay O
M O
. O

Carbonara O
, O
F O
. O

Ortolano O
, O
T O
. O

Zoerle O
, O
S O
. O

Magnoni O
, O
S O
. O

Pifferi O
, O
V O
. O

Conte O
, O
N O
. O

Stocchetti O
P340 O
- O
Cerebral O
metabolic O
effects O
of O
normobaric O
hyperoxia O
during O
the O
acute O
phase O
of O
aneurysmal O
subarachnoid O
hemorrhage O
L O
. O

Carteron O
, O
T O
. O

Suys O
, O
C O
. O

Patet O
, O
H O
. O

Quintard O
, O
M O
. O

Oddo O
P341 O
- O
Postoperative O
care O
for O
elective O
craniotomy O
: O
where O
is O
best O
done O
? O

J O
. O

A O
. O

Rubio O
, O
J O
. O

Rubio O
, O
R O
. O

Sierra O
P342 O
- O
5 O
- O
year O
follow-up O
of O
patients O
after O
transplantation O
of O
organs O
from O
donors O
from O
neurocritical O
care O
V O
. O

Spatenkova O
, O
E O
. O

Pokorna O
, O
P O
. O

Suchomel O
P343 O
- O
Evaluation O
of O
levetiracetam O
pharmacokinetics O
after O
severe O
traumatic O
brain O
injury O
in O
neurocritical O
care O
patients O
at O
a O
level O
one O
trauma O
center O
N O
. O

Ebert O
, O
J O
. O

Jancik O
, O
H O
. O

Rhodes O
P344 O
- O
Model O
based O
time O
series O
cluster O
analysis O
to O
determine O
unique O
patient O
states O
in O
traumatic O
brain O
injury O
T O
. O

Bylinski O
, O
C O
. O

Hawthorne O
, O
M O
. O

Shaw O
, O
I O
. O

Piper O
, O
J O
. O

Kinsella O
P345 O
- O
Brain O
compartment O
monitoring O
capabilities O
from O
ICP O
to O
BI O
( O
bioimpedance O
) O
during O
HS O
( O
hypertonic O
saline O
) O
administration O
. O

State O
of O
art O
simulation O
outcome O
depending O
on O
brain O
swelling O
type O
A O
. O

K O
. O

Kink O
, O
I O
. O

R O
. O

Rätsep O
P346 O
- O
Transfusion O
of O
red O
blood O
cells O
in O
patients O
with O
traumatic O
brain O
injury O
admitted O
to O
Canadian O
trauma O
health O
centers O
: O
a O
multicenter O
cohort O
study O
A O
. O

Boutin O
, O
L O
. O

Moore O
, O
M O
. O

Chasse O
, O
R O
. O

Zarychanski O
, O
F O
. O

Lauzier O
, O
S O
. O

English O
, O
L O
. O

McIntyre O
, O
J O
. O

Lacroix O
, O
D O
. O

Griesdale O
, O
P O
. O

Lessard-Bonaventure O
, O
A O
. O

F O
. O

Turgeon O
P347 O
- O
Hemoglobin O
thresholds O
and O
red O
blood O
cell O
transfusions O
in O
adult O
patients O
with O
moderate O
or O
severe O
traumatic O
brain O
injury O
: O
a O
retrospective O
cohort O
study O
A O
. O

Boutin O
, O
L O
. O

Moore O
, O
R O
. O

Green O
, O
P O
. O

Lessard-Bonaventure O
, O
M O
. O

Erdogan O
, O
M O
. O

Butler O
, O
F O
. O

Lauzier O
, O
M O
. O

Chasse O
, O
S O
. O

English O
, O
L O
. O

McIntyre O
, O
R O
. O

Zarychanski O
, O
J O
. O

Lacroix O
, O
D O
. O

Griesdale O
, O
P O
. O

Desjardins O
, O
D O
. O

A O
. O

Fergusson O
, O
A O
. O

F O
. O

Turgeon O
P348 O
- O
Characteristics O
of O
patients O
with O
gunshot O
wounds O
to O
the O
head O
- O
an O
observational O
Brazilian O
study O
B O
. O

Goncalves O
, O
B O
. O

Vidal O
, O
C O
. O

Valdez O
, O
A O
. O

C O
. O

Rodrigues O
, O
L O
. O

Miguez O
, O
G O
. O

Moralez O
P349 O
- O
Base O
excess O
as O
predictor O
for O
ICU O
admission O
and O
the O
injury O
severity O
in O
blunt O
trauma O
patients O
T O
. O

Hong O
P350 O
- O
Enhancement O
of O
usual O
emergency O
department O
care O
with O
proadrenomedullin O
to O
improve O
outcome O
prediction O
- O
Results O
from O
the O
multi-national O
, O
prospective O
, O
observational O
TRIAGE O
study O
A O
. O

Kutz O
, O
P O
. O

Hausfater O
, O
D O
. O

Amin O
, O
T O
. O

Struja O
, O
S O
. O

Haubitz O
, O
A O
. O

Huber O
, O
B O
. O

Mueller O
, O
P O
. O

Schuetz O
P351 O
- O
Developing O
an O
innovative O
emergency O
medicine O
point-of-care O
simulation O
programme O
T O
. O

Brown O
, O
J O
. O

Collinson O
, O
C O
. O

Pritchett O
, O
T O
. O

Slade O
P352 O
- O
The O
InSim O
program O
: O
an O
in O
situ O
simulation O
program O
for O
junior O
trainees O
in O
intensive O
care O
M O
. O

Le O
Guen O
, O
S O
. O

Hellings O
, O
R O
. O

Ramsaran O
P353 O
- O
Impact O
of O
excessive O
and O
inappropriate O
troponin O
testing O
in O
the O
emergency O
setting O
how O
good O
are O
we O
A O
. O

Alsheikhly O
P354 O
- O
The O
development O
of O
time O
tracking O
monitor O
at O
emergency O
department O
T O
. O

Abe O
P355 O
- O
Role O
of O
focussed O
echocardiography O
in O
emergency O
assessment O
of O
syncope O
L O
. O

Kanapeckaite O
, O
M O
. O

Abu-Habsa O
, O
R O
. O

Bahl O
P356 O
- O
Insertion O
of O
an O
open-ended O
14 O
- O
gauge O
catheter O
through O
the O
chest O
wall O
causes O
a O
significant O
pneumothorax O
in O
a O
self-ventilating O
swine O
model O
M O
. O

Q O
Russell O
, O
K O
. O

J O
. O

Real O
, O
M O
. O

Abu-Habsa O
, O
R O
. O

M O
. O

Lyon O
, O
N O
. O

P O
. O

Oveland O
P357 O
- O
Ez-io O
® O
intraosseous O
access O
teaching O
in O
the O
workplace O
using O
a O
mobile O
‘ O
tea O
trolley O
’ O
training O
method O
J O
. O

Penketh O
, O
M O
. O

Mcdonald O
, O
F O
. O

Kelly O
P358 O
- O
Black O
widow O
envenomation O
in O
Saudi O
Arabia O
: O
a O
prospective O
observational O
case O
series O
M O
. O

Alfafi O
, O
S O
. O

Alsolamy O
, O
W O
. O

Almutairi O
, O
B O
. O

Alotaibi O
P359 O
- O
Mechanical O
ventilation O
in O
patients O
with O
overdose O
not O
yet O
intubated O
on O
icu O
admission O
A O
. O

E O
. O

Van O
den O
Berg O
, O
Y O
. O

Schriel O
, O
L O
. O

Dawson O
, O
I O
. O

A O
. O

Meynaar O
P360 O
- O
Central O
nervous O
system O
depressants O
poisoning O
and O
ventilator O
associated O
pneumonia O
: O
an O
underrated O
risk O
factor O
in O
toxicological O
intensive O
care O
unit O
H O
. O

Talaie O
P361 O
- O
Acute O
barium O
intoxication O
treated O
with O
hemodiafiltration O
D O
. O

Silva O
, O
S O
. O

Fernandes O
, O
J O
. O

Gouveia O
, O
J O
. O

Santos O
Silva O
P362 O
- O
Major O
trauma O
presenting O
to O
the O
emergency O
department O
. O
the O
spectrum O
of O
cycling O
injuries O
in O
Ireland O
J O
. O

Foley O
, O
A O
. O

Kaskovagheorgescu O
, O
D O
. O

Evoy O
, O
J O
. O

Cronin O
, O
J O
. O

Ryan O
P363 O
- O
Burns O
from O
French O
military O
operations O
: O
a O
14 O
- O
year O
retrospective O
observational O
analysis O
. O

M O
. O

Huck O
, O
C O
. O

Hoffmann O
, O
J O
. O

Renner O
, O
P O
. O

Laitselart O
, O
N O
. O

Donat O
, O
A O
. O

Cirodde O
, O
J O
. O

V O
. O

Schaal O
, O
Y O
. O

Masson O
, O
A O
. O

Nau O
, O
T O
. O

Leclerc O
P364 O
- O
A O
comparison O
of O
mortality O
scores O
in O
burns O
patients O
on O
the O
intensive O
care O
unit O
. O

O O
. O

Howarth O
, O
K O
. O

Davenport O
, O
P O
. O

Jeanrenaud O
, O
S O
. O

Raftery O
P365 O
- O
Clasification O
of O
pain O
and O
its O
treatment O
and O
an O
intensive O
care O
rehabiliation O
clinic O
P O
. O

MacTavish O
, O
H O
. O

Devine O
, O
J O
. O

McPeake O
, O
M O
. O

Daniel O
, O
J O
. O

Kinsella O
, O
T O
. O

Quasim O
P366 O
- O
Pain O
management O
adequacy O
in O
critical O
care O
areas O
, O
the O
process O
and O
the O
barriers O
perceived O
by O
critical O
care O
nurses O
S O
. O

Alrabiee O
, O
A O
. O

Alrashid O
, O
S O
. O

Alsolamy O
P367 O
- O
Pain O
assessment O
in O
critically O
ill O
adult O
patients O
: O
validation O
of O
the O
Turkish O
version O
of O
the O
critical-care O
pain O
observation O
tool O
O O
. O

Gundogan O
, O
C O
. O

Bor O
, O
E O
. O

Akýn O
Korhan O
, O
K O
. O

Demirag O
, O
M O
. O

Uyar O
P368 O
- O
An O
audit O
of O
pain O
and O
sedation O
assessments O
in O
the O
intensive O
care O
unit O
: O
recommendations O
for O
clinical O
practice O
F O
. O

Frame O
, O
C O
. O

Ashton O
, O
L O
. O

Bergstrom O
Niska O
P369 O
- O
Impact O
of O
pharmaceutical O
care O
on O
treatment O
of O
pain O
and O
agitation O
in O
medical O
intensive O
care O
unit O
P O
. O

Dilokpattanamongkol O
, O
T O
. O

Suansanae O
, O
C O
. O

Suthisisang O
, O
S O
. O

Morakul O
, O
C O
. O

Karnjanarachata O
, O
V O
. O

Tangsujaritvijit O
P370 O
- O
Agitation O
in O
trauma O
ICU O
, O
prevention O
and O
outcome O
S O
. O

Mahmood O
, O
H O
. O

Al O
Thani O
, O
A O
. O

Almenyar O
P371 O
Correlation O
between O
percentages O
of O
ventilated O
patients O
developed O
vap O
and O
use O
of O
sedative O
agents O
in O
icu O
patients O
. O

A O
. O

Vakalos O
, O
V O
. O

Avramidis O
P372 O
- O
Improving O
recording O
of O
sedation O
events O
in O
the O
Emergency O
Department O
: O
The O
implementation O
of O
the O
SIVA O
International O
Taskforce O
adverse O
event O
reporting O
tool O
for O
procedural O
sedation O
R O
. O

Sharvill O
, O
J O
. O

Penketh O
P373 O
- O
Impact O
of O
sedative O
drug O
use O
on O
the O
length O
of O
mechanical O
ventilation O
S O
. O

E O
. O

Morton O
, O
Y O
. O

S O
. O

Chiew O
, O
C O
. O

Pretty O
, O
J O
. O

G O
. O

Chase O
, O
G O
. O

M O
. O

Shaw O
P374 O
- O
Co-administration O
of O
nitric O
oxide O
and O
sevoflurane O
using O
anaconda O
R O
. O

Knafelj O
, O
P O
. O

Kordis O
P375 O
- O
A O
retrospective O
study O
of O
the O
use O
of O
Dexmedetomidine O
in O
an O
oncological O
critical O
care O
setting O
S O
. O

Patel O
, O
V O
. O

Grover O
P376 O
- O
Dexmedetomidine O
and O
posttraumatic O
stress O
disorder O
incidence O
in O
alcohol O
withdrawal O
icu O
patients O
I O
. O

Kuchyn O
, O
K O
. O

Bielka O
P377 O
- O
Hemodynamic O
effects O
of O
dexmedetomidine O
in O
a O
porcine O
model O
of O
septic O
shock O
Z O
. O

Aidoni O
, O
V O
. O

Grosomanidis O
, O
K O
. O

Kotzampassi O
, O
G O
. O

Stavrou O
, O
B O
. O

Fyntanidou O
, O
S O
. O

Patsatzakis O
, O
C O
. O

Skourtis O
P378 O
- O
Ketamine O
for O
analgosedation O
in O
severe O
hypoxic O
respiratory O
failure O
S O
. O

D O
. O

Lee O
, O
K O
. O

Williams O
, O
I O
. O

D O
. O

Weltes O
P379 O
- O
Madness O
from O
the O
moon O
? O

lunar O
cycle O
and O
the O
incidence O
of O
delirium O
on O
the O
intensive O
care O
unit O
S O
. O

Berhane O
, O
C O
. O

Arrowsmith O
, O
C O
. O

Peters O
, O
S O
. O

Robert O
P380 O
- O
Impaired O
dynamic O
cerebral O
autoregulation O
after O
coronary O
artery O
bypass O
grafting O
and O
association O
with O
postoperative O
delirium O
J O
. O

Caldas O
, O
R O
. O

B O
. O

Panerai O
, O
T O
. O

G O
. O

Robinson O
, O
L O
. O

Camara O
, O
G O
. O

Ferreira O
, O
E O
. O

Borg-Seng-Shu O
, O
M O
. O

De O
Lima O
Oliveira O
, O
N O
. O

C O
. O

Mian O
, O
L O
. O

Santos O
, O
R O
. O

Nogueira O
, O
S O
. O

P O
. O

Zeferino O
, O
M O
. O

Jacobsen O
Teixeira O
, O
F O
. O

Galas O
, O
L O
. O

A O
. O

Hajjar O
P381 O
- O
Risk O
factors O
predicting O
prolonged O
intensive O
care O
unit O
length O
of O
stay O
after O
major O
elective O
surgery O
. O

P O
. O

Killeen O
, O
M O
. O

McPhail O
, O
W O
. O

Bernal O
, O
J O
. O

Maggs O
, O
J O
. O

Wendon O
, O
T O
. O

Hughes O
P382 O
- O
Systemic O
inflammatory O
response O
syndrome O
criteria O
and O
hospital O
mortality O
prediction O
in O
a O
brazilian O
cohort O
of O
critically O
ill O
patients O
L O
. O

U O
. O

Taniguchi O
, O
E O
. O

M O
. O

Siqueira O
, O
J O
. O

M O
. O

Vieira O
Jr O
, O
L O
. O

C O
. O

Azevedo O
P383 O
- O
Evaluating O
the O
efficacy O
of O
a O
risk O
predictor O
panel O
in O
identifying O
patients O
at O
elevated O
risk O
of O
morbidity O
following O
emergency O
admission O
A O
. O

N O
. O

Ahmad O
, O
M O
. O

Abu-Habsa O
, O
R O
. O

Bahl O
, O
E O
. O

Helme O
, O
S O
. O

Hadfield O
, O
R O
. O

Loveridge O
P384 O
- O
A O
retrospective O
comparison O
of O
outcomes O
for O
elective O
surgical O
patients O
admitted O
post-operatively O
to O
the O
critical O
care O
unit O
or O
general O
ward O
J O
. O

Shak O
, O
C O
. O

Senver O
, O
R O
. O

Howard-Griffin O
P385 O
- O
Effect O
of O
obesity O
on O
mortality O
in O
surgical O
critically O
ill O
patients O
. O

P O
. O

Wacharasint O
, O
P O
. O

Fuengfoo O
, O
N O
. O

Sukcharoen O
, O
R O
. O

Rangsin O
P386 O
- O
The O
national O
early O
warning O
score O
( O
news O
) O
reliably O
improves O
adverse O
clinical O
outcome O
prediction O
in O
community-acquired O
pneumonia O
- O
results O
from O
a O
6 O
year O
follow-up O
D O
. O

Sbiti-Rohr O
, O
P O
. O

Schuetz O
P387 O
- O
Clinical O
usefulness O
of O
the O
charlson O
¡ O
¯ O
s O
weighted O
index O
of O
comorbidities O
_ O
as O
prognostic O
factor O
in O
patients O
with O
prolonged O
acute O
mechanical O
ventilation O
H O
. O

Na O
, O
S O
. O

Song O
, O
S O
. O

Lee O
, O
E O
. O

Jeong O
, O
K O
. O

Lee O
P388 O
- O
Comparison O
of O
mortality O
prediction O
scoring O
systems O
in O
patients O
with O
cirrhosis O
admitted O
to O
general O
intensive O
care O
unit O
M O
. O

Cooper O
, O
K O
. O

Milinis O
, O
G O
. O

Williams O
, O
E O
. O

McCarron O
, O
S O
. O

Simants O
, O
I O
. O

Patanwala O
, O
I O
. O

D O
. O

Welters O
P389 O
- O
Impact O
of O
admission O
source O
and O
time O
of O
admission O
on O
outcome O
of O
pediatric O
intensive O
care O
patients O
: O
retrospective O
15 O
years O
study O
E O
. O

Zoumpelouli O
, O
EA O
Volakli O
, O
V O
. O

Chrysohoidou O
, O
S O
. O

Georgiou O
, O
K O
. O

Charisopoulou O
, O
E O
. O

Kotzapanagiotou O
, O
V O
. O

Panagiotidou O
, O
K O
. O

Manavidou O
, O
Z O
. O

Stathi O
, O
M O
. O

Sdougka O
P390 O
- O
Heart O
rate O
variability O
and O
outcomes O
prediction O
in O
critical O
illness O
N O
. O

Salahuddin O
, O
B O
. O

AlGhamdi O
, O
Q O
. O

Marashly O
, O
K O
. O

Zaza O
, O
M O
. O

Sharshir O
, O
M O
. O

Khurshid O
, O
Z O
. O

Ali O
, O
M O
. O

Malgapo O
, O
M O
. O

Jamil O
, O
A O
. O

Shafquat O
, O
M O
. O

Shoukri O
, O
M O
. O

Hijazi O
P391 O
- O
The O
incidence O
and O
outcome O
of O
hyperlactatemia O
in O
the O
post O
anaesthesia O
care O
unit O
T O
. O

Abe O
, O
S O
. O

Uchino O
, O
M O
. O

Takinami O
P392 O
- O
Correlation O
between O
arterial O
blood O
gas O
disturbances O
and O
arterial O
lactate O
levels O
during O
hospitalization O
and O
outcome O
in O
critically O
septic O
patients O
N O
. O

R O
. O

Rangel O
Neto O
, O
S O
. O

Oliveira O
, O
F O
. O

Q O
. O

Reis O
, O
F O
. O

A O
. O

Rocha O
P393 O
- O
External O
validation O
of O
saps O
3 O
and O
mpm O
iii O
scores O
in O
48,816 O
patients O
from O
72 O
brazilian O
icus O
G O
. O

Moralez O
, O
K O
. O

Ebecken O
, O
L O
. O

S O
. O

Rabello O
, O
M O
. O

F O
. O

Lima O
, O
R O
. O

Hatum O
, O
F O
. O

V O
. O

De O
Marco O
, O
A O
. O

Alves O
, O
J O
. O

E O
. O

Pinto O
, O
M O
. O

Godoy O
, O
P O
. O

E O
. O

Brasil O
, O
F O
. O

A O
. O

Bozza O
, O
J O
. O

I O
. O

Salluh O
, O
M O
. O

Soares O
P394 O
- O
The O
frailty O
penalty O
: O
pre-admission O
functional O
status O
confounds O
mortality O
prediction O
models O
in O
critically O
ill O
patients O
J O
. O

Krinsley O
, O
G O
. O

Kang O
P395 O
- O
‘ O
sooner O
rather O
than O
later O
” O
: O
how O
delayed O
discharge O
from O
critical O
care O
leads O
to O
increased O
out O
of O
hours O
discharges O
and O
subsequent O
increase O
in O
in-hospital O
mortality O
. O

J O
. O

Perry O
, O
H O
. O

Hines O
P396 O
- O
Identifying O
poor O
outcome O
patient O
groups O
in O
a O
resource-constrained O
critical O
care O
unit O
K O
. O

M O
. O

Wilkinson O
, O
C O
. O

Tordoff O
, O
B O
. O

Sloan O
, O
M O
. O

C O
. O

Bellamy O
P397 O
- O
Effects O
of O
icu O
weekend O
admission O
and O
discharge O
on O
mortality O
. O

E O
. O

Moreira O
, O
F O
. O

Verga O
, O
M O
. O

Barbato O
, O
G O
. O

Burghi O
P398 O
- O
Organizational O
factors O
, O
outcomes O
and O
resource O
use O
in O
9,946 O
cancer O
patients O
admitted O
to O
70 O
ICUs O
M O
Soares O
, O
U O
. O

V O
. O

Silva O
, O
L O
. O

C O
. O

Azevedo O
, O
A O
. O

P O
. O

Torelly O
, O
J O
. O

M O
. O

Kahn O
, O
D O
. O

C O
. O

Angus O
, O
M O
. O

F O
. O

Knibel O
, O
P O
. O

E O
. O

Brasil O
, O
F O
. O

A O
. O

Bozza O
, O
J O
. O

I O
. O

Salluh O
P399 O
- O
Evaluation O
of O
oncological O
critically O
ill O
patients O
, O
severity O
score O
and O
outcome O
compared O
to O
not O
oncological O
in O
a O
particular O
hospital O
cti O
. O

M O
. O

B O
. O

Velasco O
, O
D O
. O

M O
. O

Dalcomune O
P400 O
- O
Outcomes O
of O
patients O
admitted O
to O
a O
large O
uk O
critical O
care O
department O
with O
palliative O
oncological O
diagnoses O
R O
. O

Marshall O
, O
T O
. O

Gilpin O
, O
A O
. O

Tridente O
, O
A O
. O

Raithatha O
P401 O
- O
Predictors O
of O
mortality O
in O
febrile O
neutropenic O
patients O
with O
haematological O
malignancies O
admitted O
to O
an O
intensive O
care O
unit O
of O
a O
cancer O
center O
D O
. O

Mota O
, O
B O
. O

Loureiro O
, O
J O
. O

Dias O
, O
O O
. O

Afonso O
, O
F O
. O

Coelho O
, O
A O
. O

Martins O
, O
F O
. O

Faria O
P402 O
- O
Patients O
with O
hematologic O
malignancies O
requiring O
invasive O
mechanical O
ventilation O
: O
characteristics O
and O
predictors O
of O
mortality O
H O
. O

Al-Dorzi O
, O
H O
. O

Al O
Orainni O
, O
F O
. O

AlEid O
, O
H O
. O

Tlaygeh O
, O
A O
. O

Itani O
, O
A O
. O

Hejazi O
, O
Y O
. O

Arabi O
P403 O
- O
Patient-important O
outcomes O
in O
randomized O
controlled O
trials O
in O
critically O
ill O
patients O
: O
a O
systematic O
review O
S O
. O

Gaudry O
, O
J O
. O

Messika O
, O
J O
. O

D O
. O

Ricard O
, O
S O
. O

Guillo O
, O
B O
. O

Pasquet O
, O
E O
. O

Dubief O
, O
D O
. O

Dreyfuss O
, O
F O
. O

Tubach O
P404 O
- O
Alopecia O
in O
survivors O
of O
critical O
illness O
: O
a O
qualitative O
study O
C O
. O

Battle O
, O
K O
. O

James O
, O
P O
. O

Temblett O
P405 O
- O
The O
impact O
of O
mental O
health O
on O
icu O
admission O
L O
. O

Davies O
, O
C O
. O

Battle O
, O
C O
. O

Lynch O
P406 O
- O
Cognitive O
impairment O
5 O
years O
after O
ICU O
discharge O
S O
. O

Pereira O
, O
S O
. O

Cavaco O
, O
J O
. O

Fernandes O
, O
I O
. O

Moreira O
, O
E O
. O

Almeida O
, O
F O
. O

Seabra O
Pereira O
, O
M O
. O

Malheiro O
, O
F O
. O

Cardoso O
, O
I O
. O

Aragão O
, O
T O
. O

Cardoso O
P407 O
- O
Apache O
ii O
versus O
apache O
iv O
for O
octagenerians O
in O
medical O
icu O
M O
. O

Fister O
, O
R O
. O

Knafelj O
P408 O
- O
Outcomes O
of O
octagenarians O
in O
an O
indian O
icu O
P O
. O

Muraray O
Govind O
, O
N O
. O

Brahmananda O
Reddy O
, O
R O
. O

Pratheema O
, O
E O
. O

D O
. O

Arul O
, O
J O
. O

Devachandran O
P409 O
- O
Mortality O
and O
outcomes O
in O
elderly O
patients O
80 O
years O
of O
age O
or O
older O
admitted O
to O
the O
icu O
M O
. O

B O
. O

Velasco O
, O
D O
. O

M O
. O

Dalcomune O
P410 O
- O
Octagenerians O
in O
medical O
icu O
- O
adding O
days O
to O
life O
or O
life O
to O
days O
? O

R O
. O

Knafelj O
, O
M O
. O

Fister O
P411 O
- O
The O
very O
elderly O
admitted O
to O
intensive O
care O
unit O
: O
outcomes O
and O
economic O
evaluation O
N O
. O

Chin-Yee O
, O
G O
. O

D O
’ O
Egidio O
, O
K O
. O

Thavorn O
, O
D O
. O

Heyland O
, O
K O
. O

Kyeremanteng O
P412 O
- O
The O
very O
elderly O
in O
intensive O
care O
: O
relationship O
between O
acuity O
of O
illness O
and O
long-term O
mortality O
A O
. O

G O
. O

Murchison O
, O
K O
. O

Swalwell O
, O
J O
. O

Mandeville O
, O
D O
. O

Stott O
P413 O
- O
Acquired O
weakness O
in O
an O
oncological O
intensive O
care O
unit O
I O
. O

Guerreiro O
P414 O
- O
Musculoskeletal O
problems O
in O
intensive O
care O
unit O
( O
ICU O
) O
patients O
post-discharge O
H O
. O

Devine O
, O
P O
. O

MacTavish O
, O
J O
. O

McPeake O
, O
T O
. O

Quasim O
, O
J O
. O

Kinsella O
, O
M O
. O

Daniel O
P415 O
- O
Premorbid O
obesity O
, O
but O
not O
nutrition O
, O
prevents O
critical O
illness-induced O
muscle O
wasting O
and O
weakness O
C O
. O

Goossens O
M O
. O

B O
. O

Marques O
, O
S O
. O

Derde O
, O
S O
. O

Vander O
Perre O
, O
T O
. O

Dufour O
, O
S O
. O

E O
. O

Thiessen O
, O
F O
. O

Güiza O
, O
T O
. O

Janssens O
, O
G O
. O

Hermans O
, O
I O
. O

Vanhorebeek O
, O
K O
. O

De O
Bock O
, O
G O
. O

Van O
den O
Berghe O
, O
L O
. O

Langouche O
P416 O
- O
Physical O
outcome O
measures O
for O
critical O
care O
patients O
following O
intensive O
care O
unit O
( O
icu O
) O
discharge O
H O
. O

Devine O
, O
P O
. O

MacTavish O
, O
T O
. O

Quasim O
, O
J O
. O

Kinsella O
, O
M O
. O

Daniel O
, O
J O
. O

McPeake O
P417 O
- O
Improving O
active O
mobilisation O
in O
a O
general O
intensive O
care O
unit O
B O
. O

Miles O
, O
S O
. O

Madden O
, O
H O
. O

Devine O
P418 O
- O
Mobilization O
in O
patients O
on O
vasoactive O
drugs O
use O
– O
a O
pilot O
study O
. O

M O
. O

Weiler O
, O
P O
. O

Marques O
, O
C O
. O

Rodrigues O
, O
M O
. O

Boeira O
, O
K O
. O

Brenner O
, O
C O
. O

Leães O
, O
A O
. O

Machado O
, O
R O
. O

Townsend O
, O
J O
. O

Andrade O
P419 O
- O
Pharmacy O
intervention O
at O
an O
intensive O
care O
rehabilitation O
clinic O
P O
. O

MacTavish O
, O
J O
. O

McPeake O
, O
H O
. O

Devine O
, O
J O
. O

Kinsella O
, O
M O
. O

Daniel O
, O
R O
. O

Kishore O
, O
C O
. O

Fenlon O
, O
T O
. O

Quasim O
P420 O
- O
Interactive O
gaming O
is O
feasible O
and O
potentially O
increases O
icu O
patients O
’ O
motivation O
to O
be O
engaged O
in O
rehabilitation O
programs O
T O
. O

Fiks O
, O
A O
. O

Ruijter O
, O
M O
. O

Te O
Raa O
, O
P O
. O

Spronk O
P421 O
- O
Simulation-based O
design O
of O
a O
robust O
stopping O
rule O
to O
ensure O
patient O
safety O
Y O
. O

S O
. O

Chiew O
, O
P O
. O

Docherty O
, O
J O
. O

Dickson O
, O
E O
. O

Moltchanova O
, O
C O
. O

Scarrot O
, O
C O
. O

Pretty O
, O
G O
. O

M O
. O

Shaw O
, O
J O
. O

G O
. O

Chase O
P422 O
- O
Are O
daily O
blood O
tests O
on O
the O
intensive O
care O
unit O
necessary O
? O

T O
. O

Hall O
, O
W O
. O

C O
. O

Ngu O
, O
J O
. O

M O
. O

Jack O
, O
P O
. O

Morgan O
P423 O
- O
Measuring O
urine O
output O
in O
ward O
patients O
: O
is O
it O
helpful O
? O

B O
. O

Avard O
, O
A O
. O

Pavli O
, O
X O
. O

Gee O
P424 O
- O
The O
incidence O
of O
pressure O
ulcers O
in O
an O
adult O
mixed O
intensive O
care O
unit O
in O
turkey O
C O
. O

Bor O
, O
E O
. O

Akin O
Korhan O
, O
K O
. O

Demirag O
, O
M O
. O

Uyar O
P425 O
- O
Intensivist O
/ O
patient O
ratios O
in O
closed O
ICUs O
in O
Alexandria O
, O
Egypt O
; O
an O
overview O
M O
. O

Shirazy O
, O
A O
. O

Fayed O
P426 O
- O
Eicu O
( O
electronic O
intensive O
care O
unit O
) O
: O
impact O
on O
ALOS O
( O
average O
length O
of O
stay O
) O
in O
a O
developing O
country O
like O
India O
S O
. O

Gupta O
, O
A O
. O

Kaushal O
, O
S O
. O

Dewan O
, O
A O
. O

Varma O
P427 O
- O
Predicting O
deterioration O
in O
general O
ward O
using O
early O
deterioration O
indicator O
E O
. O

Ghosh O
, O
L O
. O

Yang O
, O
L O
. O

Eshelman O
, O
B O
. O

Lord O
, O
E O
. O

Carlson O
P428 O
- O
High O
impact O
enhanced O
critical O
care O
outreach O
- O
the O
imobile O
service O
: O
making O
a O
difference O
E O
. O

Helme O
, O
R O
. O

Broderick O
, O
S O
. O

Hadfield O
, O
R O
. O

Loveridge O
P429 O
- O
Impact O
of O
bed O
availability O
and O
cognitive O
load O
on O
intensive O
care O
unit O
( O
ICU O
) O
bed O
allocation O
: O
a O
vignette-based O
trial O
J O
. O

Ramos O
, O
D O
. O

Forte O
P430 O
- O
Characteristics O
of O
critically O
ill O
patients O
admitted O
through O
the O
emergency O
department O
F O
. O

Yang O
, O
P O
. O

Hou O
P431 O
- O
Admission O
to O
critical O
care O
: O
the O
quantification O
of O
functional O
reserve O
J O
. O

Dudziak O
, O
J O
. O

Feeney O
, O
K O
. O

Wilkinson O
, O
K O
. O

Bauchmuller O
, O
K O
. O

Shuker O
, O
M O
. O

Faulds O
, O
A O
. O

Raithatha O
, O
D O
. O

Bryden O
, O
L O
. O

England O
, O
N O
. O

Bolton O
, O
A O
. O

Tridente O
P432 O
- O
Admission O
to O
critical O
care O
: O
the O
importance O
of O
frailty O
K O
. O

Bauchmuller O
, O
K O
Shuker O
, O
A O
Tridente O
, O
M O
Faulds O
, O
A O
Matheson O
, O
J O
. O

Gaynor O
, O
D O
Bryden O
, O
S O
South O
Yorkshire O
Hospitals O
Research O
Collaboration O
P433 O
- O
Development O
of O
an O
instrument O
to O
aid O
triage O
decisions O
for O
intensive O
care O
unit O
admission O
J O
. O

Ramos O
, O
B O
. O

Peroni O
, O
R O
. O

Daglius-Dias O
, O
L O
. O

Miranda O
, O
C O
. O

Cohen O
, O
C O
. O

Carvalho O
, O
I O
. O

Velasco O
, O
D O
. O

Forte O
P434 O
- O
Using O
selective O
serotonin O
re-uptake O
inhibitors O
and O
serotonin-norepinephrine O
re-uptake O
inhibitors O
in O
critical O
care O
: O
a O
systematic O
review O
of O
the O
evidence O
for O
benefit O
or O
harm O
J O
. O

M O
. O

Kelly O
, O
A O
. O

Neill O
, O
G O
. O

Rubenfeld O
, O
N O
. O

Masson O
, O
A O
. O

Min O
P435 O
- O
Measuring O
adaptive O
coping O
of O
hospitalized O
patients O
with O
a O
severe O
medical O
condition O
: O
the O
sickness O
insight O
in O
coping O
questionnaire O
( O
sicq O
) O
E O
. O

Boezeman O
, O
J O
. O

Hofhuis O
, O
A O
. O

Hovingh O
, O
R O
. O

De O
Vries O
, O
P O
. O

Spronk O
P436 O
- O
Results O
of O
a O
national O
survey O
regarding O
intensive O
care O
medicine O
training O
G O
. O

Cabral-Campello O
, O
I O
. O

Aragão O
, O
T O
. O

Cardoso O
P437 O
- O
Work O
engagement O
among O
healthcare O
professionals O
in O
the O
intensive O
care O
unit O
M O
. O

Van O
Mol O
, O
M O
. O

Nijkamp O
, O
E O
. O

Kompanje O
P438 O
- O
Empowering O
the O
intensive O
care O
practitioners O
. O
is O
it O
a O
burnout O
ameliorating O
intervention O
? O

P O
. O

Ostrowski O
, O
A O
. O

Omar O
P439 O
- O
Icu O
patients O
suffer O
from O
circadian O
rhythm O
desynchronisation O
K O
. O

Kiss O
, O
B O
. O

Köves O
, O
V O
. O

Csernus O
, O
Z O
. O

Molnár O
P440 O
- O
Noise O
reduction O
in O
the O
ICU O
: O
feasible O
? O

Y O
. O

Hoydonckx O
, O
S O
. O

Vanwing O
, O
B O
. O

Stessel O
, O
A O
. O

Van O
Assche O
, O
L O
. O

Jamaer O
, O
J O
. O

Dubois O
P441 O
- O
Accidental O
removal O
of O
invasive O
devices O
in O
the O
critical O
patient O
into O
the O
bed-washing O
. O
does O
the O
presence O
of O
professional O
nurse O
modify O
his O
incidence O
? O

V O
. O

Medo O
, O
R O
. O

Galvez O
, O
J O
. O

P O
. O

Miranda O
P442 O
- O
Deprivation O
of O
liberty O
safeguards O
( O
dols O
) O
: O
audit O
of O
compliance O
in O
a O
of O
a O
16 O
- O
bed O
specialist O
cancer O
critical O
care O
unit O
. O

C O
. O

Stone O
, O
T O
. O

Wigmore O
P443 O
- O
Use O
of O
a O
modified O
cristal O
score O
to O
predict O
futility O
of O
critical O
care O
in O
the O
elderly O
Y O
. O

Arunan O
, O
A O
. O

Wheeler O
, O
K O
. O

Bauchmuller O
, O
D O
. O

Bryden O
P444 O
- O
Improvement O
of O
Referral O
Rate O
to O
Palliative O
Care O
for O
Patients O
with O
Poor O
Prognosis O
in O
Neurosurgical O
Intensive O
Care O
Unit O
Y O
. O

Wong O
, O
C O
. O

Poi O
, O
C O
. O

Gu O
P445 O
- O
Factors O
associated O
with O
limitation O
of O
life O
supporting O
care O
( O
lsc O
) O
in O
a O
medico-surgical O
intermediate O
care O
unit O
, O
and O
outcome O
of O
patients O
with O
lsc O
limitation O
: O
a O
monocentric O
, O
six-month O
study O
. O

P O
. O

Molmy O
, O
N O
. O

Van O
Grunderbeeck O
, O
O O
. O

Nigeon O
, O
M O
. O

Lemyze O
, O
D O
. O

Thevenin O
, O
J O
. O

Mallat O
P446 O
- O
Palliative O
care O
consultation O
and O
intensive O
care O
unit O
admission O
request O
: O
a O
cohort O
study O
J O
. O

Ramos O
, O
M O
. O

Correa O
, O
R O
. O

T O
. O

Carvalho O
, O
D O
. O

Forte O
P447 O
- O
Nursing O
and O
medicine O
together O
in O
postsurgical O
intensive O
care O
unit O
: O
situations O
of O
prognostic O
conflict O
at O
the O
end O
of O
life O
. O
our O
critical O
care O
nurses O
suffer O
with O
our O
medical O
activism O
? O

A O
. O

Fernandez O
, O
C O
. O

McBride O
P448 O
- O
End O
of O
life O
who O
may O
decide O
E O
. O

Koonthalloor O
, O
C O
. O

Walsh O
P449 O
- O
Correctly O
diagnosing O
death O
A O
. O

Webber O
, O
M O
. O

Ashe O
, O
K O
. O

Smith O
, O
P O
. O

Jeanrenaud O
P450 O
- O
Skin O
procurement O
performed O
by O
intensive O
care O
physicians O
: O
yes O
, O
we O
can O
. O

A O
. O

Marudi O
, O
S O
. O

Baroni O
, O
F O
. O

Ragusa O
, O
E O
. O

Bertellini O
P451 O
- O
Death O
analysis O
in O
pediatric O
intensive O
care O
patients O
E O
. O

A O
. O

Volakli O
, O
E O
. O

Chochliourou O
, O
M O
. O

Dimitriadou O
, O
A O
. O

Violaki O
, O
P O
. O

Mantzafleri O
, O
E O
. O

Samkinidou O
, O
O O
. O

Vrani O
, O
A O
. O

Arbouti O
, O
T O
. O

Varsami O
, O
M O
. O

Sdougka O
P452 O
- O
The O
potential O
impact O
of O
euthanasia O
on O
organ O
donation O
: O
analysis O
of O
data O
from O
belgium O
J O
. O

A O
. O

Bollen O
, O
T O
. O

C O
. O

Van O
Smaalen O
, O
W O
. O

C O
. O

De O
Jongh O
, O
M O
. O

M O
. O

Ten O
Hoopen O
, O
D O
. O

Ysebaert O
, O
L O
. O

W O
. O

Van O
Heurn O
, O
W O
. O

N O
. O

Van O
Mook O
P453 O
- O
Communication O
within O
an O
intensive O
care O
setting O
K O
. O

Sim O
, O
A O
. O

Fuller O
P454 O
- O
Development O
and O
implementation O
of O
a O
longitudinal O
communication O
curriculum O
for O
critical O
care O
medicine O
fellows O
A O
. O

Roze O
des O
Ordons O
, O
P O
. O

Couillard O
, O
C O
. O

Doig O
P455 O
- O
Staff-family O
conflict O
in O
a O
multi-ethnic O
intensive O
care O
unit O
R O
. O

V O
. O

Van O
Keer O
, O
R O
. O

D O
. O

Deschepper O
, O
A O
. O

F O
. O

Francke O
, O
L O
. O

H O
. O

Huyghens O
, O
J O
. O

B O
. O

Bilsen O
P456 O
- O
Does O
the O
source O
of O
admission O
to O
critical O
care O
affect O
family O
satisfaction O
? O

B O
. O

Nyamaizi O
, O
C O
. O

Dalrymple O
, O
A O
. O

Molokhia O
, O
A O
. O

Dobru O
P457 O
- O
A O
simple O
alternative O
to O
the O
family O
satisfaction O
survey O
( O
fs-icu O
) O
E O
. O

Marrinan O
, O
A O
. O

Ankuli O
, O
A O
. O

Molokhia O
P458 O
- O
A O
study O
to O
explore O
the O
experiences O
of O
patient O
and O
family O
volunteers O
in O
a O
critical O
care O
environment O
: O
a O
phenomenological O
analysis O
J O
. O

McPeake O
, O
R O
. O

Struthers O
, O
R O
. O

Crawford O
, O
H O
. O

Devine O
, O
P O
. O

Mactavish O
, O
T O
. O

Quasim O
P459 O
- O
Prevalence O
and O
risk O
factors O
of O
anxiety O
and O
depression O
in O
relatives O
of O
burn O
patients O
. O

P O
. O

Morelli O
, O
M O
. O

Degiovanangelo O
, O
F O
. O

Lemos O
, O
V O
. O

MArtinez O
, O
F O
. O

Verga O
, O
J O
. O

Cabrera O
, O
G O
. O

Burghi O
P460 O
- O
Guidance O
of O
visiting O
children O
at O
an O
adult O
intensive O
care O
unit O
( O
icu O
) O
A O
. O

Rutten O
, O
S O
. O

Van O
Ieperen O
, O
S O
. O

De O
Geer O
, O
M O
. O

Van O
Vugt O
, O
E O
. O

Der O
Kinderen O
P461 O
- O
Visiting O
policies O
in O
Italian O
pediatric O
ICUs O
: O
an O
update O
A O
. O

Giannini O
, O
G O
Miccinesi O
, O
T O
Marchesi O
, O
E O
Prandi O

Introduction O
: O
Acquired B-Symptom_TestedFor
brain I-Symptom_TestedFor
injury I-Symptom_TestedFor
( O
ABI O
) O
during O
childhood O
typically O
causes O
behavior O
problems O
in O
the O
child O
and O
high O
levels O
of O
stress O
in O
the O
family O
. O

The O
aims O
of O
this O
study O
are O
: O
( O
1 O
) O
to O
investigate O
the O
effectiveness O
and O
feasibility O
of O
a O
parenting O
intervention O
in O
improving O
behavior O
and O
self-regulation O
in O
Mexican O
children O
with O
ABI O
compared O
to O
telephone O
support O
; O
( O
2 O
) O
to O
investigate O
the O
effectiveness O
and O
feasibility O
of O
a O
parenting O
intervention O
in O
improving O
parenting O
skills O
, O
parent O
self-efficacy O
and O
decreasing O
parental O
stress O
in O
parents O
of O
children O
with O
ABI O
compared O
to O
telephone O
support O
. O

Our O
secondary O
aims O
are O
( O
1 O
) O
to O
explore O
the O
impact O
that O
parent O
characteristics O
have O
on O
the O
intervention O
outcomes O
; O
( O
2 O
) O
to O
investigate O
if O
changes O
are O
maintained O
3 O
months O
after O
the O
intervention O
. O

Methods O
: O
The O
research O
design O
is O
a O
blind O
randomized O
controlled O
trial O
( O
RCT O
) O
. O

Eligible O
participants O
include O
children O
with O
a O
diagnosis O
of O
ABI O
, O
between O
6 O
and O
12 O
years O
of O
age O
, O
and O
their O
parents O
. O

Sixty-six B-#Participants
children O
and O
their O
parents O
will O
be O
randomly O
allocated O
to O
either O
a O
parenting O
program O
group O
or O
telephone O
support O
group O
. O

The O
parenting O
program O
involves O
six O
face-to-face O
weekly O
group O
sessions O
of O
2.5 O
h O
each O
. O

Participants O
in O
the O
control O
group O
receive O
an O
information O
sheet O
with O
behavioral O
strategies O
, O
and O
six O
weekly O
phone O
calls O
, O
in O
which O
strategies O
to O
improve O
academic O
skills O
are O
provided O
. O

Children O
and O
their O
parents O
are O
evaluated O
by O
blind O
assessors O
before O
the O
intervention O
, O
immediately O
after O
the O
intervention O
and O
3 O
- O
months O
post-intervention O
. O

Discussion O
: O
This O
study O
will O
be O
the O
first O
to O
evaluate O
the O
efficacy O
and O
feasibility O
of O
a O
parenting O
program O
for O
Mexican O
parents O
of O
children O
with O
ABI O
. O

Trial O
identifier O
: O
ACTRN12617000360314 O
. O

Objective O
: O
The O
aim O
of O
this O
study O
was O
to O
study O
the O
ameliorative O
effects O
of O
Ocimum B-Medicinal food
sanctum I-Medicinal food
and O
Camellia B-Medicinal food
sinensis I-Medicinal food
on O
stress-induced B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
. O

Materials O
and O
methods O
: O
The O
study O
was O
carried O
out O
using O
male O
albino O
rats O
( O
200 O
± O
50 O
g O
) O
. O

The O
effect O
of O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
was O
evaluated O
for O
anxiety B-Symptom_WorkedFor
and O
depression B-Symptom_WorkedFor
using O
elevated O
plus O
maze O
( O
EPM O
) O
test O
, O
open O
field O
test O
( O
OFT O
) O
, O
forced O
swim O
test O
( O
FST O
) O
, O
and O
tail O
suspension O
test O
( O
TST O
) O
. O

Result O
: O
Restraint O
stress O
( O
3 O
h O
/ O
day O
for O
six O
consecutive O
days O
) O
induced O
a O
significant O
reduction O
in O
both O
the O
percentage O
number O
of O
entries O
and O
time O
spent O
in O
open O
arms O
in O
EPM O
, O
and O
these O
changes O
were O
reversed O
with O
post-treatment O
of O
aqueous O
extract O
of O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
( O
100 O
mg O
/ O
kg O
for O
6 O
days O
) O
. O

Restraint O
stress-induced O
( O
a O
) O
increased O
latency O
and O
( O
b O
) O
decreased O
ambulation O
and O
rearing O
were O
also O
reversed O
by O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
in O
OFT O
. O

A O
significant O
increase O
in O
immobility O
period O
was O
observed O
in O
FST O
and O
TST O
after O
restraint O
stress O
. O

O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
significantly O
reduced O
the O
immobility O
times O
of O
rats O
in O
FST O
and O
TST O
. O

Conclusion O
: O
O B-Medicinal food
. I-Medicinal food
sanctum I-Medicinal food
and O
C B-Medicinal food
. I-Medicinal food
sinensis I-Medicinal food
possess O
anxiolytic O
and O
antidepressant O
activities O
. O

Anxiety B-Symptom_WorkedFor
disorders I-Symptom_WorkedFor
are O
some O
of O
the O
most O
common O
psychiatric O
disorders O
, O
with O
potentially O
debilitating O
consequences O
on O
individual O
function O
. O

Existing O
pharmacotherapies O
for O
anxiety B-Symptom_WorkedFor
disorders O
are O
limited O
by O
delay O
to O
therapeutic O
effect O
, O
dependence O
, O
tolerance O
, O
withdrawal O
, O
and O
abuse O
potential O
. O

Therefore O
, O
safe O
and O
evidence-based O
complementary O
or O
alternative O
therapies O
may O
be O
important O
allies O
in O
the O
care O
of O
patients O
with O
anxiety O
disorders O
. O

Essential O
oils O
are O
lipophilic O
and O
concentrated O
botanical O
extracts O
that O
exhibit O
many O
properties O
of O
drugs O
, O
although O
they O
are O
not O
Food O
and O
Drug O
Administration O
approved O
and O
have O
limitations O
characteristic O
of O
herbal O
preparations O
. O

Lavender B-Medicinal food
essential O
oil O
has O
an O
extensive O
anecdotal O
history O
of O
anxiolytic O
benefit O
that O
has O
recently O
been O
supported O
by O
clinical O
efficacy O
studies O
. O

The O
2 O
primary O
terpenoid O
constituents O
of O
lavender B-Medicinal food
essential O
oil O
, O
linalool B-Drug/Scientific name
and O
linalyl B-Drug/Scientific name
acetate I-Drug/Scientific name
, O
may O
produce O
an O
anxiolytic O
effect O
in O
combination O
via O
inhibition O
of O
voltage-gated O
calcium O
channels O
, O
reduction O
of O
5HT1A O
receptor O
activity O
, O
and O
increased O
parasympathetic O
tone O
. O

The O
objectives O
of O
this O
article O
are O
to O
provide O
a O
brief O
overview O
of O
lavender B-Medicinal food
oil O
in O
aromatherapy O
, O
explore O
variability O
in O
the O
constituents O
of O
lavender B-Medicinal food
oil O
, O
summarize O
its O
pharmacology O
and O
safety O
profile O
, O
as O
well O
as O
describe O
its O
body O
of O
research O
that O
has O
been O
conducted O
for O
anxiety B-Symptom_WorkedFor
. O

A O
number O
of O
essential O
oils O
are O
currently O
in O
use O
as O
aromatherapy O
agents O
to O
relieve O
anxiety B-Symptom_WorkedFor
, O
stress B-Symptom_WorkedFor
, O
and O
depression B-Symptom_WorkedFor
. O

Popular O
anxiolytic O
oils O
include O
lavender B-Medicinal food
( O
Lavandula B-Drug/Scientific name
angustifolia I-Drug/Scientific name
) O
, O
rose B-Medicinal food
( O
Rosa B-Drug/Scientific name
damascena I-Drug/Scientific name
) O
, O
orange B-Medicinal food
( O
Citrus B-Drug/Scientific name
sinensis I-Drug/Scientific name
) O
, O
bergamot B-Medicinal food
( O
Citrus B-Drug/Scientific name
aurantium I-Drug/Scientific name
) O
, O
lemon B-Medicinal food
( O
Citrus B-Drug/Scientific name
limon I-Drug/Scientific name
) O
, O
sandalwood B-Medicinal food
( O
Santalum B-Drug/Scientific name
album I-Drug/Scientific name
) O
, O
clary B-Medicinal food
sage I-Medicinal food
( O
Salvia B-Drug/Scientific name
sclarea I-Drug/Scientific name
) O
, O
Roman B-Medicinal food
chamomile I-Medicinal food
( O
Anthemis B-Drug/Scientific name
nobilis I-Drug/Scientific name
) O
, O
and O
rose-scented B-Medicinal food
geranium I-Medicinal food
( O
Pelargonium B-Drug/Scientific name
spp I-Drug/Scientific name
. O
) O
. O

This O
review O
discusses O
the O
chemical O
constituents O
and O
CNS O
effects O
of O
these O
aromatherapeutic O
essential O
oils O
, O
as O
well O
as O
recent O
studies O
on O
additional O
essential O
oils O
with O
anxiolytic O
activities O
. O

Background O
: O
The O
course O
and O
predictors O
of O
women O
׳ O
s O
mood O
following O
childbirth O
have O
informed O
clinically O
significant O
phenomena O
, O
such O
as O
postpartum B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
( O
PPD O
) O
, O
with O
some O
contradictory O
findings O
due O
to O
methodological O
limitations O
. O

It O
is O
important O
to O
further O
investigate O
mood O
during O
this O
unique O
period O
of O
time O
to O
inform O
assessment O
and O
improve O
interventions O
. O

Methods O
: O
Recently O
delivered O
mothers O
( O
n O
= O
216 O
) O
recruited O
from O
the O
maternity O
unit O
at O
a O
University O
hospital O
completed O
sociodemographic O
questions O
and O
the O
Daily O
Experiences O
Questionnaire O
( O
DEQ O
) O
, O
a O
measure O
of O
Negative O
Affect O
( O
NA O
) O
and O
Positive O
Affect O
( O
PA O
) O
, O
for O
10 B-Duration
consecutive I-Duration
days I-Duration
. O

The O
Structured O
Clinical O
Interview O
for O
DSM-IV O
was O
administered O
to O
assess O
postpartum B-Symptom_WorkedFor
depression I-Symptom_WorkedFor
diagnosis O
. O

Results O
: O
Growth O
curve O
modeling O
( O
GCM O
) O
techniques O
revealed O
average O
trends O
in O
mood O
following O
delivery O
. O

NA O
changed O
in O
a O
curvilinear O
fashion O
with O
a O
peak O
at O
day O
5 O
. O

PA O
declined O
rapidly O
during O
the O
days O
immediately O
following O
delivery O
and O
then O
stabilized O
. O

Women O
diagnosed O
with O
PPD O
experienced O
higher O
overall O
levels O
of O
NA O
and O
lower O
levels O
of O
PA O
from O
delivery O
to O
10 O
days O
postpartum O
. O

Patterns O
of O
mood O
varied O
as O
a O
function O
of O
neuroticism O
and O
several O
well-established O
sociodemographic O
variables O
. O

Limitations O
: O
Small O
sample O
size O
and O
relatively O
few O
ethnic O
minority O
participants O
may O
affect O
generalizability O
of O
the O
findings O
. O

Conclusions O
: O
NA O
changed O
in O
a O
pattern O
consistent O
with O
the O
" O
peaking O
phenomenon O
" O
. O

Well-established O
risk O
factors O
of O
the O
blues O
had O
significant O
associations O
with O
mood O
from O
delivery O
to O
day O
10 O
. O

Increased O
understanding O
into O
the O
nature O
of O
NA O
and O
PA O
in O
the O
early O
postpartum O
, O
and O
its O
role O
in O
identifying O
women O
susceptible O
to O
experiencing O
PPD O
, O
can O
inform O
screening O
and O
therapeutic O
interventions O
for O
PPD O
. O

Objective O
: O
To O
determine O
the O
relative O
importance O
of O
psychosocial O
factors O
in O
arthritis B-Symptom_TestedFor
diagnosis O
in O
an O
ageing O
cohort O
of O
Australian O
women O
. O

Methods O
: O
This O
study O
focused O
on O
10,509 B-#Participants
women O
from O
the O
1946 O
- O
1951 O
cohort O
who O
responded O
to O
questions O
on O
arthritis B-Symptom_TestedFor
in O
the O
fifth O
mailed O
population-based O
survey O
of O
the O
Australian O
Longitudinal O
Study O
on O
Women's O
Health O
conducted O
in O
2007 O
. O

Results O
: O
Arthritis B-Symptom_TestedFor
was O
characterised O
by O
widespread O
psychosocial O
concerns O
, O
particularly O
relating O
to O
chronic O
stress B-Symptom_TestedFor
and O
poor O
mental B-Symptom_TestedFor
health I-Symptom_TestedFor
. O

Univariate O
analyses O
revealed O
that O
in O
comparison O
to O
women O
without O
stress O
, O
women O
with O
moderate O
/ O
high O
stress O
levels O
had O
a O
2.5 O
- O
fold O
increase O
in O
reporting O
arthritis O
. O

Experiencing O
ongoing O
negative O
interpersonal O
life O
events O
concerning O
illness O
of O
a O
family O
member O
/ O
close O
friend O
and O
relationship O
difficulties O
was O
also O
associated O
with O
a O
1.4 O
- O
fold O
increase O
in O
the O
reporting O
of O
arthritis O
. O

Likewise O
, O
significantly O
reduced O
levels O
of O
optimism O
and O
perceived O
social O
support O
were O
noted O
( O
all O
associations O
p O
< O
.001 O
) O
. O

Psychiatric O
diagnosis O
was O
also O
associated O
with O
a O
two-fold O
increase O
in O
having O
arthritis O
( O
p O
< O
.001 O
) O
. O

Following O
adjustment O
for O
behavioural O
, O
demographic O
and O
health-related O
characteristics O
, O
anxiety B-Symptom_TestedFor
was O
the O
only O
psychosocial O
factor O
associated O
with O
arthritis O
( O
OR O
= O
1.4 O
, O
95% O
CI O
= O
1.2 O
, O
1.7 O
; O
p O
< O
.001 O
) O
. O

Conclusion O
: O
This O
study O
examined O
, O
epidemiologically O
, O
the O
relative O
importance O
of O
psychosocial O
factors O
in O
arthritis O
in O
an O
ageing O
cohort O
of O
Australian O
women O
. O

The O
findings O
from O
this O
population-based O
study O
indicate O
that O
women O
with O
arthritis O
are O
more O
likely O
to O
report O
a O
range O
of O
psychosocial-related O
problems O
, O
particularly O
with O
regard O
to O
chronic O
stress O
perception O
and O
anxiety O
. O

Longitudinal O
analyses O
are O
required O
to O
examine O
the O
processes O
by O
which O
stress O
and O
psychosocial O
factors O
may O
contribute O
to O
arthritis O
risk O
and O
poor O
adaptation O
in O
terms O
of O
health-related O
quality O
of O
life O
. O

Magnolol B-Medicinal food
is O
a O
traditional O
Chinese O
medicine O
from O
the O
root O
and O
bark O
of O
Magnolia B-Drug/Scientific name
officinalis I-Drug/Scientific name
. O

It O
has O
long O
been O
used O
to O
treat O
anxiety B-Symptom_WorkedFor
, O
cough B-Symptom_WorkedFor
, O
headache B-Symptom_WorkedFor
and O
allergies B-Symptom_WorkedFor
, O
as O
well O
as O
a O
variety O
of O
inflammations O
. O

Lung O
inflammation O
is O
a O
key O
event O
in O
the O
pathogenesis O
of O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
. O

The O
present O
study O
sought O
to O
examine O
the O
effects O
of O
magnolol B-Medicinal food
on O
tumor O
necrosis O
factor O
( O
TNF O
) O
- O
α-induced O
upregulation O
of O
intercellular O
adhesion O
molecule O
- O
1 O
( O
ICAM O
- O
1 O
) O
, O
activation O
of O
the O
nuclear O
factor O
( O
NF O
) O
- O
κB O
and O
mitogen-activated O
protein O
kinase O
( O
MAPK O
) O
signaling O
pathway O
in O
cultured O
human O
pulmonary O
epithelial O
cells O
, O
and O
adhesion O
of O
human O
macrophage-like O
U937 O
cells O
to O
A549 O
cells O
. O

A549 O
cells O
were O
incubated O
with O
magnolol B-Medicinal food
at O
25 B-Dosage
and I-Dosage
50 I-Dosage
μmol I-Dosage
/ I-Dosage
l I-Dosage
. O

Then O
, O
20 O
ng O
/ O
ml O
TNF-α O
was O
used O
to O
activate O
the O
cells O
. O

Magnolol B-Medicinal food
inhibited O
the O
growth O
of O
human O
pulmonary O
epithelial O
A549 O
cells O
in O
a O
dose O
- O
and O
time-dependent O
manner O
. O

Magnolol B-Medicinal food
suppressed O
the O
adhesion O
of O
U937 O
cells O
to O
TNF-α-induced O
A549 O
cells O
. O

In O
cultured O
human O
pulmonary O
epithelial O
A549 O
cells O
, O
magnolol O
decreased O
TNF-α-induced O
upregulation O
of O
ICAM O
- O
1 O
. O

Magnolol B-Medicinal food
repressed O
TNF-α-induced O
activation O
of O
NF-κB O
and O
mitogen-activated O
protein O
kinase O
( O
MAPK O
) O
signaling O
pathways O
in O
A549 O
cells O
by O
inhibiting O
phosphorylation O
of O
NF-κB O
, O
p38 O
, O
extracellular O
signal-regulated O
kinase O
( O
ERK O
) O
1 O
/ O
2 O
, O
and O
stress-activated O
protein O
kinase O
( O
SAPK O
) O
/ O
c-Jun O
N-terminal O
kinase O
( O
JNK O
) O
. O

These O
findings O
support O
the O
hypothesis O
that O
magnolol B-Medicinal food
inhibits O
the O
inflammatory O
process O
in O
lung O
epithelial O
A549 O
cells O
by O
suppressing O
the O
ICAM O
- O
1 O
and O
NF-κB O
and O
MAPK O
signaling O
pathways O
. O

Taken O
together O
, O
these O
results O
indicate O
that O
magnolol B-Medicinal food
offers O
significant O
potential O
as O
a O
therapeutic O
treatment O
for O
inflammatory O
diseases O
of O
the O
lungs O
including O
asthma B-Symptom_WorkedFor
, O
sepsis B-Symptom_WorkedFor
, O
and O
chronic B-Symptom_WorkedFor
obstructive I-Symptom_WorkedFor
pulmonary I-Symptom_WorkedFor
disease I-Symptom_WorkedFor
. O

Background O
: O
Recent O
research O
has O
established O
correlations O
between O
stress O
, O
anxiety O
, O
insomnia O
and O
excess O
body O
weight O
and O
these O
correlations O
have O
significant O
implications O
for O
health O
. O

This O
study O
measured O
the O
effects O
of O
a O
proprietary O
blend O
of O
extracts O
of O
Magnolia B-Medicinal food
officinalis I-Medicinal food
and O
Phellodendron B-Other_ingredients
amurense I-Other_ingredients
( O
Relora B-Drug/Scientific name
) O
on O
anxiety B-Symptom_TestedFor
, O
stress B-Symptom_TestedFor
and O
sleep B-Symptom_TestedFor
in O
healthy O
premenopausal B-participant_health
women O
. O

Methods O
: O
This O
randomized O
, O
parallel O
, O
placebo O
controlled O
clinical O
study O
was O
conducted O
with O
healthy O
, O
overweight O
( O
BMI O
25 O
to O
34.9 O
) O
, O
premenopausal O
female O
adults O
, O
between O
the O
ages O
of O
20 O
and O
50 O
years O
, O
who O
typically O
eat O
more O
in O
response O
to O
stressful O
situations O
and O
scores O
above O
the O
national O
mean O
for O
women O
on O
self-reporting O
anxiety B-Symptom_TestedFor
. O

The O
intervention O
was O
Relora B-Drug/Scientific name
( O
250 B-Dosage
mg I-Dosage
capsules I-Dosage
) O
or O
identical O
placebo O
3 O
times O
daily O
for O
6 B-Duration
weeks I-Duration
. O

Anxiety B-Symptom_TestedFor
as O
measured O
by O
the O
Spielberger B-Metric
STATE-TRAIT I-Metric
questionnaires O
, O
salivary O
amylase O
and O
cortisol O
levels O
, O
Likert B-Metric
Scales I-Metric
/ I-Metric
Visual I-Metric
Analog I-Metric
Scores I-Metric
for O
sleep B-Symptom_TestedFor
quality O
and O
latency O
, O
appetite O
, O
and O
clinical O
markers O
of O
safety O
. O

The O
study O
was O
conducted O
by O
Miami O
Research O
Associates O
, O
a O
clinical O
research O
organization O
in O
Miami O
, O
FL O
. O

Results O
: O
The O
intent-to-treat O
population O
consisted O
of O
40 O
subjects O
with O
26 B-#Participants
participants O
completing O
the O
study O
. O

There O
were O
no O
significant O
adverse O
events O
. O

Relora B-Drug/Scientific name
was O
effective O
, O
in O
comparison O
to O
placebo O
, O
in O
reducing O
temporary O
, O
transitory B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
as O
measured O
by O
the O
Spielberger B-Metric
STATE I-Metric
anxiety I-Metric
questionnaire I-Metric
. O

It O
was O
not O
effective O
in O
reducing O
long-standing O
feelings O
of O
anxiety O
or O
depression B-Symptom_TestedFor
as O
measured O
using O
the O
Spielberger B-Metric
TRAIT I-Metric
questionnaire I-Metric
. O

Other O
assessments O
conducted O
in O
this O
study O
including O
salivary O
cortisol O
and O
amylase O
levels O
, O
appetite O
, O
body O
morphology O
and O
sleep O
quality O
/ O
latency O
were O
not O
significantly O
changed O
by O
Relora B-Drug/Scientific name
in O
comparison O
to O
placebo O
. O

Conclusion O
: O
This O
pilot O
study O
indicates O
that O
Relora B-Drug/Scientific name
may O
offer O
some O
relief O
for O
premenopausal O
women O
experiencing O
mild O
transitory B-Symptom_WorkedFor
anxiety I-Symptom_WorkedFor
. O

There O
were O
no O
safety O
concerns O
or O
significant O
adverse O
events O
observed O
in O
this O
study O
. O

Research O
in O
the O
area O
of O
herbal O
psychopharmacology O
has O
revealed O
a O
variety O
of O
promising O
medicines O
that O
may O
provide O
benefit O
in O
the O
treatment O
of O
general O
anxiety B-Symptom_TestedFor
and O
specific O
anxiety B-Symptom_TestedFor
disorders I-Symptom_TestedFor
. O

However O
, O
a O
comprehensive O
review O
of O
plant-based O
anxiolytics O
has O
been O
absent O
to O
date O
. O

Thus O
, O
our O
aim O
was O
to O
provide O
a O
comprehensive O
narrative O
review O
of O
plant-based O
medicines O
that O
have O
clinical O
and O
/ O
or O
preclinical O
evidence O
of O
anxiolytic B-Symptom_TestedFor
activity I-Symptom_TestedFor
. O

We O
present O
the O
article O
in O
two O
parts O
. O

In O
part O
one O
, O
we O
reviewed O
herbal O
medicines O
for O
which O
only O
preclinical O
investigations O
for O
anxiolytic B-Symptom_TestedFor
activity I-Symptom_TestedFor
have O
been O
performed O
. O

In O
this O
current O
article O
( O
part O
two O
) O
, O
we O
review O
herbal O
medicines O
for O
which O
there O
have O
been O
both O
preclinical O
and O
clinical O
investigations O
of O
anxiolytic O
activity O
. O

A O
search O
of O
MEDLINE O
( O
PubMed O
) O
, O
CINAHL O
, O
Scopus O
and O
the O
Cochrane O
Library O
databases O
was O
conducted O
( O
up O
to O
28 O
October O
2012 O
) O
for O
English O
language O
papers O
using O
the O
search O
terms O
' O
anxiety O
' O
OR O
' O
anxiety O
disorder O
' O
OR O
' O
generalized O
anxiety O
disorder O
' O
OR O
' O
social O
phobia O
' O
OR O
' O
post-traumatic O
stress O
disorder O
' O
OR O
' O
panic O
disorder O
' O
OR O
' O
agoraphobia O
' O
OR O
' O
obsessive O
compulsive O
disorder O
' O
in O
combination O
with O
the O
search O
terms O
' O
Herb O
* O
' O
OR O
' O
Medicinal O
Plants O
' O
OR O
' O
Botanical O
Medicine O
' O
OR O
' O
Chinese O
herb O
* O
' O
, O
in O
addition O
to O
individual O
herbal O
medicines O
. O

This O
search O
of O
the O
literature O
revealed O
1,525 O
papers O
, O
of O
which O
53 O
plants O
were O
included O
in O
the O
review O
( O
having O
at O
least O
one O
study O
using O
the O
whole O
plant O
extract O
) O
. O

Of O
these O
plants O
, O
21 O
had O
human O
clinical O
trial O
evidence O
( O
reviewed O
here O
in O
part O
two O
) O
, O
with O
the O
other O
32 O
having O
solely O
preclinical O
evidence O
( O
reviewed O
in O
part O
one O
) O
. O

Support O
for O
efficacy O
was O
found O
for O
chronic O
use O
( O
i.e O
. O
greater O
than O
one O
day O
) O
of O
the O
following O
herbs O
in O
treating O
a O
range O
of O
anxiety O
disorders O
in O
human O
clinical O
trials O
: O
Piper O
methysticum O
, O
Matricaria O
recutita O
, O
Ginkgo O
biloba O
, O
Scutellaria O
lateriflora O
, O
Silybum O
marianum O
, O
Passiflora O
incarnata O
, O
Withania O
somniferum O
, O
Galphimia O
glauca O
, O
Centella O
asiatica O
, O
Rhodiola O
rosea O
, O
Echinacea O
spp O
. O
, O
Melissa O
officinalis O
and O
Echium O
amoenum O
. O

For O
several O
of O
the O
plants O
studied O
, O
conclusions O
need O
to O
be O
tempered O
due O
to O
methodological O
issues O
such O
as O
small O
sample O
sizes O
, O
brief O
intervention O
durations O
and O
non-replication O
. O

Current O
evidence O
does O
not O
support O
Hypericum O
perforatum O
or O
Valeriana O
spp O
. O
for O
any O
anxiety B-Symptom_WorkedFor
disorder O
. O

Acute O
anxiolytic O
activity O
was O
found O
for O
Centella B-Medicinal food
asiatica I-Medicinal food
, O
Salvia B-Medicinal food
spp I-Medicinal food
. O
, O
Melissa B-Medicinal food
officinalis I-Medicinal food
, O
Passiflora B-Medicinal food
incarnata I-Medicinal food
and O
Citrus B-Medicinal food
aurantium I-Medicinal food
. O

Bacopa O
monnieri O
has O
shown O
anxiolytic O
effects O
in O
people O
with O
cognitive O
decline O
. O

The O
therapeutic O
application O
of O
psychotropic O
plant-based O
treatments O
for O
anxiety B-Symptom_WorkedFor
disorders O
is O
also O
discussed O
, O
specifically O
Psychotria B-Medicinal food
viridis I-Medicinal food
and O
Banisteriopsis B-Medicinal food
caarti I-Medicinal food
( O
ayahuasca B-Medicinal food
) O
, O
Psilocybe B-Medicinal food
spp I-Medicinal food
. O
and O
cannabidiol-enriched B-Medicinal food
( O
low O
tetrahydrocannabinol O
( O
Δ O
( O
9 O
) O
- O
THC O
) O
) O
Cannabis O
spp O
. O

Recent O
studies O
focused O
on O
the O
pharmacology O
and O
feasibility O
of O
herbal O
compounds O
as O
a O
potential O
strategy O
to O
target O
a O
variety O
of O
human O
diseases O
ranging O
from O
metabolic O
to O
brain O
disorders O
. O

Accordingly O
, O
bioactive O
ingredients O
which O
are O
found O
within O
a O
variety O
of O
herbal O
compounds O
are O
reported O
to O
produce O
both O
neuroprotective O
and O
psychotropic O
activities O
which O
may O
help O
to O
combat O
mental O
disorders O
such O
as O
depression O
, O
anxiety O
, O
sleep O
disturbances O
and O
cognitive O
alterations O
. O

In O
the O
present O
manuscript O
, O
we O
focus O
on O
three O
herbs O
which O
appear O
effective O
in O
mitigating O
anxiety B-Symptom_WorkedFor
or O
depression B-Symptom_WorkedFor
with O
favourable O
risk-benefit O
profiles O
, O
namely O
Scutellaria B-Medicinal food
baicalensis I-Medicinal food
( O
S B-Medicinal food
. I-Medicinal food
baicalensis I-Medicinal food
) O
, O
Hericium B-Medicinal food
erinaceus I-Medicinal food
( O
H B-Medicinal food
. I-Medicinal food
erinaceus I-Medicinal food
) O
and O
Rhodiola B-Medicinal food
rosea I-Medicinal food
( O
R B-Medicinal food
. I-Medicinal food
rosea I-Medicinal food
) O
. O

These O
three O
traditional O
folk O
medicinal O
herbs O
target O
the O
main O
biochemical O
events O
that O
are O
implicated O
in O
mental O
disorders O
, O
mimicking O
, O
to O
some O
extent O
, O
the O
mechanisms O
of O
action O
of O
conventional O
antidepressants O
and O
mood O
stabilizers O
with O
a O
wide O
margin O
of O
tolerability O
. O

In O
detail O
, O
they O
rescue O
alterations O
in O
neurotransmitter O
and O
neuro-endocrine O
systems O
, O
stimulate O
neurogenesis O
and O
the O
synthesis O
of O
neurotrophic O
factors O
, O
and O
they O
counteract O
oxidative O
stress O
, O
mitochondrial O
dysfunction O
and O
inflammation O
. O

Albeit O
the O
encouraging O
results O
that O
emerge O
from O
both O
experimental O
and O
clinical O
evidence O
, O
further O
studies O
are O
needed O
to O
confirm O
and O
better O
understand O
the O
mental-health O
promoting O
, O
and O
specifically O
, O
the O
antidepressant O
effects O
of O
these O
herbs O
. O

Posttraumatic B-participant_health
stress I-participant_health
disorder I-participant_health
( O
PTSD B-participant_health
) O
is O
a O
trauma-induced O
psychiatric O
disease O
characterized O
by O
impaired O
hyperarousal O
, O
fear O
extermination O
, O
depression O
, O
anxiety O
, O
and O
amnesic O
symptoms O
that O
may O
include O
the O
release O
of O
monoamines O
in O
the O
dread O
circuit O
. O

Curcumin B-Medicinal food
( O
CUR B-Medicinal food
) O
, O
a O
major O
diarylheptanoid O
and O
polyphenolic O
component O
of O
Curcuma O
longa O
, O
reportedly O
possesses O
several O
pharmacological O
features O
, O
including O
antidiabetic O
, O
antiatherosclerotic O
, O
anticancer O
, O
and O
neuropsychiatric O
actions O
. O

But O
the O
anxiolytic-like O
effects O
of O
CUR B-Medicinal food
and O
its O
mechanism O
of O
action O
in O
PTSD B-participant_health
are O
unclear O
. O

The O
current O
research O
measured O
some O
anxiety-related O
behavioral O
responses O
to O
examine O
the O
effects O
of O
CUR B-Medicinal food
on O
symptoms O
of O
anxiety B-Symptom_WorkedFor
in O
rats O
after O
single O
prolonged O
stress O
( O
SPS O
) O
exposure O
by O
reversing O
the O
serotonin O
( O
5 O
- O
HT O
) O
dysfunction O
. O

Rats O
received O
CUR B-Medicinal food
( O
20 O
, O
50 O
, O
or O
100 O
mg O
/ O
kg O
, O
i.p O
. O
, O
once O
daily O
) O
for O
14 O
days O
after O
SPS O
exposure O
. O

Administration O
of O
CUR B-Medicinal food
significantly O
increased O
the O
number O
of O
central O
zone O
crossings O
in O
the O
open O
field O
test O
and O
reduced O
grooming O
behavior O
in O
the O
elevated O
plus O
maze O
( O
EPM O
) O
test O
and O
increased O
the O
number O
of O
open-arm O
visits O
on O
the O
EPM O
test O
. O

CUR B-Medicinal food
administration O
significantly O
reduced O
freezing O
response O
to O
contextual O
fear O
conditioning O
. O

CUR B-Medicinal food
recovered O
neurochemical O
abnormalities O
and O
SPS-induced O
decreased O
5 O
- O
HT O
tissue O
levels O
in O
the O
hippocampus O
, O
amygdala O
, O
and O
striatum O
. O

These O
results O
suggested O
that O
CUR B-Medicinal food
has O
anxiolytic-like B-Symptom_WorkedFor
effects O
on O
biochemical O
and O
behavioral O
symptoms O
associated O
with O
anxiety B-Symptom_WorkedFor
. O

Thus O
, O
CUR B-Medicinal food
may O
be O
a O
useful O
agent O
to O
alleviate O
or O
treat O
psychiatric O
disorders O
similar O
to O
those O
observed O
in O
patients O
with O
PTSD B-participant_health
. O

Anxiety B-Symptom_WorkedFor
is O
one O
of O
the O
most O
common O
mental O
disorders O
sharing O
extreme O
or O
pathological O
anxiety B-Symptom_WorkedFor
states O
as O
the O
primary O
disturbance O
in O
mood O
or O
emotional O
tone O
, O
with O
increased O
fear O
and O
exaggerated O
acute O
stress B-Symptom_WorkedFor
responses O
. O

Medicinal O
plants O
are O
very O
variable O
, O
but O
some O
of O
them O
are O
used O
as O
a O
spice O
such O
as O
curcumin B-Medicinal food
( O
Curcuma B-Drug/Scientific name
longa I-Drug/Scientific name
) O
. O

Curcumin B-Medicinal food
shows O
a O
wide O
range O
of O
pharmacological O
potentialities O
, O
however O
, O
little O
is O
known O
about O
its O
anxiolytic B-Symptom_WorkedFor
properties O
. O

The O
aim O
of O
our O
study O
was O
to O
assess O
the O
anti-anxiety O
potential O
of O
curcumin B-Medicinal food
extract O
against O
experimental O
lead O
induced-anxiety O
in O
rats O
. O

Experiments O
were O
carried O
out O
on O
male O
Wistar O
rats O
intoxicated O
acutely O
with O
an O
intraperitoneal O
injection O
of O
Pb O
( O
25mg O
/ O
kg O
B.W O
. O
) O
and O
/ O
or O
concomitantly O
with O
administration O
of O
curcumin O
( O
30 O
mg O
/ O
kg O
B.W O
. O
) O
for O
3 O
days O
. O

Using O
immunohistochemistry O
and O
anxiety O
assessment O
tests O
( O
dark O
light O
box O
and O
elevated O
plus O
maze O
) O
, O
we O
evaluated O
, O
respectively O
, O
the O
expression O
of O
serotonin O
( O
5HT O
) O
in O
the O
dorsal O
raphe O
nucleus O
( O
DRN O
) O
and O
the O
anxiety O
state O
in O
our O
animals O
. O

Our O
results O
showed O
, O
for O
the O
first O
time O
, O
a O
noticeable O
anxiolytic B-Symptom_WorkedFor
effect O
of O
curcumin B-Medicinal food
against O
lead O
induced O
anxiety B-Symptom_WorkedFor
in O
rats O
and O
this O
may O
possibly O
result O
from O
modulation O
of O
central O
neuronal O
monoaminergic O
neurotransmission O
, O
especially O
serotonin O
, O
which O
has O
shown O
a O
significant O
reduction O
of O
the O
immunoreactivity O
within O
the O
DRN O
. O

Background O
: O
Anxiety B-Symptom_TestedFor
disorders O
are O
very O
common O
mental O
health O
problems O
in O
the O
general O
population O
and O
in O
primary O
care O
settings O
. O

Herbal O
medicines O
are O
popular O
and O
used O
worldwide O
and O
might O
be O
considered O
as O
a O
treatment O
option O
for O
anxiety B-Symptom_TestedFor
if O
shown O
to O
be O
effective O
and O
safe O
. O

Objectives O
: O
To O
investigate O
the O
effectiveness O
and O
safety O
of O
valerian B-Medicinal food
for O
treating O
anxiety B-Symptom_TestedFor
disorders O
. O

Search O
strategy O
: O
Electronic O
searches O
: O
The O
Cochrane O
Collaboration O
Depression O
, O
Anxiety O
and O
Neurosis O
Cochrane O
Controlled O
Trials O
Register O
( O
CCDANCTR-Studies O
and O
CCDANCTR-References O
) O
searched O
on O
04 O
/ O
08 O
/ O
2006 O
, O
MEDLINE O
, O
Lilacs O
. O

References O
of O
all O
identified O
studies O
were O
inspected O
for O
additional O
studies O
. O

First O
authors O
of O
each O
included O
study O
, O
manufacturers O
of O
valerian B-Medicinal food
products O
, O
and O
experts O
in O
the O
field O
were O
contacted O
for O
information O
regarding O
unpublished O
trials O
. O

Selection O
criteria O
: O
Randomised O
controlled O
trials O
( O
RCTs O
) O
and O
quasi-randomised O
trials O
of O
valerian O
extract O
of O
any O
dose O
, O
regime O
, O
or O
method O
of O
administration O
, O
for O
people O
with O
any O
primary O
diagnosis O
of O
general O
anxiety O
disorder O
, O
anxiety O
neurosis O
, O
chronic O
anxiety O
status O
, O
or O
any O
other O
disorder O
in O
which O
anxiety B-Symptom_TestedFor
is O
the O
primary O
symptom O
( O
panic O
disorder O
, O
obsessive O
compulsive O
disorder O
, O
social O
phobia O
, O
agoraphobia O
, O
other O
types O
of O
phobia O
, O
postraumatic O
stress O
disorder O
) O
. O

Effectiveness O
was O
measured O
using O
clinical O
outcome O
measures O
and O
other O
scales O
for O
anxiety B-Symptom_TestedFor
symptoms O
. O

Data O
collection O
and O
analysis O
: O
Two O
review O
authors O
independently O
applied O
inclusion O
criteria O
, O
extracted O
and O
entered O
data O
, O
and O
performed O
the O
trial O
quality O
assessments O
. O

Where O
disagreements O
occurred O
, O
the O
third O
review O
author O
was O
consulted O
. O

Methodological O
quality O
of O
included O
trials O
was O
assessed O
using O
Cochrane O
Handbook O
criteria O
. O

For O
dichotomous O
outcomes O
, O
relative O
risk O
( O
RR O
) O
was O
calculated O
, O
and O
for O
continuous O
outcomes O
, O
the O
weighted O
mean O
difference O
( O
WMD O
) O
was O
calculated O
, O
with O
their O
respective O
95% O
confidence O
intervals O
. O

Main O
results O
: O
One O
RCT O
involving O
36 O
patients O
wih O
generalised O
anxiety O
disorder O
was O
eligible O
for O
inclusion O
. O

This O
was O
a O
4 B-Duration
week I-Duration
pilot O
study O
of O
valerian B-Medicinal food
, O
diazepam B-Other_ingredients
and O
placebo O
. O

There O
were O
no O
significant O
differences O
between O
the O
valerian O
and O
placebo O
groups O
in O
HAM-A B-Metric
total O
scores O
, O
or O
in O
somatic O
and O
psychic O
factor O
scores O
. O

Similarly O
, O
there O
were O
no O
significant O
differences O
in O
HAM-A B-Metric
scores O
between O
the O
valerian B-Medicinal food
and O
diazepam B-Other_ingredients
groups O
, O
although O
based O
on O
STAI-Trait B-Metric
scores I-Metric
, O
significantly O
greater O
symptom O
improvement O
was O
indicated O
in O
the O
diazepam O
group O
. O

There O
were O
no O
significant O
differences O
between O
the O
three O
groups O
in O
the O
number O
of O
patients O
reporting O
side O
effects O
or O
in O
dropout O
rates O
. O

Authors O
' O
conclusions O
: O
Since O
only O
one O
small O
study O
is O
currently O
available O
, O
there O
is O
insufficient O
evidence O
to O
draw O
any O
conclusions O
about O
the O
efficacy O
or O
safety O
of O
valerian B-Medicinal food
compared O
with O
placebo O
or O
diazepam B-Other_ingredients
for O
anxiety B-Symptom_TestedFor
disorders O
. O

RCTs O
involving O
larger O
samples O
and O
comparing O
valerian O
with O
placebo O
or O
other O
interventions O
used O
to O
treat O
of O
anxiety B-Symptom_TestedFor
disorders O
, O
such O
as O
antidepressants O
, O
are O
needed O
. O

Stress B-Symptom_TestedFor
is O
an O
increasing O
problem O
that O
can O
result O
in O
various O
psychiatric O
and O
somatoform O
symptoms O
. O

Among O
others O
, O
benzodiazepines B-Other_ingredients
and O
valerian B-Medicinal food
preparations O
are O
used O
to O
treat O
stress B-Symptom_TestedFor
symptoms O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
the O
prescription O
of O
a O
fixed O
herbal O
extract O
combination O
of O
valerian B-Medicinal food
, O
lemon B-Medicinal food
balm I-Medicinal food
, O
passionflower B-Medicinal food
, O
and O
butterbur B-Medicinal food
( O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
) O
changes O
the O
prescription O
pattern O
of O
benzodiazepines B-Other_ingredients
in O
hospitalized O
psychiatric B-participant_health
patients O
. O

In O
a O
retrospective O
case-control O
study O
, O
anonymized O
medical O
record O
data O
from O
3,252 B-#Participants
psychiatric B-participant_health
in-house O
patients O
were O
analysed O
over B-Duration
a I-Duration
3.5 I-Duration
- I-Duration
year I-Duration
period O
. O

Cases O
( O
n O
= O
1,548 O
) O
with O
a O
prescription O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
and O
controls O
( O
n O
= O
1,704 O
) O
were O
matched O
by O
age O
, O
gender O
, O
hospitalization O
interval O
, O
and O
main O
International B-Metric
Classification I-Metric
of I-Metric
Diseases I-Metric
, I-Metric
Version I-Metric
10 I-Metric
F-diagnoses I-Metric
. O

The O
primary O
objective O
was O
to O
investigate O
the O
effect O
of O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
on O
the O
prescription O
pattern O
of O
benzodiazepines B-Other_ingredients
. O

Secondary O
objectives O
investigated O
the O
prescriptions O
of O
concomitant O
drugs O
and O
effectiveness O
of O
the O
hospital O
stay O
. O

Distribution O
of O
drug O
classes O
was O
analysed O
using O
the O
WHO's O
anatomic-therapeutic-chemical O
code O
. O

Data O
showed O
that O
both O
treatment O
modalities O
had O
a O
comparable O
clinical O
effectiveness O
but O
with O
significantly O
less O
prescriptions O
of O
benzodiazepines B-Other_ingredients
in O
the O
Ze B-Drug/Scientific name
185 I-Drug/Scientific name
group O
( O
p O
= O
.006 O
) O
. O

This O
is O
of O
clinical O
importance O
because O
suitable O
alternatives O
to O
benzodiazepines B-Other_ingredients
are O
desirable O
. O

To O
obtain O
more O
support O
for O
this O
hypothesis O
, O
a O
dedicated O
randomized O
, O
controlled O
clinical O
trial O
monitoring O
drug O
safety O
is O
required O
. O

Introduction O
: O
Data O
on O
comparison O
of O
myo-inositol O
and O
metformin O
on O
mental O
health O
parameters O
and O
biomarkers O
of O
oxidative O
stress O
in O
subjects O
with O
polycystic B-participant_health
ovary I-participant_health
syndrome I-participant_health
( O
PCOS B-participant_health
) O
are O
scarce O
. O

This O
purpose O
of O
this O
study O
was O
to O
compare O
of O
myo-inositol B-Medicinal food
and O
metformin B-Other_ingredients
on O
mental O
health O
parameters O
and O
biomarkers O
of O
oxidative O
stress O
in O
subjects O
with O
PCOS B-participant_health
. O

Methods O
: O
This O
randomized O
controlled O
trial O
was O
conducted O
among O
60 B-#Participants
subjects O
diagnosed O
with O
PCOS B-participant_health
according O
to O
the O
Rotterdam O
criteria O
. O

Subjects O
were O
randomly O
assigned O
into O
two O
groups O
to O
intake O
either O
myo-inositol B-Medicinal food
( O
n O
= O
30 O
) O
or O
metformin B-Other_ingredients
( O
n O
= O
30 O
) O
for O
12 B-Duration
weeks I-Duration
. O

Parameters O
of O
mental O
health O
were O
recorded O
at O
baseline O
and O
after O
the O
12 B-Duration
- I-Duration
week I-Duration
intervention O
. O

Fasting O
blood O
samples O
were O
obtained O
at O
baseline O
and O
the O
end O
of O
the O
study O
to O
determine O
biomarkers O
of O
biomarkers O
of O
oxidative O
stress O
. O

Results O
: O
After O
the O
12 B-Duration
- I-Duration
week I-Duration
intervention O
, O
changes O
in O
beck B-Metric
depression I-Metric
inventory I-Metric
total O
score O
( O
- O
1.0 O
± O
1.7 O
vs O
. O
- O
0.3 O
± O
0.7 O
, O
p O
= O
0.03 O
) O
, O
general O
health O
questionnaire O
scores O
( O
- O
1.7 O
± O
2.9 O
vs O
. O
- O
0.5 O
± O
1.2 O
, O
p O
= O
0.02 O
) O
, O
depression B-Symptom_WorkedFor
anxiety B-Symptom_WorkedFor
and O
stress B-Symptom_WorkedFor
scale O
scores O
( O
- O
3.9 O
± O
6.4 O
vs O
. O
- O
0.9 O
± O
1.9 O
, O
p O
= O
0.01 O
) O
and O
plasma O
total O
antioxidant O
capacity O
( O
TAC O
) O
concentrations O
( O
+ O
106.1 O
± O
69.6 O
vs O
. O
+ O
2.1 O
± O
132.4 O
mmol O
/ O
L O
, O
p O
< O
0.001 O
) O
in O
the O
myo-inositol B-Medicinal food
group O
were O
significantly O
different O
from O
the O
changes O
in O
these O
indicators O
in O
the O
metformin B-Other_ingredients
group O
. O

Myo-inositol B-Medicinal food
supplementation O
for O
12 B-Duration
weeks I-Duration
among O
patients O
with O
PCOS B-participant_health
did O
not O
affect O
plasma O
glutathione O
and O
malondialdehyde O
levels O
. O

Conclusions O
: O
Overall O
, O
our O
data O
supported O
that O
myo-inositol O
supplementation O
for O
12 B-Duration
weeks I-Duration
among O
patients O
with O
PCOS B-participant_health
had O
favorable O
effects O
on O
parameters O
of O
mental O
health O
and O
plasma O
TAC O
levels O
. O

Depression B-Symptom_WorkedFor
, O
the O
most O
common O
type O
of O
mental O
illness O
, O
is O
the O
second O
leading O
cause O
of O
disability O
and O
is O
increasing O
among O
Americans O
. O

The O
effect O
of O
improved O
nutrition O
, O
particularly O
with O
dietary O
supplements O
, O
on O
depression B-Symptom_WorkedFor
may O
provide O
an O
alternative O
to O
standard O
medical O
treatment O
. O

Some O
studies O
have O
shown O
that O
certain O
nutrients O
( O
e.g O
. O
, O
inositol O
and O
S-adenosyl O
methionine O
) O
are O
effective O
at O
improving O
depressed O
mood O
, O
although O
the O
results O
are O
not O
unequivocal O
. O

The O
current O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
a O
vitamin B-Medicinal food
B I-Medicinal food
complex O
nutritional O
supplement O
( O
Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
) O
for O
improving O
depressive O
and O
anxiety O
symptoms O
according O
to O
the O
Beck B-Metric
Depression I-Metric
and I-Metric
Anxiety I-Metric
Inventories I-Metric
( O
BDI O
and O
BAI O
) O
in O
60 B-#Participants
adults O
diagnosed O
with O
major O
depression B-participant_health
or O
other O
forms O
of O
depressive B-participant_health
disorders I-participant_health
. O

Secondary O
outcomes O
included O
quality O
of O
life O
according O
to O
the O
SF O
- O
36 O
. O

Participants O
were O
assessed O
at O
baseline O
and O
30 O
- O
and O
60 O
- O
day O
followups O
. O

Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
showed O
significant O
and O
more O
continuous O
improvements O
in O
depressive B-Symptom_WorkedFor
and O
anxiety B-Symptom_WorkedFor
symptoms O
, O
compared O
to O
placebo O
. O

Additionally O
, O
Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
showed O
significant O
improvement O
on O
the O
mental O
health O
scale O
of O
the O
SF O
- O
36 O
compared O
to O
placebo O
. O

Thus O
, O
we O
showed O
modest O
utility O
of O
Max B-Drug/Scientific name
Stress I-Drug/Scientific name
B I-Drug/Scientific name
to O
improve O
mood O
symptoms O
and O
mental O
health O
quality O
of O
life O
in O
adults O
with O
depression B-Symptom_WorkedFor
. O

